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Chapter 1: Introduction 
 
1.1 The epidemiology of depression and anxiety 
Both depressive and anxiety disorders are very common. Major depressive disorder 
(MDD) alone has a lifetime prevalence of 19.0% in the general population (Bijl et al., 
1998). Anxiety disorders are a more heterogeneous group and can be divided into 
different diagnoses: social phobia, generalised anxiety disorder (GAD), panic disorder, 
agoraphobia, specific phobia, obsessive compulsive disorder and post-traumatic stress 
disorder. The lifetime prevalence of these diagnoses is also high and ranges up to 19.3% 
in the general population (Bijl et al., 1998). The World Health Organization (WHO) 
reported that MDD is the leading cause of years lost to disability (WHO, 2004). Moreover, 
in the year 2000, MDD was ranked as the fourth largest contributor to the global burden 
of disease and it is projected to rank second by the year 2020 for all ages and both sexes, 
leaving only cardiovascular disease above it as the largest global cause of disability 
(Murray & Lopez, 1996; WHO, 2004).  
Depressive disorders exert a long lasting influence on many aspects of a person’s 
life, including social, personal and productive functioning (Ormel et al., 2008). Role-
disability has been found to be larger for psychiatric disorders than for many somatic 
disorders (Alonso et al., 2004). Therefore, MDD constitutes a considerable economic 
burden on society (Sobocki et al., 2006).  
Both MDD and anxiety follow a chronic-intermittent course. MDD is characterised 
by an episodic course with interchanging periods of remission and recurrence of 
depressive episodes; some MDD patients only experience a few episodes throughout 
their lives, while others experience an episode every year or even chronic depression 
(Keller & Baker, 1992; Spijker et al., 2002; Ormel et al., 1993; Piccinelli & Wilkinson, 1994). 
Anxiety disorders tend to follow a more chronic course trajectory with less remission than 
single MDD (Ormel et al., 1993; Keller & Hanks, 1993; Pollack & Otto, 1997; Keller, 2006; 
Tiemens et al., 1996; Penninx et al., 2011). When depression and anxiety occur together, 
prognosis is especially unfavourable with less remission and more chronicity (e.g. Penninx 
et al., 2011). 
 
1.2 The etiology of depression and anxiety 
Much research has focussed on the underlying mechanisms that determine the onset and 
course of depression and anxiety, addressing biological, social and psychological 
etiological mechanisms. Over the past decades, research has become more focussed on 
biological mechanisms (Kendler, 2005).  
Genetic studies in particular have garnered much attention during the past 
decade. Many early studies have focussed on candidate genes of depression (reviews: 
Charney & Manji, 2004; Levinson, 2006) and anxiety (review: Hamilton, 2009). More 
recently, large genome-wide association (GWA) studies have yielded possible genetic loci 




2011). However, although much was expected from these GWA studies, replicability of 
many initial results has been limited (e.g. Bosker et al., 2010; Breen et al., 2011). 
Moreover, other GWA studies have found no associations at all (Muglia et al., 2008).  
Other lines of research have focussed more upstream on the different biological 
pathways that could play a role in the pathophysiology of depression and anxiety. For 
instance, the hypothalamo-pituitary-adrenal (HPA) axis, which regulates the secretion of 
the stress hormone cortisol, has for long been hypothesized to play an important role in 
depression (Holsboer, 2000). Several studies have found dysregulated patterns of cortisol 
secretion in depressed patients (Pruessner et al., 2003; Bhagwagar et al, 2005; Vreeburg 
et al., 2009; Holsboer & Ising, 2010). However, these effects have been invariably small 
and other studies have found no differences between patients and controls or even the 
reversed effect (Stetler & Miller, 2005; Huber et al., 2006; Veen et al., 2011), leaving an 
inconsistent and inconclusive body of results. Moreover, it is still unclear whether these 
effects are the effect rather than the cause of depression and anxiety. Numerous lines of 
research have focussed on a variety of other possible underlying mechanisms, including: 
monoamines (review: Heninger et al., 1996), neuroplasticity (review: Duman & 
Monteggia, 2006) the autonomic nervous system (Licht et al., 2008; Kemp et al., 2010) 
and neuroimaging (review: Drevets et al., 2008). Many of these factors seem to play a 
role in the etiology of depression and/or anxiety, but the extent and consistency of their 
distinct and interactive roles have been hard to establish. Like biological research, studies 
that have focussed more on psychosocial factors, such as life events (Kessler, 1997), social 
support and coping styles (Coyne & Downey, 1991; Paykel, 1994) have yielded similarly 
varied results.  
Another broad and relevant field of research is that of the interactions between 
psychiatric problems and indicators of somatic health. For instance, a large body of 
psychosomatic work has shown that depression is associated with a larger risk of 
cardiovascular disease (CVD) and vice versa (e.g. Musselman, 1998; Vogelzangs et al., 
2010; Ormel & De Jonge, 2011). Increased prevalence of the metabolic syndrome 
(components) and autonomic nervous system dysregulations have been hypothesized to 
underlie both depression and CVD (Vogelzangs et al., 2009). This would explain the 
observed bi-directional link between these disorders in the population.  
 In addition to biological factors, several environmental factors have been shown to 
play a role in the etiology of both depression and anxiety. A well-known example is 
childhood trauma, which has been shown to be associated with an increased risk of 
psychopathology and chronicity in later life (e.g. Wiersma et al., 2009; Hovens et al., 
2010). Other environmental factors that have garnered much attention as potential 
etiological factors of depression are adverse life events (extensively reviewed by Kessler, 
1997). However, the findings with regard to adult life events have been less consistent 
than for childhood events and traumata, with many studies reporting no associations 
between life events and depression or anxiety (e.g. Spinhoven et al., 2010). This could be 
due to methodological differences across studies, but it is also likely that the effects of life 
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events are mediated by buffering factors, such as coping (Billings & Moos, 1981), social 
support (Cohen & Wills, 1985) and vulnerability factors, such as previous childhood 
trauma (Heim & Nemeroff, 2001). A more recent line of research has started to focus on 
the impact of daily hassles/stressors on day-to-day emotional variations and has shown 
that the magnitude of these variations is related to important clinical characteristics, 
including clinical course (Wichers et al., 2010) and treatment response (Geschwind et al., 
2011).        
In conclusion, there seem to be sufficient promising leads for further research into 
the etiology of depression and anxiety, but no general and consistent findings that could 
be regarded as undisputable textbook truisms.         
 
1.2.1 Lack of scientific progress 
Given the abovementioned inconclusive results, one would be tempted to think that we 
have been looking for the wrong causes of psychopathology. Should we try harder and 
expand our search for possible mechanisms? The answer is likely to be no. Given the large 
range of already investigated mechanisms with small and inconsistent effects, it is not 
very plausible that much will be gained by simply adding ever more new mechanisms to 
the list of possible candidate pathways, each of which is still poorly understood on an 
individual level. In fact, it seems that until now, every new and promising direction of 
research has only yielded small reward in terms of understanding the etiology of 
depression or anxiety.  
A more plausible hypothesis is that depression and anxiety are caused by many 
interacting mechanisms, each with a very small effect on its own but with a larger 
combined effect (Caspi & Moffit, 2006; Jaffee & Price, 2007). From this perspective, it 
seems only reasonable that conflicting results are found when only a single mechanism is 
investigated. Indeed, results from studies of interactions between genes and 
environmental factors have indicated that important effects can be missed if genetic and 
environmental factors are each studied in isolation (e.g. Caspi et al., 2003). However, 
these interactive effects are much more complex to investigate and have so far been hard 
to replicate (Risch et al., 2009). 
 Another plausible reason for lack of progress in understanding the etiology of 
depression and anxiety could be that we have been searching for the causes of the wrong 
disorders or, alternatively, of the wrong mental states. Although the DSM diagnoses of 
depression and anxiety have become accepted as real medical diagnoses, the DSM clearly 
states that its classification is only based on clinical consensus and does not assume that 
its categories represent distinct clinical entities with absolute borders (American 
Psychiatric Association, 2000). Moreover, no DSM diagnosis has thus far been found to be 
associated with a biological or laboratory marker (Kupfer et al., 2002; Widiger & Samuel, 
2005). Consequently, there is no reason to expect that DSM-syndromes are naturally 
occurring endpoints of biological pathways. Summarizing this point with regard to 




 The DSM has without doubt helped the clinical field of psychiatry grow into a 
professional medical discipline with a globally accepted standardized diagnostic 
classification system and has improved the communication between health-care 
professionals worldwide (First, 2005). However, despite its obvious clinical utility, the 
DSM should primarily be judged on its validity when it comes to its use in scientific 
research (Kendell & Jablensky, 2002). In fact, it is doubtful whether DSM diagnoses could 
be considered valid and suitable for this use (e.g. Kendell, 1989; Kendell & Jablensky, 
2002; Widiger & Clark, 2000; Widiger & Samuel, 2005). Taking this point even further, the 
widespread adaptation of DSM diagnoses as outcome variables in research could be 
argued to be one of the main reasons why scientific progress in psychiatry has been very 
slow during the last three decades (Shorter & Tyrer, 2003). Although this point is 
tentative and impossible to prove, the practice of pursuing the underlying mechanisms of 
a DSM-diagnosis does not seem very useful to gain more understanding of psychiatric 
problems, when we know that DSM-diagnoses were merely intended as clinical tools 
(Kendell & Jablensky, 2002).   
With regard to depression and anxiety, several important issues of the DSM have 
been raised that are problematic for clinical and scientific purposes and could explain why 
so far scientific breakthroughs have been scarce and results inconsistent. These issues 
form the background to the research that is described in this dissertation and three of the 
most important issues will be discussed: comorbidity of depression and anxiety (see 1.3), 
heterogeneity of diagnoses (see 1.4) and discontinuity between health and disease (see 
1.5) 
 
1.3 Comorbidity of depression and anxiety 
Depressive and anxiety disorders frequently co-occur. Comorbidity between the two 
diagnostic groups has been investigated in large-scale epidemiological studies and 
reported prevalence rates range from around 40 to 60%, depending on the population 
and diagnoses studied (Kaufman & Charney, 2000; Bijl et al., 1998). The rate of 
comorbidity seems to be even higher in clinical samples, probably because comorbid 
patients are more severely ill and more prone to seek help (Clark et al., 1995). The high 
rates of comorbidity of MDD and anxiety disorders have important clinical implications 
and have also given rise to a heated theoretical debate about the appropriateness of the 
division between anxiety and depression as separate entities (Mineka et al., 1998; 
Widiger & Clark, 2000; Clark et al., 1995). Below, both implications will be discussed. 
  
1.3.1 Clinical implications of comorbidity 
From a clinical perspective, comorbidity between depression and anxiety is very 
interesting because it is associated with a heavier burden of disease compared to single 
cases. In comorbid cases, prognosis is worse (Shankman & Klein, 2002; Merikangas, 2003; 
van Beljouw et al., 2010; Fichter et al., 2010; Patten et al., 2010; Penninx et al., 2011), 
severity is higher (Roy-Byrne et al., 2000), overall functioning is poorer (Roy-Byrne et al., 
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2000), response to treatment is lower (Brown et al., 1996; Kornstein & Schneider, 2001), 
and there is a higher probability of attempted and committed suicide (Beautrais et al., 
1996; Roy-Byrne et al., 2000) than in single cases. Longitudinal studies have shown that 
the course of comorbid MDD and anxiety is chronic (56.8%) much more often than the 
course of single MDD (24.5%) or single anxiety disorders (41.9%; Penninx et al., 2011). 
Unfortunately, research on the etiology and pharmacological treatment of comorbid 
patients is scarce. Despite its high prevalence, comorbidity is often an exclusion criterion 
for research because it is regarded as an anomaly that blurs the depression- or anxiety-
specific effects that researchers are usually looking for (Shorter & Tyner, 2003). Although 
comorbid patients have gained more attention in research in recent years, it seems that 
the group is still under-investigated.       
  
1.3.2 Theoretical implications of comorbidity 
The formal distinction between depression and anxiety was introduced in the first drafts 
that lead to the eventual DSM in the beginning of the 1980’s (Widiger & Clark, 2000). 
Depression and anxiety have since become widely accepted as separate clinical entities, 
which has lead clinicians and pharmacologists to organise separate lines of care for 
depression and anxiety. This has lead researchers to search for distinct etiological 
mechanisms underlying these different classes of disorders (Kendell & Jablensky, 2002). 
Indeed there seems to be some face-validity and clinical utility to the distinction between 
depression and anxiety. Semantically, the terms clearly have different meanings and 
some symptoms can easily be characterized as either depressive (e.g. ‘lack of interest’) or 
anxious (e.g. ‘feeling jumpy’). However, although some patients fit the diagnostic moulds 
nicely, real world epidemiological studies have shown that the majority of patients do not 
fit neatly into one well-defined diagnostic class, because boundaries between diagnoses 
are blurry (Kendell, 1989). From this perspective, the separation between depression and 
anxiety as separate disorders looks rather forced and artificial. In fact, one could argue 
that if a model is designed to optimally describe and organize the nosology of 
psychopathology, the boundaries should be drawn such that the resulting groups explain 
as much information as possible (Kendell, 1989). Thus, the system should be able to 
classify all patients in the simplest and most consistent way possible (Kendell, 1989; 
Kendell & Jablensky, 2002). Unfortunately, in the majority of cases, more than one 
diagnostic label is needed to diagnose the patient, which indicates that the underlying 
categorical model of the DSM is inefficient in describing reality, adding more complexity 
instead of one simple and reliable diagnostic solution for each individual (e.g. Clark, 1995; 
Widiger & Clark, 2000; Kendell & Jablensky, 2002; Widiger & Samuel, 2005).  
It has been proposed that the frequent co-occurrence and shared etiology of 
depression and anxiety show that the diagnostic categories are not valid: they are neither 
distinct on the observed level nor on the etiological level (Kendell & Jablensky, 2002). So, 
although DSM disorders seem to have clinical utility, boundary disputes and comorbidity 




that account more elegantly for the blurry boundaries between individual patients 
(Kendell & Jablensky, 2002)  
  
1.4 Heterogeneity 
An important issue that is inherent to the way the DSM works is within-diagnosis 
heterogeneity (Frances et al., 1990). DSM-diagnoses are made using a syndrome-
approach, in which a fixed number of criteria has to be met in order to get a diagnosis. An 
inevitable side effect of this approach is that patients with a similar DSM diagnosis do not 
necessarily have similar symptoms; there is considerable within-diagnosis heterogeneity 
(Clark et al., 1995; Widiger & Samuel, 2005). For instance, if two patients both meet five 
out of nine criterion symptoms for MDD, they both meet the criteria but only have to 
share one symptom. Understandably, this leads to a lot of symptom variation across MDD 
patients, who might be assumed to be very similar judged by their common diagnosis. 
Within-diagnosis heterogeneity has several important practical and theoretical 
implications.  
  
1.4.1 Clinical Implications of diagnostic heterogeneity 
In clinical practice, large diagnostic heterogeneity means that a diagnosis of MDD does 
not automatically entail one clear treatment indication. On the contrary, no two MDD 
patients respond equally to the same treatment and it is the rule rather than the 
exception that treatment has to be tailor-fitted for each individual patient’s symptoms. 
This often requires experimenting with different types of medication and/or psychosocial 
interventions. In this way, the DSM leaves a lot of additional effort to be made by the 
clinician. Therefore, attempts have been made to decrease heterogeneity in MDD and to 
reach a better correspondence between diagnosis and indicated treatment, by 
introducing MDD subtypes (Goldberg et al., 2011). Of these, the subtypes of melancholic 
and atypical depression have received most attention in the literature and indeed there 
seems to be some evidence that patients with an atypical MDD differ from patients with a 
melancholic MDD in terms of biological mechanisms, treatment response and other 
aspects of disease (reviewed by: Stewart et al., 2007; Brown, 2007). For instance, some 
studies have shown that patients with atypical MDD respond better to MAO-inhibitors 
compared to general MDD and other subtypes (Liebovitz et al., 1988). However, there are 
also studies that have found less support for the validity and usefulness of subtypes 
(Parker et al., 2002). In fact, subtypes of depression have also been found to constitute 
quite heterogeneous diagnostic classes themselves (Stewart et al., 2007) and it seems 
that they do not solve the essential problem of heterogeneity, but merely break the 
disorder up into a range of smaller subcategories. Although valid subtypes could decrease 
diagnostic heterogeneity to a certain extent, they are not likely to completely solve it. 
Each added subtype will apply to a limited group of patients, which could eventually lead 
to an unwieldy system of infrequently used subtypes (Clark et al., 1995).      
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 The problem of heterogeneity also applies to the widely used severity ratings of 
depression, which assume that all symptoms of depression contribute equally to the 
same broad underlying dimensions of severity. Such measures include the widely used 
Hamilton Depression Rating Scale (HDRS) and the Beck Depression Inventory (BDI). 
Indeed, many factor-analytical studies have shown that simply adding up symptom 
ratings to acquire a simple and broad severity score does not do justice to the 
heterogeneity of the assessed symptoms. Instead, factor analyses have repeatedly shown 
that sets of items that assess similar symptom domains cluster together on distinct 
factors, across which scores can vary independently (Shafer, 2006). So, where a one-
construct structure is often assumed, a two-, three or more-construct structure often fits 
better to the actual data. This suggests that a more complex model is needed to measure 
the several coexisting spectra of severity that play a role in depression and anxiety 
(Goekoop et al., 2007). Indeed, for many depression severity measures, well validated 
subscales that measure these spectra have been developed to assess more specific 
symptom domains (e.g. for the HRSD: Bagby et al., 2004; for the BDI: Endler et al., 1999). 
In the current dissertation this pragmatic approach to decrease the heterogeneity of 
psychiatric assessment is also explored. Chapter 3 describes the development and 
validation of a dimensional model and corresponding subscales for the widely used 
Inventory of Depressive Symptomatology Self Report (IDS-SR).   
 
1.4.2 Theoretical implications of heterogeneity 
Diagnostic heterogeneity is a particular problem for scientific research. As stated above, 
many etiological effects are expected to be very small because - especially in psychiatry - 
the etiology of disorders is hypothesized to depend on interacting biological, 
psychological and social factors in a so called biopsychosocial model (Engel, 1979). To 
detect these small individual effects, a great deal of statistical power is needed. In other 
words, the signal-to-noise ratio should be as high as possible and outcome measures 
should be internally consistent and not overly sensitive to measurement error (or random 
variations). If the measurement error is large, statistical power will remain relatively low, 
even when the sample size is increased (MacCallum et al., 2002). This is exactly the effect 
of diagnostic heterogeneity when patients with the same diagnosis are put together in an 
experimental group and made part a dichotomous variable for use in statistical analyses. 
The patients undoubtedly have something in common, but as illustrated above they also 
differ in many respects. In addition, the control group can be heterogeneous as well. 
Consequently, there is so much error-variation or ‘noise’ within the groups, that when the 
patient group is compared with the control group, ‘noise’ can obscure the true ‘signal’. 
For instance, when comparing gene frequencies, a difference in frequency can go 
undetected because the within-group variation in frequency (‘noise’) is almost equally as 
large as the between-group variation in frequency (the ‘signal’ or ‘effect’). Heterogeneity 
thus introduces two strongly related issues: (1) categories are too heterogeneous to have 




find out how the complex underlying mechanisms work, since there is a severe lack of 
statistical power. These issues revolve around each other and constitute a circular 
problem, which is not limited to genetic research: regardless of the etiological factor, 
diagnostic heterogeneity will be a problem when the expected effect or difference is 
small.  
The lack of power in psychiatric research has certainly received attention, especially in 
genetic research, but the focus has been mainly on decreasing the relative influence of 
within-group noise by increasing sample size (e.g. Wray et al., 2009). Especially in the field 
of psychiatric genetics, experts have been stating that collecting enormous samples, in 
the order of tens- or hundreds-of-thousands of subjects is the only way to gain the power 
that will be needed to detect meaningful and replicable results from genetic studies and 
genome wide screens (discussed in: Abbott, 2008). In a similar vein, power could be 
increased by performing repeated measurements within the same group of people 
(Vickers et al., 2003). Although these methods of increasing measurement quantity 
should be considered as one viable option, the abovementioned issues should also 
encourage researchers to do something about the heterogeneity of their studied 
phenotypes, since this is one of the reasons why enormous power – and thus vast 
samples and multiple measurements - are needed in the first place.  
In conclusion, diagnostic heterogeneity leads to a lack of clinical specificity and 
loss of power in scientific research. Therefore, researchers should find better ways to 
account for this. 
 
1.5 Discontinuity 
The DSM uses a syndrome approach, which intrinsically assumes that a dichotomy, or 
“point of rarity”, exists between psychiatrically ill and healthy individuals (Kendell, 1989). 
Although this makes the DSM classification conveniently similar to the systems used in 
other medical fields, there is no reason to suspect that such a dichotomy is actually valid 
for psychiatric disorders (Kendell & Jablensky, 2003). In the case of MDD, there is actually 
no clear cut-off in the population between those that are depressed and those that are 
healthy (Flett et al., 1997; Ruscio, 2000). Rather, there is a gradual transition along a 
continuum from psychiatrically healthy to subclinical depression to a full-blown MDD, 
with each stage differing quantitatively, but not qualitatively from the other (Akiskal et 
al., 1997; Judd et al., 1998; Cox et al., 2000). Following this continuum, severe MDD could 
eventually be seen as the end-point on a depression continuum of increasing severity that 
runs through the population (Flett et al., 1997). Importantly, continuity is not only evident 
in the distribution of depression in the population (between subjects) but also in the 
development of symptoms within individuals (e.g. Rao et al., 1999). Similar continuous 
distributions have been proposed for other forms of psychopathology, such as psychosis 
(van Os et al., 2000) and autism (Wing, 1988).   
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1.5.1 Clinical implications of discontinuity 
The actual continuity of psychopathology in the population is not incorporated in our 
current diagnostic system. However, there exists a considerable group of individuals that 
could be characterized as patients with subclinical illness: they do not (yet) meet the full 
criteria for a diagnosis. It has been found that even in these subclinical cases, increases in 
severity are associated with increased disability (e.g. Martin et al., 1996; Lewinsohn et al., 
2000; Cuijpers et al., 2004). Thus, these individuals could very well be in need of care or 
preventive measures. Indeed, it has been shown that preventive psychosocial treatment 
decreases the incidence of MDD, disease severity, the level of disability (Clarke et al., 
1995; 2001; Willemse et al., 2004), and the subsequent use of care in individuals with 
subclinical depression (Wells et al., 2005). However, no evidence has been found for the 
efficacy of antidepressants in sub-threshold depressive individuals (Barbui et al., 2011). 
Indeed, in a meta-analysis these were shown to be mainly effective in patients with 
severe MDD (Kirsch et al., 2008). Thus, using a strict dichotomous model to divide care 
among individuals seems to lead to a situation in which a proportion of those needing 
care are ignored. This is unfortunate, because if treatment is only started after a DSM 
diagnosis is made, the developmental end-stage of the disorder is already reached and 
the disabling effects are much harder to stop and reverse than when interventions are 
made in an earlier developmental stage (McGorry et al., 2006; McGorry; 2007).   
 
1.5.2 Theoretical implications of discontinuity 
As discussed above, most researchers divide their subjects into DSM-defined healthy and 
diseased groups. However, the continuous distribution of disease severity in the 
population causes both groups in these so called case-control studies to include subjects 
with varying levels of psychopathology, decreasing the contrast between the mean 
psychopathology levels of the two groups and thus decreasing the potential to detect a 
difference on an etiological variable. In fact, the methodology literature advises clearly 
against dichotomising variables that are actually continuously distributed, because it 
leads to a decrease in statistical power that is equal to the decrease that would be seen 
after reducing sample size by a third (Altman & Royston, 2006). In other words, if we 
choose to dichotomise depression rather than to approach it as a continuous variable, we 
need to collect 50% more data to reach the same amount of statistical power. 
Dichotomising can be seen as effectively throwing away valuable information about 
possible effects and it has been shown to lead to biased results (Royston et al., 2006). 
Therefore, phenomena with a continuous distribution throughout the population should 
ideally be analysed with continuous variables (MacCallum et al, 2002; Royston et al., 
2006).  
 
1.5.3 Patching up the DSM 
The issues, summarized above are all broadly acknowledged, and through the years, 




the issues could be solved with relatively minor adjustments or additions to the existing 
system as has been the practice for all previous editions of the DSM. Comorbidity could 
be tackled by introducing an ad hoc “mixed depression-anxiety” diagnosis in the DSM 
(Katon & Roy-Byrne, 1991; Zinbarg et al., 1994; Shorter & Tyrer, 2003). This would mould 
comorbidity into one official diagnosis, albeit without any direct consequence for 
treatment other than the already known consequences of comorbidity itself. Diagnostic 
heterogeneity could be reduced by assigning individuals to increasingly numerous and 
specific diagnostic subcategories (e.g. Carragher et al., 2009). However, for reasons listed 
above, subtypes within diagnoses have so far proven to be limited in their validity and 
usefulness (Clark et al., 1995; Stewart et al., 2007). Discontinuity could partly be 
accounted for by including a threshold for subclinical depression (e.g. Hybels et al., 2001) 
and/or anxiety to better enable staged diagnostics (Fava & Kellner, 1993; McGorry et al., 
2006). However, introduction of such a diagnosis would automatically create new 
subclinical diagnoses with limited specificity: many subtreshold cases do not need 
treatment or will not respond to it (Lyness et al., 2007). In addition, it is unclear where 
cut-offs should be defined between different preclinical stages. If natural points of rarity 
do not exist between different clinical entities (Kendell & Jablensky, 2002), it remains to 
be seen if they exist between different clinical stages.  
 
1.6 Solution of issues: a dimensional approach 
The problems with each of the abovementioned proposals are that they tackle specific 
issues in an ad hoc fashion and act as specific add-ons that bear no relation to the 
functioning of the system as a whole. Moreover, rather than to suggest that some small 
adjustments are needed to the system, the issues with the DSM go deeper and imply that 
something much more elemental is wrong with its categorical approach. Therefore, it 
would be overly optimistic to expect that the problems can simply be patched up until a 
next revision is due.      
Completely different approaches to psychopathology have been proposed that 
aim to better describe the actual characteristics of psychiatric symptoms in a more 
integrated fashion. Of the proposed approaches, the dimensional approach has been 
shown to be one of the most promising contenders. This approach is the main focus of 
this dissertation. 
 
1.6.1 A dimensional approach to psychopathology 
The most important assumption of dimensional models of psychopathology is that 
symptom severity follows a continuum, rather than a dichotomy, which, as described 
above, is more in line with observations in the general population (Goldberg, 2000). In 
addition, most dimensional models assume that psychiatric symptomatology consists of 
several co-existing symptom-domains, each varying along its own severity continuum. In 
other words: they account for heterogeneity across patients by assuming 
multidimensionality (e.g. Goekoop et al., 2007). Also, particularly in the case of 
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depression and anxiety, dimensional models circumvent and explain comorbidity, by 
assuming common and specific symptom dimensions instead of a fixed set of categories 
(Clark & Watson, 1991). For depressive and anxiety disorders, promising dimensional 
models have been developed that have been shown to be very useful in describing the 
clinical state of any individual, irrespective of his or her DSM diagnosis. 
 
1.6.2 A dimensional approach to depression and anxiety    
The starting point for the development of a dimensional approach of depression and 
anxiety was the observed high rate of comorbidity between the two disorders, as this 
highlighted an elemental flaw in the descriptive model of the DSM (Mineka et al., 1998). 
As described above, comorbid patients often have a less favourable prognosis and 
respond poorly to treatment. The obvious reason for this is that comorbidity occurs more 
often in patients that have more (severe) symptoms. Therefore, authors argued that it is 
these patients’ relatively high position on an underlying severity dimension that accounts 
for their worse prognosis and not merely the fact that they have two or more diagnoses 
(Clark et al., 1995). This assumption was central to the emergence of a series of 
dimensional models of depression and anxiety during the past two decades.  
The first question that the developers of these dimensional models sought to 
answer was how the general underlying severity dimension could be defined. Researchers 
that aimed to explain the relationship between depression and anxiety observed that 
patients with depression and anxiety show considerable overlap in their experienced 
symptoms irrespective of severity or demographics. These shared symptoms were mainly 
characterised by general psychological distress, and together they were labelled as 
‘Negative Affect’ (Watson & Clark, 1984; Watson et al, 1988). In this form, increased 
Negative Affect was found to be associated with the occurrence and persistence of both 
depression and anxiety and worse prognosis (Watson et al., 1988; Clark et al., 1994). This 
led researchers to assume that Negative Affect is indeed a central or common symptom 
domain that explains the overlap between DSM-defined depression and anxiety and their 
comorbidity (Watson et al., 1988; Clark et al, 1995).  
  
1.6.3 The tripartite model 
In 1991, Clark and Watson published an influential dimensional model that was aimed to 
describe symptoms of depression and anxiety, while circumventing the problem of 
comorbidity: the tripartite model. The model had a Negative Affect dimension as its 
central pillar, which included the symptoms that are shared by depression and anxiety, 
such as: feelings of worthlessness, guilt and pessimism. In addition, the model included 
two specific dimensions that described symptom domains that were more characteristic 
for either depression or anxiety. The dimension of ‘Positive Affect’ covers lack of positive 
emotions and energy. The addition of this dimension in the model was in line with earlier 
research that had shown that increased Negative Affect is necessary but not sufficient to 




together with decreased Positive Affect, were found to specifically characterize those 
individual with mood-related problems, such as anhedonia (Watson & Clark, 1984; 
Watson et al., 1988). Importantly, the dimensional nature of both Negative and Positive 
Affect allows a large range of combinations of both common and specific symptom 
severity to be described, and models the heterogeneity across different individuals. The 
third dimension of ‘Somatic Arousal’ included symptoms of somatic hyper arousal, such 
as sweating, trembling, palpitations and other sympathetic symptoms. This specific 
dimension was added to the model to account for panic and anxiety symptoms (Mineka 
et al., 1998; Joiner et al., 1996).  
The tripartite model was initially meant to explain comorbidity between depression and 
anxiety, and at the same time to acknowledge the specific features on which individuals 
can differ from each other. Although the tripartite approach is simple and far from 
complete in explaining all aspects of depressive and anxious symptomatology, this seems 
to have advantages. The model is easy to operationalize with a simple measurement 
scale, called the mood and anxiety symptoms questionnaire (MASQ, Watson et al., 1995a; 
1995b). Using data collected with the MASQ and other instruments, the hypothesized 3-
dimensional structure was proven to be generalizable across many populations. The 3-
dimensional structure has been replicated in school children (Chorpita et al., 2000; 2002; 
Cannon & Weems, 2006), healthy college students (Watson et al., 1995a; Keogh & Reidy, 
2000), veterans (Watson et al., 1995a), adult psychiatric outpatients (de Beurs et al., 
2007), adolescent psychiatric patients (Joiner et al., 2000), the elderly (Cook et al, 2004), 
and patients with somatic problems (e.g. Geisser et al., 2006).  
However, issues with the tripartite model have also been raised and that these 
need to be resolved. A considerable number of studies did not find a 3-dimensional 
structure to underlie the data collected with the MASQ and other instruments (e.g. Burns 
& Eidelson, 1998; Marshall et al., 2003; Buckby et al., 2008; Bedford et al., 2010; Boschen 
et al., 2006; Greaves-Lord et al., 2007). Some have interpreted this to indicate that the 
tripartite model is not applicable to all populations (Buckby et al., 2008; Marshall et al., 
2003). However, others have suggested that the MASQ is not an optimal measure of the 
tripartite model, because it includes too many items that do not clearly belong to one 
dimension (unclear items). This increases the measurement error of the MASQ scales, 
which in turn decreases the reliability of the scales and thus the replicability of the model 
it aims to measure. In addition, the inclusion of unclear items causes the MASQ scales to 
be highly correlated, which makes it harder to distinguish the independent dimensions 
each time the model is tested in another population (Boschen et al., 2006; Keogh & Reidy, 
2000). Thus, although the model seems structurally valid, measurement could be 
improved. This is the first point that will be addressed in this dissertation: the 
development of an improved version of the MASQ is described in Chapter 2. Another 
limitation of the tripartite model is that heterogeneity is still present; within the Negative 
Affect dimension in particular, many seemingly unrelated symptoms are lumped 
together, which implies that two similar Negative Affect scores do not mean that similar 
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symptoms are present. Therefore, it has been proposed that Negative Affect should be 
subdivided into more homogenous subdimensions (Mineka et al., 1998; Den Hollander-
Gijsman et al., 2010).  
Interestingly, parallel to the tripartite model, other models have also been 
proposed in the literature from a more neurobiological perspective (Shankman & Klein, 
2003). The best known of these are the approach-withdrawal model and the valence-
arousal model (Murphy & Lawrence, 2003), which make predictions about patterns of 
activation of different emotional response systems for negative (withdrawal related) and 
positive (approach related) emotions in the brain (Murphy & Lawrence, 2003). These 
emotional systems roughly correspond to Negative Affect, Positive Affect and Somatic 
Arousal. The valence-arousal model adds an extra anxiety-specific domain, called Anxious 
Apprehension (Shankman & Klein, 2003). These models make similar assumptions about 
the way affect is structured in depression and anxiety, but operationalize the framework 
in terms of brain-activation patterns in reaction to stimuli instead of questionnaire scores.           
 
1.6.4 The hierarchical model 
The realisation that Negative Affect is a very broad severity-defining construct with many 
underlying specific dimensions that account for the variation across patients has led 
researchers to take the tripartite model a step further. Several authors (Zinbarg & Barlow, 
1996; Brown et al. 1998; Mineka et al. 1998; Krueger & Finger, 2001; Kotov, 2011) 
proposed that rather than to coexist, the dimensions of the tripartite model should be 
seen in a hierarchical structure: Negative Affect was defined as a general distress factor 
with several underlying specific dimensions, including positive affect and somatic arousal, 
but also other dimensions that capture the specific features of different anxiety disorders. 
This hierarchical model has been proven very successful in explaining how different DSM 
diagnoses are interrelated in the general population (Watson et al., 2005). Depression 
and GAD on one hand and anxiety disorders on the other hand can be grouped in 
separate factors under the umbrella of one broad negative affect factor (Krueger, 1999; 
Vollebergh et al., 2001; Watson, 2005). The disorders that can be grouped under negative 
affect are often referred to as ‘internalising’ disorders, as opposed to ‘externalising’ 
disorders, such as substance abuse and antisocial behaviour, which fall under their own 
factor (Krueger, 1999). All internalising disorders are thought to have a largely shared 
aetiology, which explains why they co-occur so often (Watson et al., 2005). The same 
rationale applies to the externalising disorders.  
Recently, researchers have focussed on defining the sub-dimensions that are 
necessary to cover all internalising disorders. Watson et al (2007), not straying too far 
away from the structure of the DSM classification, developed the inventory of depressive 
and anxiety symptoms (IDAS) to measure smultiple sub-dimensions: suicidality, lassitude, 
insomnia, appetite loss, appetite gain, ill temper, well-being, panic, social anxiety, 
traumatic intrusions, general depression and dysphoria, each of which are associated with 




collected with this instrument had a hierarchical structure, operationalized in a bifactor 
factor model with one general latent factor, explaining variation in all assessed 
symptoms, and several specific latent factors explaining variation in subsets of symptoms 
(Simms et al., 2008). Importantly, the hierarchical, bifactor model was also found to fit 
well on data collected with other instruments (Simms et al., 2011; Den Hollander-Gijsman 
et al., 2011). 
 
1.6.5 The hierarchical model versus the tripartite model 
What distinguishes the hierarchical model from the tripartite model is that the former 
defines negative affect as a latent factor that loads on all lower level dimensions. 
Negative Affect is thus solely represented in the high covariances between the lower level 
dimensions. Measures that aim to assess these lower level dimensions consequently do 
not include a common Negative Affect scale (e.g. the IDAS). In contrast, the tripartite 
model defines negative affect as a part of a symptom profile that can be measured 
alongside other, more specific dimensions. The hierarchical model has the advantage that 
it works elegantly to explain the structure of psychopathology. The tripartite model has 
the advantage that all of its dimensions, including Negative Affect, can be easily measured 
and used as variables in etiological research. Thus, although the hierarchical model  may 
be superior in describing how disorders co-occur within the DSM in the way they do, the 
tripartite model is a more descriptive model that can be used to describe an individual’s 
clinical state with a dimensional profile, irrespective of DSM-diagnosis. Both approaches 
have potential clinical and scientific use.  
 
1.7 Towards the use of dimensions in the DSM 
Dimensional approaches have gained a lot of attention as potential alternatives or 
additions to the DSM. Several dimensional models – especially for depression and anxiety 
- have proven to be structurally valid and effective in describing patients’ clinical states.  
Some work groups have investigated whether it is possible to implement a 
paradigm shift and add dimensions to the existing system or to completely replace some 
categories with dimensions in the DSM-V (Helzer et al., 2008). The latter has, for instance, 
been proposed for Axis-II personality disorders and there is a fair chance that Axis II will 
become largely dimensional in the DSM-V, mainly because widely accepted dimensional 
operationalisations of personality have been around for decades (e.g. the MMPI; the Big 
Five) and have already become a trusted part of the working clinicians’ vocabulary. 
However, especially for those, who work in a strictly medical environment, the transition 
from Axis-II disorders to dimensions will be less natural and it will probably take time 
before the new approach will be completely trusted and accepted within the field.   
Unfortunately, the debate has been much more complex with regard to Axis-I 
disorders. Several dimensional approaches have been developed for depression and 
anxiety, autism and psychosis. However, most find it premature to introduce dimensions 
into the DSM and have plausible objections against it, some of which are discussed below. 




1.7.1 Coverage and integration  
The most general objection to introducing dimensions into the DSM-V is that there is 
currently no dimensional model that is ready to be implemented as the clinical standard. 
Most published dimensional models cover a limited range of disorders (e.g. depression or 
autism or psychosis), each offering strong proof of concept but not a readily usable clinical 
approach. Although recent attempts to integrate a broader range of symptoms in a single 
model have been quite successful (e.g. Watson, 2005), no well-validated model covers all 
clinically relevant symptoms that would be needed for daily diagnostic practice.   
        
1.7.2 Acceptability of dimensions 
The current psychiatric system has been designed around the DSM. Clinicians, scientists, 
insurance companies and drug administration bodies such as the Federal Drug 
Administration have all become used to thinking in terms of categorical diagnoses. 
Describing patients with DSM-diagnoses has become second nature within the field, 
making any alternative approach seem unintuitive.  
Even if an all-encompassing, completely valid and intuitively acceptable 
dimensional approach existed, introduction into the DSM would have many undesirable 
side effects. For instance, additional dimensional ratings could increase the workload for 
already busy clinicians (Frances, 2009). More generally, a shift to a dimensional paradigm 
would have severe consequences for the continuity within the field: mental health care 
administration systems would all need to be reformed and previous DSM-based scientific 
findings would become hard to interpret (First, 2005). Although realistic and relevant, 
these objections would be rendered obsolete if a dimensional approach was proven to 
have significant clinical and scientific benefits. However, as long as dimensional models 
remain in the realm of theory and have not been operationalized for actual practical 
applications, these objections stand firmly. As Frances (2009) aptly stated: “…introducing 
a botched dimensional system prematurely into DSM–V may
 
have the negative effect of 
poisoning the well for their future
 
acceptance by clinicians … “.  
 
1.8 The validity of dimensions 
It is fair to state that if DSM categories were to be replaced because they lack validity, the 
dimensional alternative should at least be superior in this aspect. Although many factor-
analytical studies have yielded strong support for the internal validity of dimensional 
models for depression and anxiety, this does not mean that the dimensions that make up 
these models automatically have any biological or clinical significance. In fact, factor-
analytical models only explain the structure of variables that they were designed to 
explain: the symptom-assessments that formed the input-data for the model. 
Dimensional models should also explain something more and should thus be associated 
with other variables, such as different etiological factors and, ideally, different clinical 




The external validity of current dimensional models is far from established and has 
received far less attention than their internal validity. With regard to the tripartite model, 
some etiological studies have been conducted showing that Negative Affect and Positive 
Affect  are associated with biological factors, such as the HPA-axis (e.g. Veen et al., 2011). 
Also, studies of the course and outcome of psychopathology have shown that NA and PA 
predict the outcome of depression and anxiety in certain settings (e.g. Joiner & Lonigan, 
2000; Lonigan et al., 2003; Clark et al., 2003). However, these studies have been limited in 
relative size and scope, when compared to studies of internal validity, summarized in 
paragraph 1.6.3.  
Meaningful associations between dimensions and etiological factors, such as 
genetic, biological and environmental factors could be established where DSM diagnoses 
show inconsistent or very small associations. If dimensions really add something on top of 
DSM diagnoses in terms of explanatory power and are shown to have their own 
underlying mechanisms, this would be strong evidence that dimensions are not just 
psychometric constructs, but naturally occurring phenomena (Kendell & Jablensky, 2002). 
The value of dimensions can only be established if they are shown to represent endpoints 
of different etiological mechanisms. Ideally, factor analytical and etiological research 
should thus be combined for the validation of dimensional psychopathology.   
 
1.9 The current project 
The aim of this dissertation was (1) to further improve measurement of dimensions of 
depression and anxiety by improving the validity of the measurement scales and (2) to 
investigate the added value of the measured dimensions in etiological and clinical 
psychiatric research.    
The first step was to find optimal ways to measure dimensions across different 
settings. In Chapter 2, the development and validation of an instrument that can be used 
to efficiently measure the three dimensions of the tripartite model is described. In 
Chapter 3, a pragmatic approach is described to optimally measure specific symptom 
dimensions, extracted from an already widely used self-report questionnaire.  
The second step of the project was dedicated to the investigation of associations 
between dimensions and a range of potential etiological factors and to establish whether 
the dimensions did show more specific associations. In Chapter 4, a study of the 
association between dimensions and the HPA-axis is described. In Chapter 5, a study of 
the associations between dimensions and different metabolic factors is described. 
Chapters 6 describes studies of the dynamic associations between dimensions and 
different types of life events. 
The third step of the project was aimed to explore the added value of dimensions 
in clinical research. In Chapter 7 and Chapter 8 investigations of the utility of different 
dimensional approaches to predict the course and outcome of psychopathology over a 2 








Development and Validation of a 30 Item Short Adaptation of the 










The original Mood and Anxiety Symptoms Questionnaire (MASQ) is a 90 item self report, 
designed to measure the dimensions of Clark and Watson’s tripartite model. We 
developed and validated a 30-item short adaptation of the MASQ: the MASQ-D30, which 
is more suitable for large scale psychopathology research and has a clearer factor 
structure. The MASQ-D30 was developed through a process of item reduction and 
grouping of the appropriate subscales in a sample of 489 psychiatric outpatients, using a 
validated Dutch translation, based on the original English MASQ, as a starting point. 
Validation was done in 2 other large samples of respectively 1461 and 2471 subjects with 
an anxiety, somatoform and/or depression diagnosis or no psychiatric diagnosis. 
Psychometric properties were investigated and compared between the MASQ-D30 and 
the full (adapted) MASQ. A 3-dimensional model (negative affect, positive affect and 
somatic arousal) was found to represent the data well, indicating good construct validity. 
The scales of the MASQ-D30 showed good internal consistency (all alphas > 0.87) in 
patient-samples. Correlations of the subscales with other instruments indicated 
acceptable convergent validity. Psychometric properties were similar for the MASQ-D30 
and the full questionnaire. In conclusion, the MASQ-D30 is a valid instrument to assess 
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The validity of the traditional conceptual distinction between anxiety and depression has 
often been challenged. Anxiety and depressive moods often co-occur, and their key 
symptoms show substantial overlap (Mineka et al., 1998). As a result, self report 
instruments that assess symptoms of anxiety and depression are often highly correlated, 
indicating only modest discriminant validity (Clark and Watson, 1991). With their 
tripartite model, Clark and Watson (1991) proposed a way to model and assess both the 
shared and distinct symptoms of anxiety and depression and to circumvent the problem 
of comorbidity. The model is based on the assumption that mood can be dissected into 
two components: Negative Affect (NA) and Positive Affect (PA) (Tellegen et al., 1999). 
Clark and Watson (1991) added a third dimension of Somatic Arousal (SA). Whereas NA is 
characterized by aversive emotional states such as fear, anger and guilt that are 
associated with both anxiety and depression, PA represents positive emotional states 
such as feeling active, excited, delighted, enthusiastic and interested. A lack of PA is 
described as feeling ‘tired and sluggish’ and is associated with depressive moods (Clark 
and Watson, 1991). The SA dimension represents symptoms of physiological hyperarousal 
such as trembling, shaking, dizziness, sweating and heart racing. These symptoms 
appeared to better differentiate anxiety (especially panic disorder) from depression than 
symptoms of subjective fear (Joiner et al., 1999). The tripartite model has found broad 
acceptance and is supported by several studies in psychiatric patients (Joiner et al., 1996; 
Keogh and Reidy, 2000; Chorpita and Daleiden, 2002; Marshall et al., 2003; De Beurs et 
al., 2007). To measure the dimensions of the tripartite model, Watson et al. (1995a, 
1995b) developed the Mood and Anxiety Symptoms Questionnaire (MASQ). The MASQ is 
a 90 item self-report questionnaire that consists of five symptom scales. The Anhedonic 
Depression (AD) scale measures a lack of PA and the Anxious Arousal (AA) scale measures 
symptoms of SA. The General Distress (GD) scale measures non-specific symptoms of 
General Distress or NA, the General Distress-Depression (GD-D) scale measures NA 
symptoms that are traditionally considered depressive and the General Distress Anxiety 
(GD-A) scale measures NA symptoms that are traditionally viewed as anxious. Watson et 
al. (1995a, 1995b) found the MASQ scales to have acceptable psychometric properties. 
This was replicated later (Reidy and Keogh, 1997; Keogh and Reidy, 2000). Although the 
MASQ was found to be a good representation of the tripartite model by De Beurs et al. 
(2007), other authors found that a 3-dimensional model did not adequately fit the MASQ, 
when tested with confirmatory factor analysis (CFA) (Burns and Eidelson, 1998; Boschen 
and Oei, 2006; Buckby et al., 2008). In addition, about a third of the items appeared to 
show weak or complex loadings on the three factors of the tripartite model (Bedford, 
1997; Keogh and Reidy, 2000; De Beurs et al, 2007). Removal of these items could 
improve the validity of the MASQ (Boschen and Oei, 2007). In addition, the questionnaire 
is rather lengthy, which hampers inclusion in a comprehensive assessment. The 
administration is time-consuming and therefore expensive. The aim of the present study 




can be used in large scale prospective cohort studies and trials, taking the Dutch 
translation of the MASQ that is based on the original English MASQ, as starting point. Use 
of short and self-report questionnaires is the most effective method to decrease 
respondent burden, increase response rates and to reduce possible bias due to selective 
loss (Dillman et al., 1993). Therefore, we developed a 30 item short adaptation of the 
MASQ (MASQ-D30) to use in large scale research into shared and distinctive features of 
anxiety and depression. We aimed for the psychometric qualities to be as close as 
possible to the full questionnaire. To evaluate this, a number of analyses were conducted. 
First, we assessed indices of internal consistency and evaluated the inter-correlations of 
the AD, AA and GD scales. Second, we investigated convergent validity by comparison of 
the 3 scale scores with other psychometric instruments. Third, we compared these 
psychometric results between the MASQ-D30 and the full questionnaire. Fourth, we 
investigated the dimensional structure of the MASQ-D30 with confirmatory factor 
analysis. The initial development of the short-form was done by use of data from a large 
sample of psychiatric outpatients (n = 489): the Routine Outcome Monitoring (ROM). We 
carried out subsequent analyses with more data from ROM (n = 1461) and with data from 
a large sample of psychiatric patients: the Netherlands Study of Depression and Anxiety 
(NESDA,_n=2471).  
 
2. 2 Methods 
 
Participants and procedures 
 
Routine outcome monitoring participants 
The sample in which the MASQ-D30 was developed (sample 1) and the evaluation sample 
(sample 2) both consisted of participants in a Routine Outcome Monitoring (ROM) 
programme (De Beurs and Zitman, 2007). These samples were composed of outpatients 
who were referred by General Practices to different clinics of the Rivierduinen Psychiatric 
Hospital with an anxiety, mood or somatoform disorder between January 2002 and 
December 2003 (sample1) and between July 2006 and May 2007 (sample2). About 80% of 
all referred patients participated in the ROM project. Patients were excluded when they 
refused to participate, they withheld their consent for use of their data for research, the 
assessment was deemed too invasive or their mastery of the Dutch language was 
insufficient. All participants were administered a standardized diagnostic interview and 
several rating scales (for both somatic and/or mental complaints) during an assessment 
session with a trained research nurse. A computer program was used to administer 
various self report questionnaires. In sample 1 (n=489), there were 297 women (60.7%) 
and 192 men (39.3%) and the mean age was 37.5 years (SD=11.7, range 18-65). In sample 
2 (n=1461), there were 941 women (64.4 %) and 520 men (35.6%) and the mean age was 
38.7 years (SD=13.1, range 18-65).  
 





Sample 3 was composed of participants in the NESDA study (Penninx et al., 2008). NESDA 
is a large scale longitudinal research project, in which 2981 participants with an anxiety 
disorder, depressive disorder and no psychiatric diagnosis are included from different 
locations in the Netherlands and in different settings (community, primary care and 
mental health care organizations). The baseline assessment consisted of a blood draw, a 
cognitive task, a medical exam, a psychiatric interview and administration of several self 
report questionnaires. Of all participants, 82.9% completed all questionnaires that were 
used for the present analyses (n=2471). In sample 3 there were 1652 women (66.9 %) and 
819 men (33.1%) and the mean age was 42.1 years (SD=13.1, range 18-65).  
 For subgroup analyses, three subsamples were drawn from sample 3, based on 
mental health care setting. A primary care group (n=909) was composed of patients who 
received care in general practices (for general, somatic and/or mental complaints), a 
mental health care group (n=621) was composed of patients who were referred to mental 
health care organizations and a healthy control group (n=577) was composed of subjects 
without any lifetime psychiatric diagnosis. The protocol of the NESDA study was approved 
centrally by the Ethical Review Board of the Leiden University Medical Centre and by local 





Dutch translation based on the MASQ  
All participants in sample 1 and sample 2 filled out the Dutch translation that was based 
on the original MASQ. The translation process and psychometric evaluation of this 
adapted MASQ were described by De Beurs et al. (2007). Like in the original English 
version of the MASQ, on this adapted MASQ individuals are asked to rate how much in 
the past week they have experienced “feelings, sensations, problems and experiences 
that people sometimes have” on a 5-point Likert scale, with 1 being “not at all” and 5 
being “extremely”. Sum scores were computed, using the items described by De Beurs et 
al. (2007) with a GD scale of 20 items, an AD scale of 22 items and an AA scale of 18 
items. 
 
Short adaptation of the MASQ (MASQ-D30)  
For the development of the short-form, the methodological steps for short-form 
development described by Smith et al. (2000) were followed. In short, the items of the 
MASQ-D30 with their loadings on the dimensions of the tripartite model are shown in 
Table 2.1. A principle components analysis with varimax rotation was conducted in 
sample 2 using the SPSS 14.0 statistical package (SPSS Inc. Chicago, Illinois, USA). 
Inspection of a scree-plot suggested that three factors could be extracted that 




factor loadings >0.50) with sufficient ability to differentiate (difference of at least 0.20 
between loadings on different factors) were selected from each of the three extracted 
factors to construct short scales. Next, the content of the selected items was evaluated by 
clinical experts and several redundant and overlapping items were replaced by items with 
a lower factor loading (none <0.50) that contributed to better content coverage.   
 
Other instruments in sample 1 and 2 (ROM) 
The Mini International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998; Van Vliet 
and De Beurs, 2007: Dutch version), a standardized diagnostic interview with 23 modules 
that assess the presence of DSM criteria for the main Axis I psychiatric disorders (mood, 
anxiety, psychotic, somatoform and eating disorders) was used to assess diagnostic 
status. The Brief Symptom Inventory (BSI) (Derogatis, 1975: De Beurs and Zitman, 2006: 
Dutch version), a list of 53 symptoms, was administered to all patients. A 5-point Likert 
scale (0 =“not at all”, 4=“extremely”) was used to assess to what extent respondents 
experienced each of these symptoms in the past week. The BSI, with subscales for 
somatic complaints, depression, anxiety, phobic avoidance and interpersonal sensitivity 
was completed by all respondents. The total BSI score was used as an index of general 
psychopathology. The Beck Depression Inventory II (BDI) (Beck and Steer, 1987; Beck et 
al., 2002: Dutch version) was completed by patients with a current major depression or 
dysthymia diagnosis. The psychopathology of the patients was also rated by the research 
nurse, using two subscales from a shortened version of the Comprehensive Psychiatric 
Rating Scale (CPRS), a scale of 25 items (Goekoop et al., 1991: Dutch version). The used 
subscales were the Brief Anxiety Scale (BAS, 10 items) and the Montgomery-Åsberg 
Depression Rating scale (MADRS, 10 items). Different response options for each of the 
items of the CPRS were rated on a 7 point scale anchored at 4 points (1, 3, 5 and 7).  
 
Other instruments in sample 3 (NESDA) 
The Composite International Diagnostic Interview (CIDI, WHO version 2.1) was used to 
assess the presence of DSM-IV criteria for depressive disorders (i.e. major depressive 
disorder and dysthymia) and anxiety disorders (i.e. panic disorder, social phobia, 
generalized anxiety disorder and agoraphobia). The Beck Anxiety Inventory (BAI) (Beck et 
al., 1988), a self report of 21 items rated on a 4-point severity scale was used to assess 
affective and somatic symptoms of anxiety. The Inventory of Depressive Symptomatology 
(IDS) (Rush et al., 1996; Nolen and Dingemans, 2004: Dutch translation), a self report of 
30 items rated on a 4-point severity scale (1=“not at all”; 5=“extremely”) was used to 
assess symptoms of depression. The Distress scale of the Four Dimensional Symptoms 
Questionnaire (4DSQ-distress) (Terluin et al., 2006), a self report of 16 items, rated on a 5-
point scale (1=”no”, 2=”sometimes”, 3=”regularly”, 4=”often”, 5=”very often or 
continuously”) was used to assess general psychological distress. The 4-DSQ was originally 
developed in Dutch. All other instruments were Dutch translations of the original English 
versions. 





Analyses were conducted using the SPSS 14.0 and EQS 6.1 (Multivariate Software Inc., 
Encino, California, USA) software packages. First, the internal consistency coefficients 
(Cronbach’s alpha) of the scales were computed. Second, the bivariate correlations 
between the MASQ-D30 subscales were computed to assess whether the subscales 
measure distinct constructs. Third, bivariate correlations between the MASQ-D30 
subscales with other instruments were calculated to investigate convergent validity. 
Fourth, internal consistency and validity were compared between the MASQ-D30 and the 
full MASQ. Fifth, the analyses were repeated in sample 3 and the subsamples to obtain 
independent replications. Sixth, confirmatory factor analysis (CFA) was used in sample 3 
and the subsamples to evaluate the fit of a 3-dimensional model to the data, based on a 
maximum likelihood estimation method. To assess the fit of the model to the data with 
CFA, several approaches can be used. Model fit can be assessed with a χ2 statistic or a 
robust Satorra-Bentler (S-B) χ2 statistic, which is less impacted by deviations from 
normality. In this test, a non significant result indicates good fit. However, in large 
samples the χ2 statistic is oversensitive to minor derivations from perfect model fit, which 
makes it practically not useful for this study. Thus, the fit of the model was assessed with 
fit-indices that are less affected by sample size (Byrne, 2006). The used fit indices were: 
the comparative fit index (CFI), the normed fit index (NFI), the non-normed fit index 
(NNFI) and the root mean square error of approximation (RMSEA). A CFI, NFI and NNFI of 
at least 0.90 indicate satisfactory fit and a RMSEA, lower than 0.06 indicates that the 
model is a good descriptor of the data (Byrne, 2006).  
 
Missing Data 
In samples 1 and 2, no data were missing. In sample 3, 2624 (90.8%) of 2891 subjects 
completed the MASQ-D30; 357 subjects (9.2%) did not return the MASQ-D30 
questionnaire they received to complete at home. This group of non-responders had a 
higher percentage of males, a lower mean age and fewer years of education than the 
group of responders, which could have made our sample slightly less representative.  
 Of the 2624 subjects that completed the MASQ-D30, 153 (5.8%) subjects had one 
or more missing responses. All items were categorical with a strongly skewed distribution. 
Therefore, we decided not to impute the missing values, because each method could 
introduce new sources of bias into our data. Thus, subjects with missing values were 
excluded from the analyses. This resulted in a sample size of 2471 subjects. We checked 
whether the psychometric results of the MASQ-D30 differed between this sample and the 
original sample of 2624 subjects and found that the psychometric results were largely 
similar. This makes it unlikely that exclusion of incomplete cases has biased our results.  
 
2.3 Results 
Throughout the results section and in the tables, the name MASQ refers to the full Dutch 





Diagnoses and demographic variables 
The demographic information and the lifetime diagnoses of depressive, anxiety, 
somatoform and comorbid diagnoses for each of the three studied samples are shown in 
Table 2.2. From the table it can be seen that there is a considerable amount of 
comorbidity between anxiety and depression in each of the samples. However, the 
percentages of subjects with anxiety, depressive or both disorders differ significantly 
between the samples. Somatoform disorders were only diagnosed in samples 1 and 2; the 
percentages of these disorders (single and together with anxiety and/or depression) did 
not differ significantly between the samples. 
The observed differences between the developmental and validation samples make it 
possible to evaluate the consistency of the characteristics of the MASQ-D30 across 
different patient groups.   
 
Internal Consistency 
Internal consistency coefficients (Cronbach’s alpha) for each of the three scales are 
presented in Table 2.3. These ranged from 0.93 to 0.96 for the full MASQ and from 0.87 
to 0.93 for the MASQ-D30. We used the Spearman-Brown formula (Nunnally and 
Bernstein, 1994, pp. 262-264) to assess whether the lower alphas of the MASQ-D30 scales 
could be attributed to the reduced number of items. Using this formula we computed the 
estimated alpha coefficients of the MASQ-D30 scales when expanded back to original 
length. These estimated alpha coefficients ranged from 0.91 to 0.96, indicating that the 
internal consistency was preserved with item reduction.  
 In sample 3, we found a similar pattern of Cronbach’s alpha coefficients (0.85 to 
0.95) for the MASQ-D30. In the subgroups, the alpha coefficients ranged from 0.81 to 
0.94 in the primary care group and from 0.85 to 0.94 in the mental health care group. In 
the healthy control group, the alphas of the GD and AD scale were 0.84 and 0.93 
respectively. However, for the AA scale, alpha was considerably lower (0.70), which 
indicated only moderate internal consistency. These results indicate that the MASQ-D30 
scale reliability, estimated by internal consistency, is good and stable over different 
patient subsamples and only less for the AA scale in non-patients.  
 
Subscale inter-correlations   
Table 2.3 shows the correlations between the subscales of the MASQ-D30 and the full 
MASQ. In sample 2 the AD and AA scales showed low inter-correlations (MASQ: r=0.35; 
MASQ-D30: r=0.30), while both scales showed considerable correlations with GD (MASQ: 
r=0.62,  r=0.59; MASQ-D30: r=0.56, r=0.57). These results were largely similar for the 
MASQ and the MASQ-D30, indicating that the scale inter-correlations were maintained in 
the MASQ-D30. Comparable patterns of scale inter-correlations were found in sample 3 
and the sub-samples. Together, these results implicate that the AD and AA scales assess 




fairly distinct symptom domains, while GD is related to both AD and AA. This is in line 
with the tripartite model. 
 
Table 2.1: Factor loadings on the dimensions of the tripartite model for the MASQ-D30 
in 489 subjects    






1 Felt confused 0.59 0.12 0.35 
4 Felt worthless  0.76 0.29 0.05 
7 Felt irritable 0.54 0.19 0.34 
10 Felt hopeless 0.76 0.28 0.23 
12 Blamed myself for a lot of things 0.70 0.10 0.10 
13 Felt dissatisfied with everything 0.67 0.35 0.20 
17 Felt pessimistic about the future 0.65 0.23 0.10 
23 Felt inferior to others 0.70 0.17 0.08 
25 Had trouble making decisions 0.62 0.19 0.19 
28 Worried a lot about things 0.62 0.19 0.24 
3 Felt successful 0.18 0.67 0.13 
6 Felt really happy 0.35 0.62 0.13 
9 Felt optimistic 0.27 0.71 0.02 
11 Felt like I was having a lot of fun 0.23 0.75 0.14 
14 Felt like I accomplished a lot  0.17 0.73 0.06 
16 Felt like I had a lot to look forward to 0.15 0.71 0.04 
19 Felt really talkative 0.16 0.58 0.02 
22 Felt really ‘up’ or lively 0.27 0.73 0.13 
26 Felt like I had a lot of energy  0.21 0.69 0.07 
29 Felt really good about myself 0.39 0.68 0.09 
2 Startled easily  0.35 -0.06 0.57 
5 Felt nauseous 0.17 0.09 0.58 
8 Felt dizzy or light-headed 0.14 0.14 0.66 
15 Was trembling or shaking 0.18 0.10 0.72 
18 Had pain in my chest 0.01 0.04 0.61 
20 Had hot or cold spells 0.18 0.14 0.65 
21 Was short of breath 0.12 0.04 0.57 
24 Muscles were tense or sore  0.05 0.12 0.65 
27 Heart was racing or pounding 0.20 0.08 0.61 
30 Had trouble swallowing 0.14 -0.04 0.61 
Results from factor analysis in sample 1. Only the factor loadings for the short form 
items are presented, the remaining 60 MASQ items are not included. The highest 





Table 2.2: Demographic and diagnostic information for samples 1, 2 and 3  
 Sample 1 Sample 2 Sample 3 P 
value1 
Source study ROM ROM NESDA  
N 489 1461 2471  
Male 192 (39.3%) 520 (35.6%) 819 (33.1%) 0.03 
Female 297 (60.7%) 941 (64.4%) 1652 (66.9%)  
Age mean (SD)   37.5 (11.7) 38.7 (13.1) 42.1 (13.1) <0.001  
Age range  18-65 18-65 18-65  
Lifetime psychiatric diagnoses:     
Diagnostic instrument MINI MINI CIDI  
Only depressive disorder 76 (15%) 302 (21%) 478 (19%) 0.05 
Only anxiety disorder 103 (21%) 371 (25%) 294 (12%) <0.001 
Only somatoform disorder 28 (6%) 70 (5%) - 0.48 
Comorbidity: depression and 
anxiety 
105 (22%) 294 (20%) 1122 (46%) <0.001 
Comorbidity: depression and/or  
anxiety and Somatoform disorder 
42 (8%) 128 (9%) - 0.91 
No lifetime diagnosis  135 (28%) 296 (20%) 577 (23%) 0.002 
 
1)Tests of significance using ANOVAs or χ2-tests. ROM = Routine Outcome Monitoring; 
NESDA = Netherlands Study of Depression and Anxiety; MINI = Mini International 




Table 2.4 shows the correlation coefficients between the scales of the MASQ-D30 and the 
MASQ (Dutch adaptation) and other instruments. The GD scale of the MASQ-D30 was 
highly correlated with the BSI-total scale (r=0.83) and the 4DSQ-distress scale (r=0.83). In 
addition, correlations of GD with more specific scales ranged from 0.53 with the BSI- 
somatisation scale to 0.85 with the BSI-depression scale. These results indicate that the 
GD is associated with general psychological distress, depression, anxiety andsomatisation. 
The AD scale of the MASQ-D30 showed robust but modest correlations with the MADRS 
(r=0.61), the BDI-total (r=0.56), the BDI-affective (r=0.57), the BSI-depression (r = 0.60) 
and the IDS (r =0.67). Conversely, AD showed lower correlations with measures of anxiety 
and somatisation (correlation coefficients ranged from 0.31 with BSI-somatic to 0.49 with 
the BAI). These results indicate that the AD scale is moderately specific to depression and 
less to anxiety and somatisation. The AA scale of the MASQ-D30 showed considerable 
correlations with measures of anxiety and somatisation (BSI-somatic: r=0.89, BAI: r =0.76, 
BSI-anxiety: r=0.70 and BAS: r=0.60) and lower correlations with measures of depression 
(MADRS: r=0.52, BSI-depression:  r=0.51, BDI-affect: r=0.44). This suggests that AA is 




mostly specific to anxiety and somatisation and less to depressed state. Remarkably, the 
correlation of the IDS with AD (r=0.67) was similar to that with AA (r=0.66), while the IDS 
is intended as a measure of depression. This could be caused by the fact that the IDS is 
heterogeneous and also measures somatic and anxious symptoms along with symptoms 
of depression. Table 2.4 reveals that the correlations are largely similar for the MASQ-D30 
and MASQ scales. This indicates that the convergent validity of the MASQ is preserved in 
the MASQ-D30.  The correlations of the MASQ-D30 scales with the BAI, IDS and the 4DSQ- 
distress scale were similar in the 3 healthcare subgroups of sample 3. Thus, convergent 
validity was consistent across different health care settings. 
 
Table 2.3: Reliability and inter correlations of the MASQ-D30 scales and the full MASQ 
scales  












Item number 20a 10 22a 10 18a 10 
Sample 2 GD 0.95 0.91 (0.95)b - - - - 
(n=1461) AD 0.62 0.57 0.96 0.93 (0.96)b - - 
 AA 0.59 0.56 0.35 0.30 0.93 0.87 (0.92)b 
Sample 3 GD - 0.92 - - - - 
(n=2471) AD - 0.68 - 0.95 - - 
 AA - 0.63 - 0.48 - 0.85 
        
HC GD - 0.84 - - - - 
(n=577) AD - 0.48 - 0.93 - - 
 AA - 0.45 - 0.26 - 0.70 
PC GD - 0.91 - - - - 
(n=909) AD - 0.62 - 0.94 - - 
 AA - 0.54 - 0.39 - 0.81 
MHC GD - 0.90 - - - - 
(n=621) AD - 0.62 - 0.94 - - 
 AA - 0.53 - 0.33 - 0.85 
Cronbach’s alpha coefficients are underlined; MASQ = Dutch Adaptation of the Mood and 
Anxiety Symptoms Questionnaire; MASQ-D30 = Short Form of the Dutch adaptation of the 
MASQ; GD =General Distress; AD = Anhedonic Depression; AA = Anxious Arousal; HC = healthy 
control group; PC = primary care group; MHC = mental health care group (all correlations  p < 
0.01).  
aComputation of GD, AD and AA scales following de Beurs et al. (2007).  






Construct validity  
We conducted CFA to assess the fit of a 3 factor model to the MASQ-D30 data of several 
samples, with items 1, 4, 7, 10, 12, 13, 17, 23, 25 and 28 loading on a GD factor, items 3, 
6, 9, 11, 14, 16, 19, 22, 26, and 29 loading on an AD factor and items 2, 5, 8, 15, 18, 20, 21, 
24, 27, and 30 loading on an AA factors. The 3 factors were left free to inter-correlate. 
Table 2.5 shows the χ2 statistics and indices. The 3 factor model showed acceptable fit to 
the MASQ-D30 data of sample 3, with fit indices that all exceeded their respective critical 
cut-off values (NNFI, NFI and CFI > 0.90 and RMSEA < 0.06). Similar results of acceptable 
model fit were found in the primary care group, mental health care group, healthy control 
group and the male and female subpopulations of sample 3. These results indicate that 
the MASQ-D30 represents the 3 dimensions it was designed to measure and that the 
underlying structure is invariant over different subpopulations, which supports the 
construct validity of the instrument.  
 
2.4 Discussion 
We present a shortened 30 item adaptation of the MASQ: the MASQ-D30, which we 
constructed by use of factor analysis and the additional judgement of clinical experts. The 
MASQ-D30 questionnaire was constructed to represent the dimensions of the tripartite 
model and we demonstrated its scales to have acceptable internal consistency and 
convergent validity that were comparable with the full MASQ. In addition, we found 
support for the construct validity of the MASQ-D30.   
The MASQ-D30 has two major advantages. First, problematic items with weak or 
complex loadings in the MASQ are not present in the MASQ-D30, which is likely to make it 
a more stable representation of the tripartite model. Second, administration of the 
MASQ-D30 takes less time, which makes the application less expensive.  
The MASQ-D30 represents an underlying tripartite structure, analogue to the model that 
has been found in earlier studies with the MASQ (Keogh and Reidy, 2000; De Beurs et al., 
2007). Research on the tripartite model has mostly relied on the study of associations 
between self report measures, structured interviews and observer ratings (Watson et al., 
1995a, b; Keogh and Reidy, 2000; De Beurs et al., 2007) and has regularly used 
instruments that were not primarily designed to measure the dimensions of the tripartite 
model (De Beurs et al., 2005). Because of its improved applicability, the MASQ-D30 can 
help to study the tripartite model more thoroughly and to compare this dimensional 
approach to the categorical DSM-IV method. In addition, the MASQ-D30 can be used in 
epidemiological studies and trials to study the relation between the tripartite model and 
biological markers and psychosocial determinants. 
The MASQ-D30 could eventually be used to place the tripartite model in a broad 
dimensional framework of anxiety and depression together with aspects of other models, 
like the approach-withdrawal model and the valence-arousal model. These models have a 
comparable theoretical approach but a different perspective and make assumptions 




about the neural substrates of distinct behavioural dimensions that could underlie 
symptoms of depression and anxiety (Shankman and Klein, 2003).  
 
Table 2.4: The bivariate correlation coefficients of the MASQ-D30 and full MASQ scales 
with rating scales and self-report measures in sample 2 (n =1461), sample 3 (n = 2471), 
the healthy control group (HC), the primary care group (PC) and the mental health care 
group (MHC) 
Scale:  General  
Distress  
(GD) 













MADRS 1416 0.72 0.70 0.64 0.61 0.53 0.52 
BAS 1416 0.57 0.56 0.45 0.42 0.60 0.60 
        
BDI-affa  961 0.73 0.71 0.61 0.57 0.49 0.47 
BDI-soma 961 0.64 0.63 0.52 0.48 0.58 0.55 
BDI-coga 961 0.71 0.72 0.47 0.44 0.42 0.40 
BDI-tota 961 0.79 0.78 0.60 0.56 0.57 0.55 
        
BSI-dep 1456 0.87 0.85 0.63 0.60 0.52 0.51 
BSI-anx 1456 0.67 0.66 0.40 0.36 0.70 0.70 
BSI-pho 1456 0.58 0.57 0.39 0.34 0.59 0.58 
BSI-som 1456 0.54 0.53 0.35 0.31 0.88 0.89 
BSI-int  1456 0.70 0.71 0.44 0.40 0.42 0.42 
BSI-tot 1456 0.84 0.83 0.53 0.49 0.72 0.71 
IDS 2471 - 0.75 - 0.67 - 0.66 
BAI 2471 - 0.60 - 0.49 - 0.76 
4DQSd 2471 - 0.83 - 0.67 - 0.65 
        
HC IDS 577 - 0.60 - 0.50 - 0.55 
 BAI 577 - 0.50 - 0.37 - 0.61 
 4DQSd 577 - 0.65 - 0.41 - 0.40 
         
PC IDS 909 - 0.67 - 0.59 - 0.56 
 BAI 909 - 0.48 - 0.37 - 0.68 
 4DQSd 909 - 0.79 - 0.61 - 0.59 
         
MHC IDS 621 - 0.65 - 0.57 - 0.56 
 BAI 621 - 0.45 - 0.28 - 0.72 





Table 4 (continued). Legend: MASQ = Dutch Adaptation of the Mood and Anxiety 
Symptoms Questionnaire; MASQ-D30 = Short Form of the Dutch adaptation of the 
MASQ; MADRS = Montgomery Åsberg Depression Rating Scale; BAS = Brief Anxiety 
Scale; BDI = Beck Depression Inventory II: aff = affectivity, som = somatisation, cog = 
cognition, tot = total score; BSI = Brief Symptom Inventory: dep = depression, anx 
=anxiety, pho = phobic anxiety, som = somatic complaints, int = interpersonal 
sensitivity, tot = total score; IDS = Inventory of Depressive Symptoms; BAI = Beck 
Anxiety Inventory; 4DSQd  = 4-Dimensional Symptoms Questionnaire Distress scale; HC 
= healthy control group; PC = primary care group; MHC = mental health care group (all 
correlations p<0.01 two-tailed) 
a The BDI was only administered to patients who met criteria for a mood disorder. 
 
 
Table 2.5: Results of confirmatory factor analysis with a 3-dimensional model of the 
MASQ-D30 in sample 3, the healthy control group (HC), the primary care group (PC) and 
the mental health care group (MHC) and separately for males and females in sample 3. 
 
Sample N S-Bχ2 a  NFI NNFI CFI RMSEA (90% CI) 
Sample 3 2471 2375.46 0.94 0.94 0.95 0.045 (0.043-0.046) 
PC 909 1149.93 0.91 0.94 0.94 0.045 (0.042-0.048) 
MHC 621 979.35 0.90 0.94 0.94 0.048 (0.044-0.052) 
HC 577 671.60 0.82 0.91 0.92 0.034 (0.030-0.039) 
Male 819 1102.24 0.92 0.94 0.95 0.046 (0.043-0.049) 
Female 1652 1770.30 0.93 0.94 0.94 0.045 (0.043-0.048) 
 
MASQ-D30 = Short Form of the Dutch Adaptation of the Mood and Anxiety Symptoms 
Questionnaire; NFI = Normed fit index; NNFI = non-normed fit index; CFI = comparative 
fit index; RMSEA = root mean-square error of approximation; 90% CI = 90% confidence 
interval  
a)All Satorra-Bentler χ2 statistics with 402 degrees of freedom; all p-values <0.001 
  
 In spite of broad scientific support, some aspects of the tripartite model and the MASQ 
have remained subject of debate. An important point of disagreement in the literature is 
the assumption that elevated SA is specific to anxiety in general. Several studies have 
shown that SA is mostly specific to panic disorder and that other aspects of anxiety are 
underrepresented by the model (Mineka et al., 1998; Joiner et al., 1999; Chorpita, 2002). 
Some authors thus suggest that the tripartite model and the MASQ should be extended to 
grant a more complete representation of anxiety symptoms. Mineka et al. (1998), for 
instance proposed an integrated hierarchical model in which each anxiety syndrome is 
hypothesized to contain a common (NA) and a unique component. In this model, SA is 




defined as a specific component for panic disorder and all other anxiety disorders have 
other unique components. This model was further extended and modified by Watson 
(2005), based on a review of results about the underlying structure of the DSM 
categories. In addition, a symptom level, dimensional approach was described by Watson 
et al. (2005).  
A second issue is that the PA scale largely consists of high-PA reverse-key items 
(for instance, ‘I felt optimistic’). Consequently, the loadings of all high-PA items on one 
factor could be due to methodological artefact rather than a shared underlying construct 
(Brown, 2006). However, a high-PA scale and a low-PA scale were found to be 
interrelated (Watson et al., 1995b), indicating that high and low PA items both represent 
a PA construct.   
The present study has several strengths. First, we developed the MASQ-D30 using 
a systematic method that is firmly based in the psychometric literature (Smith et al., 
2000). Second, large samples from the general population, primary care and mental 
health care were used, which gives our findings about the MASQ-D30 a high degree of 
external validity for the intended fields of use. Third, we used confirmatory factor analysis 
in addition to exploratory factor analysis, which enabled us evaluate and statistically 
confirm the fit of the underlying dimensional structure (Fabrigar et al., 1999).  
There are also some limitations in the present study. First, our results apply to a 
Dutch adaptation of the MASQ. However, we expect that the results from this translation 
are generalizable to English language (and other Western) populations, because the 
Dutch translation of the MASQ was shown to have good psychometric properties that 
were comparable to the original English MASQ (de Beurs et al., 2007). In addition, there 
are no striking cultural differences in the assessment and definition of mental illness 
between the US and the Netherlands as illustrated by the fact that in both countries the 
DSM-IV is used to define mental illness and the fact that other Dutch have not been 
problematic (e.g. Dutch BDI-II, Beck et al., 2002). Second, we only tested the fit of one 
model with CFA, which does not completely rule out the possibility of another, unknown 
better fitting model. Previous studies (Burns and Eidelson, 1998; Boschen and Oei, 2006) 
tested more models (2, 3 and 5 dimensional) based on five original MASQ subscales 
(Watson et al., 1995a, b). However, this structure of 5 subscales was not preserved in the 
MASQ-D30, because it was constructed to be truly 3-dimensional. This made it impossible 
to test the fit of the alternative models from the literature. Third, the used samples 
consist of subjects with a broad range of DSM-IV diagnoses as well as healthy subjects, 
which could conceal differences in factor structure between clinical conditions. However, 
we think that the 3 dimensional structure of the MASQ-D30 should be consistent across 
individuals irrespective of categorical diagnosis. This should be further investigated.  
An important point that should be addressed in future research is comparison of 
the MASQ-D30 to the Mini-MASQ, a short form of the original MASQ (Casillas and Clark, 
2000). The Mini-MASQ consists of 26 items and was developed in the US in healthy 




used as a measure of psychological wellbeing in a community study of lower income 
families (e.g. Cutrona et al., 2000). The MASQ-D30 and the Mini-MASQ share little overlap 
and are thus expected to have different psychometric characteristics, possibly due to 
differences in development sample (psychiatric patients versus community dwelling 
adults) and/or chance effects. These issues should be investigated in subsequent 
research.   
 In conclusion, the MASQ-D30 is a reliable and valid instrument with the advantage 
of being compact and therefore broadly applicable. The questionnaire provides a 
promising basic framework for the study of dimensional psychopathology. Therefore we 
have included the MASQ-D30 in NESDA to investigate the tripartite model in relation to 
biological measures and other external criteria. Large scale efforts like these could 
eventually provide the knowledge that is needed to establish the dimensional approach 
to psychopathology as a credible clinical and scientific supplement for the mainstream 
































The Structure and Dimensionality 
of the Inventory of Depressive Symptomatology Self Report (IDS-SR) in 
Patients with Depressive Disorders 












Background: The inventory of depressive symptomatology self report (IDS-SR) is a widely 
used but heterogeneous measure of depression severity. Insight in its factor structure and 
dimensionality could help to develop more homogeneous IDS-SR subscales. However 
previous factoranalytical studies have found mixed results. Therefore, the present study 
tested which factor structure underlies the IDS-SR and, in addition, if the factors can be 
used as unidimensional subscales. Methods: Confirmatory factor analysis (CFA) was done 
to identify the best fitting factor structure. The study sample consisted of 2600 individuals 
(mean age 40.5 ± 12.1). We assessed model fit in 4 groups: 957 Major Depressive 
Disorder (MDD) patients, 450 remitted MDD patients, 570 patients with an anxiety 
disorder and 623 healthy controls to test the consistency of model fit. Rasch analyses in 
the full sample were used to evaluate and optimize the unidimensionality and 
psychometric quality of the factors.   
Results:  CFA indicated that a 3-factor model fits the IDS-SR data best and is consistent 
across groups, with a ‘mood/cognition’ factor, an ‘anxiety/ arousal’ factor and a ‘sleep’ 
factor. In addition, Rasch analyses indicated that the ‘mood/cognition’ and 
‘anxiety/arousal’ factors could be optimized to be used as unidimensional subscales.  
Limitations: The fit of only 4 models was tested, ranging from a 1- to 4-factor model.   
Conclusions: The IDS-SR is a heterogeneous instrument with a multifactorial underlying 
structure. It is possible to measure more homogenous symptomatology with IDS-SR 
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Major Depressive Disorder (MDD) is a heterogeneous disease; patients vary in terms of 
severity, age of onset, duration, recurrence and symptom profiles (Kendler, 1999). 
Consequently, the ‘depression’ label provides limited information about the particular 
problems experienced by a patient. The description of a patient’s condition in terms of 
symptom dimensions creates possibilities for more specific diagnosis, treatment 
evaluation and research (Shafer, 2006; Andrews et al., 2007). Therefore, in the present 
study we evaluated which factor structure underlies the widely used Inventory of 
Depressive Symptomatology self report (IDS-SR) and whether the identified factors could 
be used as unidimensional subscales.       
 The IDS-SR is a self report questionnaire that was introduced by Rush et al (1986; 
1996) as a measure of depression severity. The IDS-SR comprises all symptoms of 
depression, as defined by the DSM-III-R / IV-TR, including melancholic, atypical and 
anxious symptoms. The questionnaire has been shown to have adequate reliability, 
acceptable validity, good responsiveness and good discriminative ability (Rush et al., 
1996, 2003; Corruble et al., 1999; Trivedi et al., 2004).  
 The IDS was aimed to measure a unitary construct of depressive symptom severity 
(Rush et al., 1996; Trivedi et al., 2004). However, different underlying factor structures 
have been described for the IDS-SR, with solutions of two factors (Bernstein, 2006), three 
factors (Rush et al., 1996) and four factors (Rush et al., 1986). Although the numbers of 
factors are different, the models show conceptual overlap: all the multifactorial models 
make some distinction between a ‘depression/mood’ and an ‘anxiety/somatic’ dimension 
(Bernstein, 2006; Rush et al., 1986; 1996). In addition, the 3-dimensional model contains a 
‘sleeping problems’ factor and the 4-dimensional model contains an ‘atypical’ and an 
‘endogenous’ factor.  
 Differences between the presented structures may be attributed to differences in 
characteristics of the analyzed samples and analytic approaches (Fabrigar et al., 1999). 
One study (Bernstein, 2006) used principal components analysis (PCA) to explore the 
underlying structure of the IDS-SR. Two studies used PCA with a predefined number of 
components to be extracted (Rush et al., 1986, 1996). Yet, confirmatory factor analysis 
(CFA) would provide valuable information about the appropriateness of hypothesized 
factor structures. Trivedi et al (2004) used CFA to test the fit of a 1-factor model to a large 
set of items, including the IDS-SR, and found it to fit well. However, CFA should ideally be 
used to investigate and compare the fit of several hypothesized structural models (Brown 
et al., 2006).   
  A stable factor model for the IDS-SR would have a potential utility in patient care 
and to address specific research questions. It could help uncover clusters of symptoms 
that are systematically related to each other, which could potentially be used as IDS-SR 
subscales. However, before a set of items is used as an additive interval scale, it should be 
determined if it is really unidimensional. This can be investigated with Rasch modelling 




probability of endorsement of each item in an instrument as a function of its location on 
the underlying symptom-severity dimension. If all items fit adequately to the Rasch 
model, this indicates that the items are ordered along one dimension and that the added 
up raw, ordinal item-responses can be interpreted as a true interval scale (Wright & 
Masters, 1982). In addition, Rasch analyses can be used to investigate the discriminative 
ability of a measure, and whether items function consistently across different person 
characteristics. Importantly, if the factor structure and the fit to the Rasch model are 
consistent across healthy subjects and patients, this would indicate that each subscale 
measures the same underlying severity dimension, irrespective of an individual’s 
categorical diagnosis. 
 We aimed to find the best-fitting, most consistent factor structure for the IDS-SR 
and to investigate the usability of the factors as subscales. To this end, we tested and 
compared the fit of four factor models from the literature using CFA in patients with 
current MDD (n=957). Next, we investigated the consistency of the best-fitting model 
across patients with a remitted MDD (n=450), patients with a lifetime anxiety disorder 
(n=570) and healthy control subjects (n=623). Rasch analyses were conducted to evaluate 
unidimensionality of the factors and to investigate whether the added up, raw responses 
on each factor could be used as subscales with sufficient discriminative ability and 
stability across different person characteristics. We conducted these analyses on data 




Sample and procedures 
Participants came from the NESDA study, a large scale longitudinal study conducted 
among 2981 adult subjects (mean age 41.9, age range: 18-65; 1002 men and 1979 
women) (Penninx et al., 2008). The NESDA sample consists of 2329 subjects with a 
lifetime diagnosis of depressive or anxiety disorder and 652 subjects without a lifetime 
psychiatric diagnosis. These were recruited from three different settings: community, 
primary care and mental health care organizations. All participants were interviewed and 
assessed during a visit to a research location.  
 For the CFA analyses, subjects that completed the IDS-SR without missing values 
(n=2600) were included in one of 4 non-overlapping groups. Group 1 consisted of all 
subjects with a current MDD diagnosis (within last 6 months; with or without MDD in the 
past; n=957). Group 2 consisted of subjects with MDD in remission during the past 6 
months; n=450). Group 3 (n=570) consisted of patients with a lifetime anxiety disorder 
and no lifetime depression. Group 4 (n=623) consisted of all mentally healthy control 
subjects. The protocol of the NESDA study was approved centrally by the Ethical Review 
Board of the Leiden University Medical Center and by local review boards of participating 
centres. All subjects signed informed consent.     
 




All participants completed the Dutch translation of the IDS-SR (Rush et al., 1996) that 
consists of 30 equally weighed items, rated on a four-point scale (range 0-3). 28 of the 30 
items are summed to a standard total score, ranging from 0 to 84 (as only appetite and 
weight increase or decrease is scored). For the analyses of the 1, 2 and 3-factor models 
and the Rasch analyses, items 11 and 12 and items 13 and 14 were rescored into a single 
‘change of appetite’ (item 11/12) variable and a ‘weight change’ variable (item 13/14). 
Only for the analysis of the 4-factor model, items 11, 12, 13 and 14 were treated as 
separate variables. The Composite International Diagnostic Interview (CIDI, WHO version 
2.1) was used to assess the DSM-IV criteria for depressive disorders (MDD and dysthymia) 
and anxiety disorders (panic disorder, social phobia, generalized anxiety disorder and 
agoraphobia).  
 
Statistical analyses  
 
Principal Component Analysis 
To gain some preliminary insight into the number of components that could be expected 
to underlie the IDS-SR, an initial PCA was conducted in all subjects that completed the 
IDS-SR (n=2600). Parallel analysis was used for factor extraction. With this method, the 
eigenvalues generated with PCA in the real data are compared with the (95th percentile 
of) eigenvalues that are generated in 1000 random datasets with the same number of 
variables and observations. Only the components are retained for which the eigenvalues 
in the real data exceed the randomly generated eigenvalues, and thus are higher than 
expected by chance. This method has been shown to be superior to traditionally used 
extraction techniques like Kaiser’s criterion (O’Connor, 2000). PROMAX was used for 
oblique component rotation. The analyses were conducted with SPSS (version 16).   
  
Confirmatory factor Analysis (CFA)  
To investigate and compare the fit of four factor-models from the literature, CFA was 
conducted in current MDD patients (group 1), because all four hypothesized models were 
developed in comparable samples of depressed (out)patients. To test model-fit with CFA, 
the models were first defined based on the (PCA) factor loadings reported in each 
publication (Rush et al., 1986, 1996; Trivedi et al., 2004; Bernstein, 2006). For each item it 
was evaluated on which factor it had its highest (primary) loading in the PCA results. In 
the CFA model, this primary loading was set to be freely estimated and the factor loadings 
on other factors were fixed to zero. Items with high loadings on more than one factor 
(differing <0.15) were set to load freely on both factors. To scale the estimated factors, on 
each factor the loading of one item was fixed to 1 (Brown, 2006). In the multi-factorial 
models, factor covariances were set to be freely estimated.  
 In the 1-factor model all items loaded on one ‘depression’ factor (Trivedi et al., 




and a ‘somatic’ factor (items 25, 26 and 28). In the 3-factor model (Rush et al., 1996), 
there was a ‘mood/cognition’ factor (items 5, 8, 10, 11-14 and 17-22), an ‘anxiety/ 
arousal’ factor (items 6, 7, 23-27 and 30) and a ‘sleep’ factor (items 1-4). Items 9, 15, 20 
and 29 loaded on the ‘mood/cognition’ and ‘somatic’ factors and item 24 loaded on the 
‘somatic’ and ‘sleep’ factors. In the 4-factor model (Rush et al., 1986; 28 item version) 
there was a mood/cognition factor (items 5-8 and 15-22), an ‘anxious/hypochondria’ 
factor (items 24-28), an ‘endogenous’ factor (items 2, 3, 9, 11 and 13) and an ‘atypical’ 
factor (items 4, 12 and 14). Item 23 loaded on the first two factors, item 1 loaded on the 
second and third factor. 
 Because the IDS-SR items were categorical and had a non-normal distribution, 
estimation of model fit with maximum likelihood (ML) would likely lead to an 
underestimation of model-fit (Byrne, 2006). Therefore, we used an adapted approach for 
categorical data (Bentler, 2006). First, a matrix of polychoric correlations between the 
items was generated. Second, ML was used to estimate model fit-statistics. Third, the ML-
based statistics were corrected using an appropriate weight-matrix to obtain robust fit-
statistics (Satorra and Bentler, 1988), which have been shown to perform well for 
categorical and non-normal data (Byrne, 2006). Model-fit was evaluated with fit-indices, 
in stead of the traditional χ2-test, which is oversensitive to minor deviations from perfect 
fit in large samples and with complex models (Brown, 2006). The following fit-indices 
were used: the Comparative Fit Index (CFI), the Root Mean Square Error of Approximation 
(RMSEA) and the Akaike Information Criterion (AIC). A CFI of at least 0.95 indicates good 
fit and a RMSEA smaller than 0.06 indicates good fit (Hu and Bentler, 1999). The AIC can 
be used to compare different models, balancing statistical goodness-of-fit and the 
number of model parameters. The model with the lowest AIC can be regarded as 
potentially most useful (Bentler, 2006). In addition to the CFA in group 1, CFA was 
performed in groups 2, 3 and 4 with the best fitting model from group 1 to investigate the 
consistency of model-fit across different groups. The EQS statistical package (Multivariate 
Software Inc., Encino, California, USA) was used to conduct the analyses. 
 
Rasch Analyses 
To test if the identified factors were unidimensional measurement scales, fit to the Rasch 
model was investigated. The Rasch model assumes that the probability of a person’s 
response on an item is described by a logistic function of the distance between the 
location of the person and the location of the item on the underlying linear severity 
dimension. Thus, if a person is located higher on the dimension than the item, the 
probability of responding with the highest response option is high. Conversely, if the 
person is located lower than the item, the probability of responding with the lowest 
response option is high. If all items fit adequately to the Rasch model, this indicates that 
all items are lined up along one underlying dimension in order of increasing severity. In 
addition, fit to the Rasch model indicates that the ordinal responses on the items can be 
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added up to a linear interval-scale that is a sufficient statistic for the underlying severity 
dimension.  
 The unrestricted partial credit model was used for fit-estimation. To estimate the 
fit to the Rasch model, the unweighted mean square standardized residual (outfit) was 
calculated for each item (formulas from: Wright & Masters, 1982, p100). Outfit was used 
in the current study because it is essentially a χ2 statistic divided by its degrees of 
freedom (n), and thus less affected by the large sample size than traditional significance-
tests of (mis)fit. An outfit close to 1 (within the range of 0.7 to 1.3) was considered to 
indicate adequate fit to the Rasch model (Wright & Stone, 1979). Persons with extreme 
scores (with a total score of 0 or with fit-residuals>|2.5|) were excluded from model-fit 
calculations because they do not behave in line with model expectations. 
 For each factor, the same analytic procedure was followed to assess and improve 
fit to the Rasch model. First, the fit of the items to the Rasch model was assessed. Second, 
the thresholds between adjacent response categories were inspected for ordering 
problems. If the response scale was disordered, for instance, if a category was never most 
probable to be endorsed (redundant), adjacent categories were collapsed. Third, the fit of 
the items was assessed again to see if fit had improved. Items with inadequate fit were 
removed to arrive at a unidimensional subscale with optimal fit to the Rasch model. The 
locations were inspected to see how the items were distributed along the underlying 
dimension. Fourth, all items in the final subscale were tested for differential item 
functioning (DIF) across person characteristics (Age group (young: 18-42 versus old: 43-
65), gender and lifetime depression). An ANOVA was used to compare scores between 
levels of each person characteristic (uniform DIF) and across different classes of severity 
(non-uniform DIF). To investigate the actual extent and implications of DIF, the location 
and outfit were assessed for the different levels of the person characteristic (e.g. men vs. 
women). Because the ANOVA was likely to pick up less relevant DIF due to the large 
sample size (statistical power), a large difference in location (we chose >0.5 logits as cut-
off) and model fit between two characteristic subgroups (e.g. men and women) was taken 
to indicate that the generalizability of item functioning is potentially problematic. Fifth, 
unidimensionality was additionally checked with a PCA of the residuals. Two subsets of 
items with respectively positive and negative loadings on the first component of this PCA 
were selected and person estimates were calculated for these subsets of items. If these 
estimates differed significantly from the full-scale estimates (as indicated by t>|1.96| in 
more than 5% of individuals), this indicated that the responses on the subsets were 
interdependent (when controlled for the primary underlying dimension) and that there 
was still some multidimensionality present in the measure (Smith, 2004). Sixth, to 
evaluate clinical usefulness of each subscale, the person-separation index was calculated 
and the number of severity strata that could be discriminated was derived from the 
separation-ratio (G). Additionally, to evaluate the (multi)dimensionality of the complete 
IDS-SR, its fit to the Rasch model was also investigated. Calculations were done with 





Missing Data  
In group 1, 139 of 1096 subjects (12.7%) were excluded because they had one or more 
missing responses on the IDS-SR, resulting in a group of 957 subjects. In groups 2, 3 and 4, 
respectively 50 (10%), 48 (7.2%) and 58 (9.2%) subjects were excluded because of missing 
responses. The subjects with missing values were found to be younger and have less 
years of education than the subject with complete data (data not shown). However, it 
was decided not to impute missing items because to our knowledge there is no widely 
supported method to impute non-normal, categorical data without introducing new and 
unknown sources of bias.  
 
Table 3.1: Demographic and diagnostic information of the studied subgroups in the 
NESDA data (n=2600) 













N 957 450 570 623 
Women (%) 639 (66.8%) 319 (70.9%) 377 (66.1%) 382 (61.3%) 
Men (%) 318 (33.2%) 131 (29.1%) 193 (33.9%) 241 (38.7%) 
Mean age (SD) 40.5 (12.1) 43.8 (12.6) 41.7 (13.0) 40.8 (14.8) 
Age range 18–64 18-65 18-65 18-65 
Mean Yrs of Ed (SD) 11.7 (3.2) 12.5 (3.2) 12.3 (3.2) 12.9 (3.2) 
DSM-IV diagnosesa     
Only current MDDb 331 (34.6%) 0 0 0 
Only current anxiety 0 0 490 (86.0%) 0 
Current comorbidity 626 (65.4%) 0 0 0 
Only remitted MDD 0 301 (66.9%) 0 0 
Only remitted anxiety 0 0 80 (14.0%) 0 
Remitted comorbidity 0 149 (33.1%) 0 0 
 
MDD = Major Depressive Disorder,  Mean Yrs of Ed = mean years of education 
a  DSM-IV diagnoses assessed with the CIDI 













Diagnoses and demographic variables  
The demographic and diagnostic information for the four non-overlapping study groups 
are shown in Table 3.1. The distribution of gender as well as mean age and mean years of 
education were largely comparable across the 4 groups. In group 1 (Current MDD), the 
majority (65.4%) of current MDD patients had a comorbid anxiety disorder. In group 2 
(Remitted MDD), the majority (33.1%) of subjects had a comorbid remitted anxiety 
disorder. In group 3 (Lifetime anxiety disorders, no MDD), the majority (86.0%) of subjects 
had a current anxiety diagnosis. In group 4, by definition nobody had a psychiatric 
diagnosis. 
 
Principal Component Analysis 
The results of the initial PCA are shown in Table 3.2. Parallel analysis indicated that 3 
components should be extracted. After rotation, items that covered symptoms of 
(depressed) mood, affect and cognitions loaded on the first component 
(‘mood/cognition’), items that covered anxiety and somatic arousal and somatic 
complaints loaded on the second component (‘anxiety/arousal’) and items that covered 
sleep symptoms loaded on the third component (‘sleep’). The extracted components 
were largely similar to the 3 components reported by Rush et al. (1996): only 7 of the 28 
items had a completely different primary loading in the present study (items 6, 7, 15, 
11/12, 13/14, 23 and 29). These results indicate that a 3-factor structure is likely to 
underlie the IDS-SR across a wide variety of subjects.   
 
Confirmatory Factor Analysis 
To test and compare the fit of the 4 models of the IDS-SR (1, 2, 3 and 4-facor), CFA was 
conducted in group 1 (Current MDD). The results are shown in Table 3.3. For the 3-factor 
model, the CFI was highest (CFI=0.95) and the RMSEA was lowest (RMSEA=0.056), which 
both indicated better fit than the 1, 2 and 4-factor models (all: CFI≤0.93; RMSEA≥0.065). 
In addition, the AIC was lowest for the 3-factor model (AIC=684.70), which indicates that 
this model is potentially most useful, taking into account both model-fit and the number 
of model-parameters. These results indicate that the 3-factor model proposed by Rush et 
al. (1996) best represents the underlying structure of the IDS-SR. 
 
Confirmatory Factor Analysis in different groups 
To investigate the consistency of model-fit of the 3-factor model, CFA was conducted in 
groups 2, 3 and 4. Results are shown in Table 3.4. The indices-of-fit indicated good model-
fit in all groups (CFI≥0.95; RMSEA≤0.049), which indicated that the fit of the 3-factor 
model is consistent across subjects with remitted MDD, subjects with a lifetime anxiety 






Table 3.2 Results of a Principal Components Analysis in the complete dataset (n=2600): 
factor loadings and eigenvalues  
 Component  
Factor in 
Rush et al. 
(1996)1  








21. Pleasure or enjoyment (not sex) 0.92 -0.17 0.04 1 
5. Feeling sad 0.89 -0.09 0.02 1 
8. Reactivity of mood 0.86 -0.26 0.06 1 
19. Interest in people/activities 0.84 -0.10 0.01 1 
17. Future pessimism 0.78 -0.06 0.03 1 
10. Quality of mood 0.72 -0.01 -0.03 1 
16. Self criticism and blame 0.66 0.02 -0.10 1 
15. Concentration/decision making 0.64 0.14 0.01 2 
18. Suicidal thoughts 0.60 -0.07 0.01 1 
6. Feeling irritable 0.59 0.14 0.01 2 
23. Psychomotor retardation 0.57 0.10 0.04 2 
20. Energy/fatiguability 0.57 0.27 -0.05 1 
22. Interest in Sex  0.53 0.05 0.08 1 
29. Interpersonal sensitivity 0.51 0.20 -0.16 2 
7. Feeling anxious or tense 0.50 0.32 0.03 2 
30. Leaden paralysis/physical energy 0.46 0.39 -0.04 2 
28. Constipation/diarrhoea -0.22 0.79 -0.03 2 
25. Aches and pains -0.06 0.69 0.14 2 
26. Sympathetic arousal 0.08 0.58 0.13 2 
27. Panic/phobic symptoms 0.08 0.56 -0.04 2 
13/14. Weight disturbance  -0.13 0.53 0.01 1 
11/12. Appetite disturbance 0.23 0.43 -0.09 1 
24. Psychomotor agitation 0.25 0.29 0.10 2 
3. Early morning awakening 0.12 0.00 0.69 3 
2. Middle insomnia -0.06 0.19 0.68 3 
4. Sleeping too much  0.15 0.31 -0.56 3 
1. Initial insomnia 0.16 0.19 0.42 3 
9. Diurnal variation of mood 0.16 0.16 -0.04 - 
Eigenvalue (in real data) 9.97 1.47 1.26  
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Table 3.2 (continued). Legend: IDS-SR = Inventory of Depressive Symptomatology Self 
Report; communalities after extraction ranged from 0.21 to 0.70; the components were 
rotated with PROMAX; the primary loading for each item is printed in bold font 
1)  Components on which each item had its highest loading in PCA results by Rush et al. 
(1996): 1 = ‘mood/cognition’, 2= ‘anxiety/arousal’, 3 = ‘sleep’; an underlined number 
indicates that the item loads on a different component in the present study 
 
 
Table 3.3: Confirmatory factor analysis of  four factor-models of the IDS-SR in group 1 





















347 1845.39 0.93 0.067 (0.064 -0.070) 1151.39 
3-factor Rush et al. 
(1996) 
343 1370.70 0.95 0.056 (0.053 – 0.059) 684.70 
4-factora  
 
Rush et al. 
(1986) 
291  1466.78 0.93 0.065 (0.061 - 0.068) 880.78 
 
IDS-SR = Inventory of Depressive Symptomatology Self Report; Df = Degrees of 
freedom; CFI = Comparative fit index; Standardized root mean-square residual; RMSEA 
= Root mean square error of approximation; 90% CI (RMSEA) = 90% confidence interval 
of the RMSEA; AIC = Akaike Information criterion 
CFA based on polychoric correlation matrix with robust Satorra-Bentler correction 
aThe 4-factor input model included 26 of the 28 IDS-SR items: of the 4 appetite/weight 
items, only item 11 (decreased appetite) and item 14 (increased weight) were included 
because the polychoric correlations between item 11 and item 12 (increased appetite) 
and between item 13 and item 14 (decreased weight) both approached -1.0, resulting 
in a non-positive definite correlation matrix, which can not be used to estimate model-
fit. By including only one item of each pair in the model, this problem was solved and 
the proposed distinction between an atypical and endogenous factor was still 












The full IDS-SR 
Of the 28 items in the IDS-SR, 10 items showed poor fit to the Rasch model, which is 
further evidence for the multidimensionality of the IDS-SR. 
 
The IDS-SR ‘Mood/Cognition’ subscale 
All 15 items that were set to load on the ‘Mood/Cognition’ factor in the CFA were 
investigated for fit to the Rasch model. Items 9, 13/14, 19 and 21 did have an outfit 
statistic outside the acceptable range. Inspection of the threshold-ordering revealed that 
seven items (9, 11/12, 14-17 and 29) had disordered thresholds, which resulted from 
category 1 or 2 to be redundant in each of these items. Therefore, it was decided to 
collapse category 1 and 2, resulting in a 3-point response scale (0=0, 1=1, 2=1 and 3=2). 
For ease of use all items were rescored accordingly. The thresholds, locations and outfit 
after rescoring are shown in Table 3.5. All thresholds were now ordered correctly and 
item-fit had mostly increased after rescoring. However, the same four items still fit poorly 
and were therefore removed. This resulted in a final 11-item subscale with item-locations 
ordered as follows (in ascending order): 29, 16, 17, 10, 15, 20, 5, 22, 11/12, 8 and 18. 
Thus, interpersonal sensitivity (item 29), problematic self view (item 16) and pessimism 
about the future (item 17) were at the low end of the ‘mood/cognition’ dimension and 
decreased reactivity of mood (item 8) and suicidal thoughts (item 18) were at the severe 
end. 
Several items displayed DIF (significant DIF and difference between locations>0.5). 
Item 5 displayed DIF between depressed (location=-0.24) and non-depressed subjects 
(location=0.51) but had adequate outfit in both subgroups (0.7<outfit<1.3). Item 8 
displayed DIF between men (location=0.66) and women (location=1.37) but showed 
adequate outfit in both groups. Item 29 displayed DIF between men (location=-0.55) and 
women (location=-1.09) and between young (location=-1.23) and old subjects (location=-
0.60) but had adequate outfit in all subgroups. Inspection of the location-ordering 
indicated that the items were generally ordered in the same way in the different person-
factor groups, with items 29, 16 and 17 at the lowest and items 8 and 18 at the highest 
end of the severity dimension. Thus, although items 5, 8 and 29 show some DIF, the 
consistent adequate outfit and threshold ordering across subgroups indicates this does 
not severely affect the generalizability of measurement.  
 Comparing the person estimates between the PCA item-subsets and the final 11 
item ‘mood/cognition’ subscale indicated no significant difference for any person (all t-
values <|1.96|), which forms further evidence for unidimensionality. 
 The 11-item ‘mood/cognition’ subscale had a person-separation-index of 0.88, 
which indicates that the scale can be used to discriminate around 4 severity strata (G≈3; 
Wright & Masters, 1982). The removal of 4 items from the initial 15-item subscale only 
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led to a 0.01 reduction of the person-separation-index, indicating that these items did not 
contribute substantially to the discriminative ability of the subscale.   
 
Table 3.4: Confirmatory factor analysis of the 3-factor model of the IDS-SR in group 2 
(remitted MDD), group 3 (Lifetime anxiety) and group 4 (Healthy controls) 
Model Group Df Satorra- 
Bentler χ2 
CFI RMSEA (90% CI) 
 
3-factor  2 (remitted MDD),  
n = 450 
 
343 670.34 0.96 0.046 (0.041 – 0.051) 
3 (Anxiety),  
n = 570 
  
343 821.17 0.95 0.049 (0.045 – 0.054) 
4 (healthy Controls),  
n = 623 
343 752.14 0.96 0.044 (0.040 – 0.048) 
IDS-SR = Inventory of Depressive Symptomatology Self Report ; MDD = Major 
Depressive Disorder; Df = Degrees of freedom; CFI = Comparative fit index; 
Standardized root mean-square residual; RMSEA = Root mean square error of 
approximation; 90% CI (RMSEA) = 90% confidence interval of the RMSEA 
CFA based on polychoric correlation matrix with robust Satorra-Bentler correction. 
 
The IDS-SR ‘Anxiety/Arousal’ subscale 
All nine items that were set to load on the ‘anxiety/arousal’ factor in the CFA were 
investigated for fit to the Rasch model. Only item 7 fit poorly (outfit=0.63). Inspection of 
the threshold-ordering again revealed redundancy of category 1 or 2 in some items (items 
23, 24 and 30). Therefore, the items in the ‘anxiety/arousal’ subscale were also rescored 
to a 3-point scale (0=0, 1=1, 2=1 and 3=2). The thresholds, locations and outfit statistics 
are shown in table 3.5. All thresholds were now ordered correctly and item fit had mostly 
increased after rescoring. However, item 7 still fit poorly and was removed. This resulted 
in an 8-item subscale with item-locations ordered as follows: 30, 25, 6, 27, 28, 24, 26 and 
23. Thus, symptoms such as leaden paralysis (item 30), aches and pains (item 25) and 
feeling irritable (item 6) were at the lower end of the severity dimension and 
psychomotor agitation (item 24), sympathetic symptoms (e.g. arrhythmic or pounding 
heartbeat, blurred vision, sweating; item 26) and psychomotor retardation (item 23) were 
on the severe end. 
 Items 24 and 25 displayed DIF between men (location=-0.03 and -0.23) and 
women (location=0.58 and -0.77) but both had adequate fit in both subgroups 
(0.7<outfit<1.3). Item 6 displayed DIF between young (location=-0.53) and old (location=-
0.05) but had adequate fit in both groups. Item 27 displayed DIF between depressed 
(location=0.34) and non-depressed (location=-0.20) and showed poorer fit in the 




the location-ordering indicated that the items were generally ordered in the same way in 
the different person-factor groups, with items 30, 25 and 6 at the lowest and items 24, 26 
and 23 at the highest end of the dimension. The results indicate that items 24 and 25 
showed some DIF that was not likely to severely affect the generalizability of 
measurement. The DIF for item 27 was more serious, although its outfit statistic of 0.69 in 
depressed subjects was only just below the cut-off of 0.70, the function of this item could 
be less consistent. 
 
3.4 Discussion 
The present study used CFA to identify the best fitting structural model of the IDS-SR. An 
initial PCA indicated that 3 factors were expected to underlie the IDS-SR and when the fit 
of four models from the literature was tested with CFA, the 3-factor model (Rush et al., 
1996) was indeed found to fit best to the data. This model consisted of a 
‘mood/cognition’, ‘anxiety/arousal’ and ‘sleep’ factor and was found to fit well across 
different groups of patients and healthy controls. To evaluate if they could be used as 
subscales, the factors were tested and fine-tuned using Rasch analyses: items were 
rescored to a more optimal 3-point scale (0, 1, 1, 2) and items that fit the model poorly 
were removed. This resulted in two unidimensional IDS-SR subscales: the 11-item 
‘mood/cognition’ subscale and the 8-item ‘anxiety/arousal’ subscale. The adequate fit to 
the Rasch model indicated that the sum scores on these subscales can be regarded as 
sufficient statistic for their underlying symptom dimensions. An additional PCA of the 
residuals indicated that the scales were unidimensional. DIF analyses showed that some 
items functioned differently across groups, though measurement characteristics generally 
seemed consistent. Finally, the subscales were found to have adequate discriminative 
ability. Importantly, Rasch analyses with the total IDS-SR indicated that it is 
multidimensional, underlining the need for more homogeneous symptom measures.  
The IDS-SR subscales could be helpful for both clinicians and researchers who seek 
less heterogeneous symptom-severity measures. Using the subscales could have added 
value because: (1) they function well as ‘measurement scales’ (as shown by the Rasch 
results), (2) they assess severity for more specific symptom-domains and (3) different 
patterns of subscale scores could indicate different treatment indications and/or disease 
prognosis.  In addition, the finding of two symptom dimensions could indicate (partly) 
distinct underlying etiological mechanisms.The present results have some additional 
general implications. First, the traditionally used total sum score on the IDS-SR does not 
seem to be a unidimensional measure of depression-severity. This is a general problem 
that is also observed for other widely used instruments like the Hamilton Depression 
Rating Scale (HDRS; Gibbons et al, 1993) the Beck Depression Inventory (BDI; Gibbons et 
al., 1985) and the Centre for Epidemiological Studies Depression Scale (CES-D; Stansbury 
et al., 2006). Second, the finding that a 3-dimensional model fit the IDS-SR better than the 
4-dimensional model (Rush et al., 1986), does contradict the traditional idea of distinct 
‘atypical’ and ‘melancholic/endogenous’ symptom domains. 
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Table 3.5: The location and outfit statistic for each of the items in the IDS-SR 




‘Anxiety Arousal’ subscale 









5. Feeling sad -2.38 2.09 -0.15 0.72 - - - - 
6. Feeling irritable - - - - -2.56 1.99 -0.28 0.84 
7. Feeling anxious or tense - - - - -2.61 2.13 -0.24 0.67 
8. Reactivity of Mood -0.56 2.50 -0.97 1.01 - - - - 
9. Diurnal variation of mood -0.50 0.60 0.05 2.26 - - - - 
10. Quality of mood -1.36 0.56 -0.40 0.79 - - - - 
11/12. Appetite disturbance -1.15 1.01 -0.07 1.04 - - - - 
13/14. Weight disturbance -1.42 0.89 -0.26 2.31 - - - - 
15. Concentration/decision 
making 
-2.37 1.79 -0.29 0.82 - - - - 
16. Self criticism and blame -1.07 -0.46 -0.76 0.96 - - - - 
17. Future pessimism -2.90 2.06 -0.42 0.82 - - - - 
18. Suicidal thoughts -3.42 2.92 0.29 1.01 - - - - 
19. Interest in people/ 
activities 
-1.04 1.59 0.27 0.62 - - - - 
20. Energy/fatiguability -2.26 1.96 -0.15 0.82 - - - - 
21. Pleasure or enjoyment -1.17 3.08 0.96 0.60 - - - - 
22. Interest in sex -1.37 1.19 -0.09 1.26 - -  - 
23. Psychomotor retardation - - - - -0.34 2.36 1.01 0.72 
24. Psychomotor agitation - - - - -1.36 2.03 0.33 1.01 
25. Aches and pains - - - - -3.07 1.91 -0.58 0.96 
26. Sympathetic arousal - - - - -2.52 3.81 -0.65 0.85 
27. Panic/phobic symptoms - - - - -1.66 1.92 0.13 0.96 
28. Constipation/diarrhoea - - - - -1.45 1.78 0.16 1.19 
29. Interpersonal Sensitivity -2.45 0.55 -0.95 1.01 - - - - 
30. Leaden Paralysis - - - - -2.85 0.49 -1.18 0.76 
IDS-SR = Inventory of Depressive Symptomatology Self Report. Items 1 to 4 are omitted from the 
table. Threshold 1= location of threshold between response option 0 and 1; threshold 2=location 
of threshold between response option 1 and 2; Location = value between threshold 1 and 2. Items 
with an outfit in bold font were retained in the subscale  
  
Evidence of heterogeneity has been found for many widely used depression scales (e.g. 
the HDRS, BDI and CES-D), and many shorter, unidimensional versions and/or subscales 




‘core symptoms’ of depression (Bech et al, 1981; Maier and Philipp, 1985; Santor et al., 
2008). These ‘subscales’ were indeed shown to function as unidimensional measures with 
IRT analyses (e.g. Bech et al., 1981; Gibbons et al., 1993; Santor et al, 2008). Recently, the 
same was found for the self rated HDRS version (Bech et al., 2009). For the BDI, several 
revisions and subscales have been proposed. For instance, Gibbons et al (1985) found the 
BDI to be more unidimensional without vegetative symptoms. Bouman & Kok (1987) 
further subdivided the BDI into three unidimensional subscales using Rasch analyses: 
‘mood/inhibition’, ‘guilt/failure’ and ‘vegetative’. This subdivision is in line with the most 
commonly found factor structure for the BDI (review: Beck et al., 1988; Shafer, 2006). 
Also for the CES-D shorter (IRT derived) unidimensional subscales have been developed 
(e.g. Cole et al., 2004; Stansbury et al., 2006). The current IDS-SR ‘mood/cognition’ 
subscale can be regarded as conceptually similar to the abovementioned attempts to 
create a more homogenous depression measure. However, coverage seems to vary 
somewhat across the different subscales, most likely because each original instrument 
has a slightly different focus and item-pool to select from. The IDS-SR ‘anxiety/arousal’ 
subscale mostly resembles the item-sets that have been found to load on one ‘anxiety-
agitation’ factor or two distinct ‘somatic anxiety’ and ‘psychic anxiety’ factors in the HDRS 
(Bagby et al., 2004; Shafer et al., 2006). However, these factors have received less 
attention, which is not surprising given that the instrument is mainly used as a depression 
measure in antidepressant trials. Both the BDI and CES-D mainly focus on depressed 
mood and/or cognitions and cover only a few somatic/vegetative symptoms, which is not 
enough to construct a reliable subscale (Gibbons et al., 1985). The present finding of a 
’sleep’ factor is in line with other studies that found sleeping problems to load on a 
separate ‘insomnia’ factor (HDRS) or on a  ‘neurovegetative’ factor (BDI; CES-D) (Shafer, 
2006).  
 The present study has several strong characteristics. First, CFA was conducted in 
large and representative samples of healthy subjects and psychiatric patients, which 
makes the results generalizable to a broad range of settings and patients. Second, CFA 
was used to test the fit of multiple hypothesized models, which allowed both for 
assessment of model fit and selection of a best-fitting model from among several 
plausible models. Third, a CFA approach was used that minimized bias due to the 
categorical and non-normal nature of the IDS-SR data, increasing the validity of the 
results. Fourth, the Rasch analyses resulted in subscales that can really be regarded as 
unidimensional measurement scales; something that would not have been achieved with 
classical psychometric analyses. The results should be interpreted in the light of some 
limitations. First, only the fit of four models from the literature was tested, which does 
not rule out that an unknown model with a different structure (e.g. more factors) might 
fit better. However, the initial PCA in the present study did not suggest that this was the 
case. Second, the current analyses were conducted in a group of subjects with relatively 
mild psychopathology. Future research should point out whether our findings can also be 
generalized to more severely ill and/or institutionalized patients. Finally, although DIF did 
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not seem to be very problematic for general use, researchers that are specifically 
interested in score differences between groups (e.g. men and women) should be aware of 
DIF that could reduce subscale-score comparability. They could leave DIF items out of the 
subscale calculations.  
 In conclusion, the IDS-SR has three underlying factors, of which two can be 
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Background: Results on the association between depression and the HPA-axis have been 
inconsistent, possibly due to heterogeneity of the DSM-IV category of depression. Specific 
symptom-dimensions could be used as a more homogenous phenotype in HPA-axis 
research.  
Methods: 1029 subjects with a lifetime depression and/or anxiety disorder from the 
NESDA study (mean age: 43.0±12.7; 67.4% female) provided 7 saliva samples to yield the 
cortisol awakening response (CAR), evening cortisol and dexamethasone suppression 
data. The dimensions of the tripartite model (General Distress, Anhedonic Depression and 
Anxious Arousal) were measured with the 30-item adapted Mood and Anxiety Symptoms 
Questionnaire (MASQ-D30) and analyzed in association with the cortisol measures using 
linear and non-linear regression. 
Results: Median (interquartile range) scores of General Distress, Anhedonic Depression 
and Anxious Arousal were respectively 20 (14-27), 36 (28-44) and 15 (12-19), indicating 
large variability. Non-linear associations with the shape of an inverted U were found 
between General Distress, Anhedonic Depression and Anxious Arousal on one hand and 
total morning secretion and the dynamic of the CAR on the other hand. Both high and low 
severity levels were associated with a lower CAR, compared to intermediate levels of 
severity. Most of the associations remained significant when adjusted for covariates and 
the presence of DSM-IV diagnoses. 
Conclusions: Non-linear associations were found between the CAR and the dimensions of 
the tripartite model. This could explain previous inconsistent findings regarding HPA-axis 
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Dysregulation of the Hypothalamo-Pituitary-Adrenal (HPA) axis may play a role in the 
etiology of depression (Holsboer & Barden, 1996; De Kloet, 2005). A hyperactive HPA-axis 
has indeed been found in severely depressed patients and, to a lesser extent, in 
outpatients and mildly depressed patients, measured through e.g. increased evening 
cortisol levels, a higher cortisol awakening response (CAR), an altered dexamethasone 
suppression test (DST) or a decreased response on the ‘Dexamethasone Suppression Test’ 
and the more sensitive ‘Dexamethasone Corticotrophin Releasing Hormone (CRH) 
Suppression Test’ (Bhagwaghar et al., 2005; Pruessner et al., 2003; Holsboer & Ising, 
2010). Our group found a slightly higher CAR in subjects with a current or lifetime MDD 
and higher evening cortisol in subjects with a current MDD but found no differences in 
suppression on the DST (Vreeburg et al., 2009a). However, others have found no or other 
HPA-axis dysregulations in MDD outpatients (Stetler & Miller, 2005; Huber et al., 2006). 
 A possible explanation for these modest and inconsistent findings could be that 
the DSM-IV category of MDD is not an optimal clinical phenotype for HPA-axis research. 
Patients may even receive the same MDD diagnosis if they only overlap on one of nine 
criterion symptoms, resulting in a heterogeneous patient group. When comparing these 
patients to healthy controls, specific associations between symptoms and cortisol levels 
can easily go undetected. Similar problems arise with overall measures of ‘depression 
severity’, because persons with the same severity score can still have very different 
symptom patterns. There is much overlap in clinical features between MDD and anxiety 
disorders, leading to high comorbidity (Hasin et al., 2005), and both groups of disorders 
respond to similar treatments. This indicates that research should not be limited to MDD 
only, because a lot of underlying pathophysiology is likely to be shared with anxiety. 
Indeed, an altered HPA-axis has also been observed in anxious patients versus healthy 
controls (Schreiber et al, 1996; Erhardt et al., 2006, Abelson et al., 2007) and our research 
group found increased morning cortisol in current anxiety patients, mainly in current 
panic disorder with agoraphobia (Vreeburg et al., 2010). Research on the HPA-axis should 
thus address both specific and shared symptom domains of depression and anxiety.   
 A way to investigate symptom-specific associations with the HPA-axis can be 
through the use of symptom-dimensions as clinical determinants. A symptom dimension 
represents a continuum of increasing severity on a symptom-domain (Goldberg, 2000). 
Each dimension covers specific symptomatology, which can help to distinguish symptom-
specific pathophysiological effects. In addition, dimensions are continuous, providing 
more statistical power to detect small -but potentially relevant- effects (MacCallum et al., 
2002). Additionally, using continuous dimensions, non-linear (curved) associations can be 
effectively investigated. This is useful given the observations that both hypo-and 
hyperactivity of the HPA-axis are associated with higher risk of depression, indicating a 
non-linear, U-shaped association between HPA-axis activity and depression (Bremmer et 




 A well-known dimensional model of anxiety and depression is the ‘tripartite 
model’ (Clark & Watson, 1991). In this model, a ‘General Distress’ dimension covers 
symptoms of general psychological distress (e.g. pessimism and feelings of guilt), common 
to both depression and anxiety. In addition, a specific ‘Anhedonic Depression’ dimension 
covers anhedonic symptoms (i.e. lack of positive affect and emotionality), associated with 
depression. An ‘Anxious Arousal’ dimension covers symptoms of somatic hyperarousal 
(e.g. sweating, trembling and palpitations), associated rather specifically with 
anxiety/panic disorder. Several studies have found this model to work well in different 
patient populations (Keogh & Reidy, 2000; Marshall et al., 2003; de Beurs et al., 2007; 
Wardenaar et al., 2010). The association between the tripartite dimensions and the HPA-
axis was investigated by our group (Veen et al., 2011). We recently found that General 
Distress and Anhedonic Depression were both associated with morning cortisol. These 
associations had an “inverted U-shape": low and high dimensional scores were associated 
with decreased morning cortisol. This observation can explain why low and high HPA-axis 
activity is observed in depressed patients depending on their specific profile of 
symptomatology, which could cause the inconsistencies in the literature so far. Using the 
dimensions of the tripartite model can thus have added value for HPA-axis research.  
Therefore, the present study aimed to answer several questions. First, we investigated 
whether the dimensions of the tripartite model were associated with the HPA-axis in a 
large sample of lifetime depression and/or anxiety patients (n=1029). Second, we 
investigated the shape of these associations. Third, we investigated whether the 
dimensional associations were generalizable across different DSM-IV groups (e.g. current 
versus lifetime patients) and whether they provided additional information about HPA-
axis variability on top of the DSM-IV diagnoses that were previously found to be 
associated with the HPA-axis (e.g. lifetime/current MDD, current anxiety).  
 
4.2 Methods and Materials 
 
Subjects  
Subjects came from the NESDA study, a large longitudinal study to investigate the course 
of depressive and anxiety disorders. The NESDA sample consists of 2.981 subjects (mean 
age 41.9; 1.002 men and 1.979 women), who were recruited from community, primary 
care and specialized mental health care organizations. The sample consists of 2.329 
subjects with a lifetime diagnosis of depressive or anxiety disorder and 652 subjects 
without a lifetime psychiatric diagnosis. Detailed objectives and rationales can be found 
elsewhere (Penninx et al., 2008). The protocol of the NESDA study was approved centrally 
by the Ethical Review Board of the Leiden University Medical Center and by local review 
boards of the participating centres. All participants signed informed consent. 
 Of the 2981 subjects in NESDA, 2167 (72.6%) returned saliva samples. These 
subjects were older (p<0.001) and had more years of education (p<0.001) than the 
subjects who did not return the saliva samples. 130 subjects were excluded because they 
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used corticosteroids, 19 because they were pregnant or breastfeeding and 50 subjects 
using tricyclic antidepressants (TCA; WHO Anatomical Therapeutic Chemical classification 
N06AA) because TCA’s were shown to affect the HPA-axis in previous research (6). Users 
of selective serotonin reuptake inhibitors (SSRIs; N06AB) and other antidepressants 
(N06AF, N06AG and N06AX) were not excluded. Of the remaining 1968 subjects, 1782 
subjects returned the required questionnaires. These were significantly younger (p=0.03) 
and had more years of education (p<0.001) than subjects who did not return all 
questionnaires. During data cleaning (described below), 278 subjects were excluded, 
resulting in a group of 1378 subjects with usable cortisol samples. Of these, 1029 subjects 
had a lifetime depression and/or anxiety disorder and were used as study group for the 
main analyses. 
 
Salivary Cortisol Measurements 
An extensive description of the cortisol measurement and analysis was presented 
previously (6). Participants were instructed to collect saliva samples at home on a regular 
working day. Saliva was collected with Salivettes® (Starstedt AG, Germany) at seven 
sampling points. The CAR was assessed with four time points: at awakening (T1), 30 (T2), 
45 (T3) and 60 minutes later (T4). Two samples were collected at 22h00 (T5) and 23h00 
(T6) to assess the (basal) evening cortisol level. Directly after T6, participants ingested 0.5 
mg of dexamethasone and the next morning saliva was collected at awakening (T7). 
Samples were centrifuged at 2000g (for 10 min), aliquoted and stored at -80°C. The 
analysis of cortisol was done with competitive electrochemiluminescence immunoassay 
(E170, Roche, Switzerland) (van Aken et al., 2003). The functional detection limit was 2.0 
nmol/l and the intra- and interassay variability coefficients were less than 10% in the 
measurement range.  
 During data cleaning, 149 subjects who collected their cortisol samples more than 
five minutes before or after the right protocol time were excluded. Also, 129 subjects 
were excluded because they had cortisol samples with values higher than two standard 
deviations above the mean. These values exceeded the realistic range for saliva cortisol 
and were likely to be a result of measurement factors (e.g. bleedings of the gums after 
tooth brushing or as a result of gingivitis). Three cortisol indicators were computed: the 
CAR, the evening cortisol level and the DST. The CAR was assessed by calculation of the 
area under the curve with respect to the ground (AUCg) and with respect to the increase 
(AUCi), by use of a trapezoid formula (Pruessner et al., 2003). The AUCg estimates the 
total body exposure to cortisol and predicts mean saliva cortisol exposure throughout the 
day. The AUCi is a measure of the dynamic of the CAR, related to the sensitivity of the 
system and change in cortisol exposure over time (Pruessner et al., 2003; Edwards et al., 
2001). The mean of cortisol levels at T5 and T6 was calculated as a measure of evening 
cortisol. The DST was assessed using the samples at T1 and T7. The percentage of 
suppression by dexamethasone was calculated by taking the ratio of T1/T7, with higher 






All participants completed the shortened, 30-item, Dutch adaptation of the MASQ 
(Watson et al., 1995a,b: the MASQ-D30 (Wardenaar et al., 2010). In the MASQ-D30, 
individuals rate how much in the past week they have experienced “feelings, sensations, 
problems and experiences that people sometimes have” on a 5-point scale, with 1 being 
“not at all” and 5 being “extremely”. The MASQ-D30 consists of three 10-item subscales 
that measure General Distress, Anhedonic Depression and Anxious Arousal and has good 
psychometric characteristics (Wardenaar et al., 2010). The Composite International 
Diagnostic Interview (CIDI, WHO version 2.1) was used to assess the DSM-IV criteria for 
depressive disorders (i.e. MDD and dysthymia) and anxiety disorders (i.e. panic disorder, 
social phobia, generalized anxiety disorder and agoraphobia). 
 
Covariates 
Sociodemographic variables (gender, age), sampling factors (time of awakening, working 
status, seasonality and sleep duration) and physical health indicators (smoking, alcohol 
use/dependence, physical activity, cardiovascular disease [CVD]) have been found to be 
associated with salivary cortisol levels in previous research using the NESDA data 
(Vreeburg et al., 2009b). These determinants were treated as covariates in the present 
analyses. Each participant reported time of awakening and working status. The month of 
cortisol collection was dichotomized into months with less (October – February) versus 
more (March – September) daylight. Sleep duration was dichotomized as more or less 
than 6 hours/night. Smoking was dichotomized into current and non-smokers. The 
International Physical Activity Questionnaire (IPAQ) was used to assess physical activity, 
expressed in 100 MET-minutes (metabolic equivalent of number of calories spent per 
minute) per week (Craig et al., 2003). Prevalent CVD was established using an algorithm 
based on self-report and medication use. The Alcohol Use Disorder Identification Test 
(Saunders et al., 1993) was used to assess the number of daily ingested alcoholic 
beverages and the presence of alcohol dependence (a score >14 for males and >12 for 
females). 
Statistical Analyses 
The AUCs and the DST (T1/T7) were log-transformed to improve normality. Inspection of 
the plotted standardized residuals and normal (P-P) plots of all univariate and 
multivariate models revealed that the residuals were normally distributed.  
To investigate the associations of the dimensions with cortisol exposure, several 
regression analyses were conducted. In each analysis, one of the dimensions was the 
continuous predictor variable and a cortisol indicator the outcome variable. Next, to test 
if the association had the shape of a curve instead of a straight line, a quadratic term of 
the scale was added as predictor variable (e.g. both General Distress and [General 
Distress]2); If the regression coefficients were significant for both the linear and quadratic 
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term, the association with cortisol would have a curved shape. All analyses were 
conducted without (Crude) and with covariates (Model 1). Finally, lifetime MDD, current 
(6-month) MDD, and current anxiety were added as dichotomous covariates (Model 2). If 
the regression coefficients of the dimension did not change in this incremental model, 
this would indicate that the dimension explained variation in the cortisol indicator, 
independently from DSM-IV status. For each model, the proportion of explained variance 
was calculated (R2). The variance inflation factor (VIF) was calculated to check for 
collinearity. Only in the non-linear models, the VIF indicated collinearity between the 
dimension and its quadratic term, which is a well-documented phenomenon for 
polynomial regression models (33). This collinearity was not likely to affect the reliability 
of our results, since the collinear variables are mathematically related to each other and 
not intended as independent predictors. Moreover, eliminating the collinearity by 
centering the linear and non-linear terms (Brauner & Shacham, 1998; data not shown) did 
not lead to large changes in the observed results, which further indicated that collinearity 
did not affect our findings. Durbin-Watson coefficients were calculated to test for auto-
correlated residuals. For all models, the coefficients (range: 1.96-2.03) suggested to reject 
the hypothesis of auto-correlated residuals (Savin & White, 1977). P-values <0.05 were 
considered significant. Because we tested only a priori hypothesized associations and for 
confounding, we did not correct for multiple testing.  
 Additional analyses were conducted to evaluate to what extent the associations 
were generalizable across different diagnostic groups (healthy, remitted patients and 
current patients). To investigate whether the inclusion of remitted patients in the main 
research group, all analyses were rerun in a group of current patients only (n=729). To 
investigate whether the associations could be generalized across the complete spectrum 
of diagnostic severity (from healthy to ill), all analyses were rerun in a group including 




Demographic information and diagnoses 
The demographic and diagnostic information of the study group is shown in Table 4.1. 
The mean age was 43.0 years (SD=12.7) and the percentage of women was 67.4%. Of the 
subjects, 45.6% had a current and 24.7% had a remitted MDD diagnosis with or without a 
comorbid anxiety disorder. In addition, 25.3% had a current and 4.4% had a remitted 
anxiety diagnosis without MDD. Of the subjects 19.8% used SSRIs and 8.0% used other 
antidepressants.  
General Distress had a median of 20 (interquartile range [IQR]: 14-26; Anhedonic 
Depression had a median of 36 (IQR: 29-43); and Anxious Arousal had a median of 15 






The cortisol awakening response: AUCg and AUCi 
None of the AUC’s showed a linear association with any of the symptom-dimensions 
(Table 4.2). The results of the regression analyses with the added quadratic terms are 
shown in Table 4.3. The AUCg showed a significant curved association with Anhedonic 
Depression. The AUCi showed significant curved associations with General Distress, 
Anhedonic Depression and Anxious Arousal. All associations remained statistically 
significant when covariates were added (Model 1 in Table 4.3). In addition, when lifetime 
MDD, current MDD and current anxiety disorders were added as covariates (Model 2 in 
Table 4.3), all associations remained significant and regression coefficients barely 
changed (1.6 to 6.0%). This indicated that the curve-shaped associations explain variation 
in the AUC’s, independently from lifetime and current DSM-IV diagnoses. 
R2-statistics indicated that 6.7 to 10.6% of the variance in the AUCs was explained 
by the different multivariate regression models. The dimensions alone explained 0.8 to 
1.0% of the variance in the AUCs, which indicated a small effect size, but these 
percentages were considerably more substantial for each individual dimension than for 
lifetime MDD, current MDD and Current Anxiety together, which only added 0.2-0.6% of 
explained variance in the AUCs (Model 2 compared to Model 1 in Table 4.3). For all 
analyzed associations, the regression coefficient was positive for the linear term and 
negative for the quadratic term of the dimension. In other words, the associations had an 
inverted U-shape. The AUC first increased with increasing dimensional score, then slowly 
flattened and eventually decreased at the severe end of the dimension (see Figure 4.1; to 
aid interpretation of the figure, categorized dimensions are depicted on the x-axis).  
 When the non-linear associations between each dimension and the AUCs were 
additionally adjusted for the other two dimensions, the results remained the same (data 
not shown). This indicates that the observation of similarly shaped associations between 
each of the dimensions and the AUCs were not merely an artefact of (linear) correlations 
between the dimensions (ρ=0.44-0.66 in the current research group).  
In the research group with only current patients (n=729; see Supplementary Table 4.4 
[S1]), the AUCi showed significant curved associations with General Distress, Anhedonic 
Depression and Anxious Arousal. The AUCg showed a borderline significant curved 
association with Anhedonic Depression. These results were largely similar to the main 
results; they hardly changed after excluding remitted patients. In the research group with 
lifetime patients and healthy subjects (n=1378; Supplementary Table 4.5 [S2]), the AUCi 
also showed curved associations with General Distress, Anhedonic Depression and 
Anxious Arousal. The AUCg showed a curved association with General Distress and 
Anhedonic Depression. These results hardly differed from the main results. The curved 
associations thus seem to be generalizable across the complete spectrum of healthy 
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Table 4.1: Characteristics of the study group 
Characteristic Total 
N 1029 
% female 67.4% 
Age (Mean, SD) 43.0 (12.7) 
% working on sampling day 60.4% 
% sampling in light month 57.6% 
% < 6 hours of sleep 30.5% 
% smoking 33.9% 
Physical activity (mean 1000 MET-min/week; SD) 3.5 (3.0) 
Current (6-month) MDD and/or dysthymia 178 (17.3%) 
Current (6-month) anxiety disorder 260 (25.3%) 
Current (6-month) MDD and/or dysthymia with comorbid anxiety 
disorder 
291 (28.3%) 
Remitted (6-month) MDD and/or dysthymia 172 (16.7%) 
Remitted (6-month) anxiety disorder 45 (4.4%) 
Remitted (6-month) MDD and/or dysthymia with comorbid anxiety 
disorder 
83 (8.0%) 
Medication use  
SSRI  19.8% 
Other antidepressants 8.0% 
Median MASQ scale scores (median and interquartile range)   
- General Distress 20 (14-26) 
- Anhedonic Depression  36 (29-43) 
- Anxious Arousal  15 (12-18) 
Cortisol measurements, mean (SD)  
Cortisol T1, at awakening (nmol/l) 16.4 (6.0) 
Cortisol T2, + 30 min (nmol/l) 21.0 (8.7) 
Cortisol T3, + 45 min (nmol/l) 19.6 (9.4) 
Cortisol T4, + 60 min (nmol/l) 17.1 (8.2) 
AUCg (nmol/l/h)1 17.8 (17.4-18.2) 
AUCi (nmol/l/h)1 2.4 (2.0-2.8) 
Cortisol T5, at 10pm (nmol/l) 5.2 (2.9) 
Cortisol T6, at 11pm (nmol/l) 5.1 (3.0) 
Evening cortisol (T5+T6 / 2) 5.1 (2.6) 
Cortisol T7, at awakening the next day (nmol/l) 6.9 (3.5) 








Table 4.1 (continued). Legend: AUCg  = area under the curve with respect to the ground; 
AUCi = area under the curve with respect to the increase; MDD = major depressive 
disorder; MET-min = metabolic equivalent of number of calories spent per minute; SSRI = 
selective serotonin reuptake inhibitor; T1 to T7 = 7 time points of salivary cortisol 
collection;  
1 Because of their skewed distributions, back-transformed geometric mean and 95% 
confidence intervals are presented. 
2 Cortisol suppression ratio = log (salivary cortisol level at T1/salivary cortisol level at T7) 
 
Evening cortisol levels and the DST 
General Distress showed a linear association with the DST, which remained significant 
after addition of covariates (Model 1), and current and lifetime MDD and current anxiety 
(Model 2). However, when remitted MDD patients were excluded from the study group, 
the association was no longer significant, indicating that the association between general 
distress and the DST was partly explained by diagnostic status. Anhedonic Depression and 
Anxious Arousal were not associated with the DST. None of the dimensions was 
associated with evening cortisol.  
 
4.4 Discussion 
The present study investigated the associations between several HPA-axis indicators and 
the dimensions of the tripartite model in a large group of psychiatric outpatients with a 
lifetime depression and/or anxiety disorder. Analyses with the AUCg and AUCi showed 
the dimension Anhedonic Depression to be associated with both total cortisol exposure 
and the dynamic of the CAR. The dimensions General Distress and Anxious Arousal were 
only associated with the dynamic of the CAR. Notably, the associations had the curved 
shape of an inverted U: both low and high dimensional scores were associated with a 
lower morning cortisol exposure, compared to intermediate dimension scores. 
Importantly, each individual dimension explained more variation in morning cortisol 
exposure than was explained by lifetime MDD, current MDD, and current anxiety 
disorders together. Interestingly, largely similar associations were found when only 
patients with a current diagnosis were included in the analyses and when lifetime 
patients and healthy subjects were analysed together. This indicates that the identified 
associations are not limited to (current) psychiatric patients only, but can be generalized 
to a broader group, including remitted patients and healthy subjects. Evening cortisol and 
the DST did not show any consistent associations with the tripartite dimensions.  








Table 4.2: Linear associations between the MASQ-D30 dimensions and cortisol indices in 1029 subjects with lifetime 
psychopathology. 
Dimension Log AUCg 
 











Crude 0.03 (0.28) 0.001 0.05 (0.14) 0.002 -0.02 (0.62) 0.000 0.05 (0.10) 0.003* 
Model 1 0.05 (0.08) 0.101 0.04 (0.17) 0.057 -0.03 (0.24) 0.176 0.06 (0.04) 0.046* 





Crude 0.04 (0.26) 0.001 0.03 (0.42) 0.001 0.03 (0.29) 0.001 0.00 (0.97) 0.000 
Model 1 0.03 (0.30) 0.099 0.03 (0.36) 0.056 0.00 (0.99) 0.174 0.03 (0.36) 0.043 




Crude 0.02 (0.45) 0.001 0.03 (0.34) 0.001 0.02 (0.53) 0.000 0.01 (0.75) 0.000 
Model 1 0.03 (0.26) 0.100 0.03 (0.37) 0.056 0.00 (0.91) 0.174 0.03 (0.38) 0.043 
Model 2 0.02 (0.45) 0.106 0.02 (0.48) 0.059 0.00 (0.94) 0.180 0.04 (0.27) 0.045 
Data are β-coefficients (p-value); AUCg = area under the curve with respect to the ground; AUCi = area under the curve with 
respect to the increase; DST = dexamethasone suppression test 
Model 1 is adjusted for sociodemographic factors (sex, age and Northern European ancestry), sampling factors (working, time of 
awakening, sleep duration and months with more or less daylight), and health indicators (smoking, alcohol use (# of daily 
beverages), alcohol dependence, physical activity, cardiovascular disease). Model 2 is additionally adjusted for current major 
depressive disorder and current anxiety disorder. 




Table 4.3: Non-linear associations between the MASQ-D30 dimensions and cortisol indices in 1029 subjects with lifetime psychopathology. 










0.003 0.51 (0.003) 
-0.47 (0.005) 











0.104 0.50 (0.003) 
-0.46 (0.006) 











0.111 0.47 (0.005) 
-0.44 (0.008) 














0.010 0.66 (0.005) 
-0.64 (0.007) 











0.106 0.59 (0.011) 
-0.57 (0.014) 











0.112 0.57 (0.016) 
-0.55 (0.019) 













0.003 0.51 (0.003) 
-0.49 (0.004) 











0.102 0.51 (0.003) 
-0.48 (0.004) 











0.108 0.48 (0.005) 
-0.46 (0.007) 







Data are β-coefficients (p-value); AUCg = area under the curve with respect to the ground; AUCi = area under the curve with respect to the increase; DST = 
dexamethasone suppression test. Model 1 is adjusted for sociodemographic factors (sex, age and Northern European ancestry), sampling factors (working, 
time of awakening, sleep duration and months with more or less daylight), and health indicators (smoking, alcohol use (# of daily beverages), alcohol 
dependence, physical activity, cardiovascular disease). Model 2 is additionally adjusted for lifetime and current major depressive disorder and current anxiety.  






Figure 4.1: Plots of the association between each tripartite model dimension (x-axis) and 
the area under the curve with respect to the ground (AUCg, upper plots y-axis) and the 
area under the curve with respect to the increase (AUCi, lower plots y-axis) of the cortisol 
morning response. Both AUCs had a slightly skewed distribution and were log-
transformed before analysis; displayed are the back-transformed means and standard 
errors. Categorized dimensions are depicted on the x-axis to aid interpretability. The 
categorized dimensions on the x-axis were only used to aid clearer interpretability of the 
figure; the tripartite dimensions were actually treated as continuous variables in all 
analyses. 
 
These results have some interesting implications. Change in HPA-axis activity seems not 
to be exclusively linked to DSM-IV diagnosis, but also to specific symptom patterns and 
severity. For instance, the association of morning cortisol exposure with Anhedonic 
Depression across subjects with lifetime MDD, current MDD and/or current anxiety 
(treated as covariates), indicates that it is not merely the presence of a diagnosis, but also 
the amount of, for instance,  associated Anhedonic Depression that predicts the height 
and shape of cortisol exposure during the CAR. Thus, etiological research with the HPA-
axis ought not to be limited to the specific group of MDD patients, because the HPA-axis 
is very likely to play a broader role, for instance in the etiology of subtreshold depression 




on previous findings of increased morning cortisol in lifetime MDD and anxiety (Vreeburg 
et al., 2009a; 2010).  
Our use of a dimensional approach enabled us to detect non-linear associations 
that would have gone undetected, had we only used DSM-IV diagnoses. The observed 
‘inversed U’-shaped associations between the CAR indicators and the dimensions 
replicates earlier findings by our group in another, smaller sample (Veen et al., 2011) and 
indicates that, depending on his/her dimensional symptom profile, a patient is more likely 
to have higher or lower exposure to cortisol during the morning. This could explain why 
both hypo- and hypercortisolemia are observed in depressed (elderly) patients (Bremmer 
et al., 2007; Penninx et al., 2007). A possible explanation for the inverted U-shape of the 
observed associations is that cortisol levels increase with dimensional symptom severity 
until a critical threshold is reached and the HPA-axis is down-regulated or exhausted 
(Veen et al., 2011). There are several potential underlying mechanisms for such 
“hypocortisolism” (Heim et al., 2000). It could be related to a down-regulation of CRH 
receptors in the pituitary, following a longer period of stress-induced hypothalamic CRH 
secretion, resulting in lower adrenocorticotropic hormone (ACTH) and reduced cortisol 
levels. Other possible mechanisms that have found some support from studies in both 
humans and animals could be a reduced biosynthesis or depletion of CRH, ACTH, cortisol 
(Heim et al., 2000) or increased sensitivity of the HPA-axis to negative feedback (Holsboer 
et al., 1985). Although some studies found that especially patients with severe (psychotic) 
major depression showed a higher cortisol exposure during the CAR versus healthy 
controls (Belanoff et al., 2001; Posener et al., 2000), other studies in humans and animals 
have found the HPA-axis to be down-regulated in response to prolonged severe stress, 
leading to a blunted CAR (Oldehinkel et al., 2001; Meinlschmidt et al., 2005). Our results 
fit in with both lines of evidence and suggest that they are not necessarily inconsistent. 
 The association between General Distress and Anhedonic Depression on the one 
hand and the HPA-axis on the other hand, has been investigated in previous studies 
outside the tripartite framework (using various different questionnaires). Several studies 
found an association between measures of General Distress (also called ‘Negative Affect’) 
and increased HPA-axis activity in healthy adults (van Eck et al., 1996; Smyth et al., 1998; 
Buchanan et al., 1999; Jacobs et al., 2007; Polk et al., 2005). Our findings are in line with 
this, since we also found an increase of the CAR when scores increased within the lower 
(healthy) spectrum of General Distress. Previous studies mainly investigated the 
association between the HPA-axis and the opposite pole of Anhedonic Depression, called 
‘Positive Affect’. These studies generally found decreasing cortisol levels with increasing 
Positive Affect (Smyth et al., 1998; Polk et al., 2005; La et al., 2005; Steptoe et al., 2008). 
Our findings are in line with this, because we found an increase in cortisol exposure 
during the CAR with increasing Anhedonic Depression (i.e. lack of Positive Affect). The 
only previous study to investigate the association between Anxious Arousal and (morning) 
cortisol (n=36) did not find an association (Veen et al., 2011). However, larger statistical 
power due to the much larger sample size in the present study (n=1029) could explain 
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why we did find an association between Anxious Arousal and the dynamic of morning 
cortisol exposure. Interestingly, our observed U-shaped associations were not found by 
any of the abovementioned studies, possibly because they used healthy subjects with 
relatively low symptom severity and were thus unable to detect a decrease in subjects 
with severe symptomatology, or because only linear associations were explored.  
 Our findings could be regarded as further (external) validation of the dimensions 
of the tripartite model and the MASQ-D30. The associations of the MASQ-D30 scales with 
different aspects of the CAR indicate that they are not merely psychometric constructs, 
but also have a biological substrate. The tripartite dimensions (as measured with the 
MASQ-D30) could thus be a promising clinical phenotype for future etiological research. 
 The present study has some strong characteristics. First, the studied group was 
one of the largest to date, which increased the reliability of our results. Second, we were 
able to test the associations across groups including current and remitted MDD patients, 
anxiety patients and healthy subjects, making our results broadly generalizable. Third, a 
wide range of determinants of the HPA-axis (Vreeburg et al., 2009b) were considered as 
possible confounders. Fourth, we studied multiple cortisol indicators that were all 
indicative of different aspects of the HPA-axis across the day. The present results should 
also be interpreted in the light of some limitations. First, our results are cross-sectional 
and cannot indicate change over time or causality. Second, the saliva samples were 
collected by the participants themselves at home and compliance with the sampling 
protocol was not monitored. This may have resulted in some measurement error 
(Vreeburg et al., 2009a). Third, we only measured cortisol during one day, possibly 
missing day-to-day variations in cortisol levels, which could have further increased 
measurement error. Fourth, systematic differences between those that did and did not 
return saliva samples may have biased our results somewhat towards an older and higher 
educated population. Fifth, our results apply to outpatients with relatively low levels of 
symptom severity, which limits generalizability of our results to severely ill psychiatric 
inpatients. Sixth, we only used three, quite broad symptom-dimensions, whereas in 
reality more (sub)dimensions may exist (Hollander-Gijsman et al., 2010). Finally, the 
effect sizes suggest that many more factors play a role in symptom dimensions of 
depression and anxiety on top of cortisol, which, for now, prevents the use of cortisol 
measurements as clinical marker for psychopathology in individual patients. 
 In future research, a prospective design should be used to investigate the 
association between symptom-dimensions and cortisol indicators across a large range of 
clinical patients (from subtreshold to inpatient), using a broad range of symptom 
dimensions.  
 In conclusion, the dimensions of the tripartite model were found to be associated 
with morning cortisol exposure. Because the dimensions were continuous, non-linear 
associations could be detected, demonstrating the added value of symptom-dimensions 
when investigating the role of small and/or complex neuroendocrine mechanisms, 




Supplementary Table 4.4 (S1): Non-linear associations between the MASQ-D30 dimensions and cortisol indices in 729 subjects with a current major depressive 
disorder and/or an anxiety disorder. 
















0.006 0.60 (0.003) 
-0.58 (0.005) 
0.012 -0.10 (0.63) 
0.12 (0.58) 








-0.34 ( 0.09) 
0.105 0.59 (0.003) 
-0.56 (0.006) 
0.065 -0.20 (0.30) 
0.18 (0.34) 









0.110 0.59 (0.004) 
-0.55 (0.006) 
0.069 -0.23 (0.23) 
0.19 (0.32) 










0.008 0.70 (0.016) 
-0.70 (0.017) 
0.008 -0.04 (0.89) 
0.08 (0.78) 









0.103 0.59 (0.042) 
-0.59 (0.044) 
0.059 -0.19 (0.49) 
0.19 (0.49) 









0.110 0.58 (0.045) 
-0.58 (0.048) 
0.063 -0.15 (0.59) 
0.13 (0.64) 










0.007 0.53 (0.011) 
-0.53 (0.012) 
0.009 0.08 (0.72) 
-0.03 (0.88) 









0.106 0.54 (0.010) 
-0.54 (0.010) 
0.062 -0.07 (0.73) 
0.09 (0.64) 









0.110 0.55 (0.010) 
-0.54 (0.011) 
0.066 -0.06 (0.76) 
0.08 (0.67) 
0.194 0.21 (0.33) 
-0.19 (0.38) 
0.050 
Data are  β-coefficients (p-value); AUCg = area under the curve with respect to the ground; AUCi = area under the curve with respect to the increase; DST = 
dexamethasone suppression testModel 1 is adjusted for sociodemographic factors (sex, age and Northern European ancestry), sampling factors (working, time 
of awakening, sleep duration and months with more or less daylight), and health indicators (smoking, alcohol use (# of daily beverages), alcohol dependence, 




Supplementary Table 4.5 (S2): Non-linear associations between the MASQ-D30 dimensions and cortisol indices in 1378 subjects with and without lifetime 
psychopathology  
















0.009 0.47 (0.001) 
-0.41 (0.004) 
0.011 0.01 (0.95) 
0.01 (0.92) 
0.000 0.13 (0.38) 
-0.08 (0.58) 
0.003 




0.100 0.43 (0.002) 
-0.37 (0.008) 
0.067 -0.04 (0.78) 
0.03 (0.85) 
0.165 0.13 (0.36) 
-0.07 (0.63) 
0.043 




0.105 0.37 (0.011) 
-0.33 (0.021) 
0.068 -0.06 (0.66) 
0.03 (0.84) 










0.008 0.56 (0.004) 
-0.51 (0.009) 
0.008 -0.04 (0.85) 
0.09 (0.65) 
0.003 0.18 (0.37) 
-0.16 (0.41) 
0.001 




0.094 0.47 (0.013) 
-0.43 (0.025) 
0.064 -0.20 (0.27) 
0.20 (0.28) 
0.165 0.23 (0.23) 
-0.18 (0.35) 
0.042 




0.102 0.45 (0.043) 
-0.41(0.041) 
0.067 -0.18 (0.32) 
0.16 (0.38) 










0.006 0.48 (0.001) 
-0.44 (0.003) 
0.009 0.19 (0.19) 
-0.15 (0.32) 
0.003 0.15 (0.31) 
-0.14 (0.34) 
0.001 




0.095 0.45 (0.002) 
-0.42 (0.004) 
0.066 0.02 (0.89) 
-0.01 (0.96) 
0.165 0.21 (0.15) 
-0.19 (0.20) 
0.041 




0.102 0.45 (0.002) 
-0.42 (0.004) 
0.066 0.01 (0.94) 
-0.01 (0.97) 
0.169 0.26 (0.08) 
-0.22 (0.13) 
0.042 
Data are  β -coefficients (p-value); AUCg = area under the curve with respect to the ground; AUCi = area under the curve with respect to the increase; DST = 
dexamethasone suppression test. Model 1 is adjusted for sociodemographic factors (sex, age and Northern European ancestry), sampling factors (working, time 
of awakening, sleep duration and months with more or less daylight), and health indicators (smoking, alcohol use (# of daily beverages), alcohol dependence, 







Dimensions of Depression and Anxiety and the  
Metabolic Syndrome: Somatic Arousal is Associated with Somatic 










Objective: To investigate the association between depression and anxiety symptoms and 
the metabolic syndrome (MetSyn), using a dimensional approach. The association 
between depression and anxiety, on the one hand, and the MetSyn as a cluster or its 
individual components, on the other hand, is equivocal. The categorical nature of the 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition might partly explain 
the inconsistent findings. Methods: In 2,433 Netherlands Study of Depression and Anxiety 
participants (mean age, 42.3 years; 33.1% male), three symptoms dimensions—lack of 
positive affect (PA, depression specific); negative affect (NA, aspecific); and somatic 
arousal (SA, anxiety specific)—were assessed by a shortened adaptation of the Mood and 
Anxiety Symptom Questionnaire. The association between symptom dimensions and 
MetSyn components (waist circumference, triglycerides, high-density lipoprotein 
cholesterol, glucose, and mean blood pressure) was analyzed, using linear regression 
analysis. Results: The occurrence rate of the MetSyn was 20.1% (n=490). SA, but not PA 
and NA, was strongly associated with four out of five MetSyn components, especially 
waist circumference, triglycerides, and blood pressure (β=0.046, p<.01; β=0.077, p<.001; 
and β=0.069, p<.001, respectively), and with the total number of MetSyn components 
(β=0.098, p<.001). Conclusions: Our results demonstrate a strong association of most of 
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Penninx, BWJH (2011). Somatic arousal is associated with somatic symptoms of the 









Note: Troughout the literature, different interchangeable names are used for the 
measured dimensions of the tripartite model. In this published chapter, the names that 
were used to describe the dimensions differ from the names that were used in the other 
chapters. In this chapter, the name negative affect (NA) is used in stead of general 
distress, the name positive affect (PA) is used in stead of anhedonic depression, and the 
name somatic arousal (SA) is used in stead of anxious arousal. This difference of 




Mood and anxiety disorders are related to an increased risk of cardiovascular morbidity 
and mortality (Penninx et al., 2001; Barth et al., 2004). The metabolic syndrome (MetSyn) 
is a cluster of cardiovascular risk factors (i.e., elevated waist circumference, triglycerides, 
blood pressure, and fasting glucose, and reduced high-density lipoprotein [HDL]) 
cholesterol) (Grundy et al., 2005) and is thought to mediate partly this relationship 
(Bjorntorp, 2001). The association between depression and anxiety and the MetSyn has 
been extensively investigated. Most studies (Heiskanen et al., 2007) focused on the 
association between depression and the cluster of the MetSyn and its individual 
components. Other studies (Skilton et al., 2007; Carroll et al., 2009), however less 
numerous, investigated the association between anxiety and both the MetSyn cluster and 
its individual components. In addition, in a recent publication (Reedt Dortland et al., 
2010), we examined whether disorder status and symptom severity were associated with 
the MetSyn. No significant difference was found between subjects with and without 
psychopathology (both depression and/or anxiety). Only the subgroups of the most 
severely depressed or anxious subjects had increased occurrence rates of the MetSyn, an 
association predominantly driven by abdominal obesity and dyslipidemia. Despite these 
observations, the question remains whether a complete mood disorder diagnosis or 
rather only specific symptom dimensions are related to the MetSyn and whether the 
dichotomous MetSyn diagnosis or only some 
of its components are related to psychopathology dimensions.  
 There are three major reasons that could explain why this question has so far 
remained unanswered. First, the studies have been conducted in widely differing 
samples, which limit the possibilities to formulate a broadly generalizable model. For 
instance, there have been differences in the settings (e.g., clinical population or the 
general population) (Ierodiakonou & Iacovides, 1987), age of the subjects (an elderly 
population or young adult patients) (Almeida et al., 2009; Franko et al., 2005), and the 
assessment of psychopathology (questionnaires versus clinical diagnoses) (Koponen et al., 
2010; Goldbacher et al., 2009). Second, the categorical diagnostic approach (using 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-IV]) for 
depressive and anxiety disorders, lumping together disparate symptom clusters, may 




same diagnosis can be very different in terms of their symptom profiles, whereas other 
individuals with important mental health problems fail to meet the diagnostic criteria due 
to symptom heterogeneity. Third, like the DSM-IV diagnosis, the MetSyn concept is also 
heterogeneous, and is the subject of substantial debate (Kahn et al., 2005; Reaven, 2005). 
Because at least three of five components are needed to fulfil the criteria of the MetSyn, 
there are numerous combinations of components possible that all lead to the same 
MetSyn diagnosis. Studies (Tolker & Shirom, 2008) have shown that sometimes only 
specific components of the MetSyn are associated with depression, which cast doubt over 
the usability of the total MetSyn concept in psychopathology research. It is possible that, 
in the large variety of depression/anxiety symptoms, some are “specifically” associated 
with a distinct MetSyn component (e.g., energy loss, often leading to decreased physical 
activity, might lead to elevated waist circumference [WC]). Based on the criticized 
definition of the MetSyn and the possible specific associations between diagnostic and 
MetSyn symptoms, it would thus be informative to investigate the association between 
specific depression/anxiety symptoms, on the one hand, and the MetSyn, both defined as 
a cluster of symptoms and as individual components, on the other hand.  
 So far, research on the association between depression and anxiety and the 
MetSyn has mainly focused on categorical and heterogeneous assessments of affective 
disorders symptomatology or anxiety and depression severity scales (Barefoot & Schroll, 
1996; Frasure-Smith & Lesperance, 2005). In addition, diagnoses show overlapping 
criteria and comorbidity rates are high (Kessler et al., 2005; Brown et al., 2001). To 
overcome these problems, diagnoses should be more homogeneous and not 
dichotomous. A feasible alternative for categorical diagnoses is the use of a dimensional 
approach. Within a dimensional approach, a patient is described in terms of coexisting 
different symptom domains or dimensions, and not in terms of presence or absence of 
psychopathology. Each dimension provides specific information on the level of a specific 
symptom domain, running from absent or healthy to severe. Importantly, dimensions are 
continuous by principle. Along a continuous scale, changes from one level to another are 
subtle, whereas in a dichotomous scale, changes are rough and restricted (e.g., depressed 
versus non-depressed). This makes continuous variables more sensible for detection of 
(small) differentiating factors (Veen et al., 2011), thus increasing statistical power 
(MacCallum et al., 2002).  
 A well-known dimensional model is the tripartite model for depression and 
anxiety (Clark & Watson, 1991), which distinguishes three symptom dimensions. The 
broad “negative affect” (NA) dimension describes general symptoms of psychological 
distress (e.g., lack of concentration or pessimism) that are seen both in depression and 
anxiety and could account for their high comorbidity. The (lack of) “positive affect” (PA) 
dimension (also called anhedonic depression), covers anhedonic symptoms, which are 
mainly specific to depression. The “somatic arousal” (SA) dimension covers symptoms of 
hyperarousal (e.g., palpitations, shortness of breath, and dizziness), which are specific for 
anxiety, especially panic disorder. The dimensional model was not developed for 




detection of DSM-IV diagnoses, but rather to provide a descriptive alternative for the 
presence or absence of psychopathological symptoms in a subject. The tripartite model 
was developed to circumvent the lack of diagnostic specificity due to the high levels of 
comorbidity observed in depression and anxiety, one of the major problems of the DSM-
IV “golden standard.” Typifying patients in terms of their NA, PA, and SA scores has two 
advantages: first, comorbidity is circumvented; and second, based on the profile of the 
scores, patients can be described in more specific terms of symptomatology. Several 
studies (de Beurs et al., 2007, Watson et al., 1995a) have shown these specific dimensions 
to be specifically increased in depression (PA) and anxiety (mainly panic disorder, SA) and 
that NA was more indicative for overall severity across patients.  
 The aim of the present study was to investigate the relationship between the 
symptom dimensions of depression and anxiety of the tripartite model, and the MetSyn 
and its individual components within the Netherlands Study of Depression and Anxiety 
(NESDA), as a dimensional approach makes it possible to look more specifically into these 
associations. 
 
5.2 Methods and Materials 
 
Subjects 
Subjects selected for these analyses were baseline participants of NESDA, a cohort study 
among 2,981 individuals aged 18 years through 65 years. Respondents were recruited in 
the community, in primary care, and in specialized mental healthcare settings from 
September 2004 through February 2007, throughout The Netherlands. All subjects 
completed a medical examination, a face-to-face interview, and self-report 
questionnaires. A detailed description of NESDA is reported elsewhere (Penninx et al., 
2008). The study protocol was approved by the Ethical Review Board of each participating 
centre and all subjects signed an informed consent.  
 In the same study sample, tricyclic antidepressant (TCA) users were found to have 
a significantly increased prevalence of the MetSyn (Reedt Dortland et al., 2010). This 
association was not found for users of other types of antidepressants, such as selective 
serotonin reuptake inhibitors (Reedt Dortland et al., 2010). Therefore, the relatively small 
group of TCA users (n = 80) was excluded from our analyses, so that the results would not 
be affected by the potential confounding influence of TCAs. Subjects with missing MetSyn 
or Mood and Anxiety Symptom Questionnaire (MASQ) values (n = 468) were excluded as 
well, resulting in a sample of 2,433 (81.6%) subjects. An important number of the 
included subjects comprised healthy controls or remitted patients (n=1449), whereas 
other subjects had a current diagnosis of pure depression (n=222), pure anxiety (n=226), 
or comorbid disorder (n=536). No inpatients were included. The included subjects did not 
differ from the excluded group in sex distribution, presence of cardiovascular disease 
(CVD), and physical activity. Included subjects were older (42.3 years versus 40.0 years, 




(35.8% current smokers versus 50.9%, p<.001), and consumed more alcohol (16.4% 




MASQ dimensions  
The three dimensions of the tripartite model were measured with the 30-item adaptation 
(MASQ-D30) of the MASQ (Watson et al., 1995a; 1995b). The MASQ-D30 was previously 
validated and showed reliability and validity within the NESDA study (de Beurs et al., 
2007; Chorpita & Daleiden, 2002; Wardenaar et al., 2010). The MASQ-D30 consists of 
three ten-item scales, representing NA, PA, and SA (Table 1). On each item, participants 
were asked to rate how much in the past week they have experienced “feelings, 
sensations, problems and experiences that people sometimes have” on a 5 point scale, 1 
being “not at all” and 5 being “extremely.” Higher scores indicate more severe symptom 
levels for that specific dimension. 
 
MetSyn 
The MetSyn and its components, when expressed as dichotomous variables (i.e., elevated 
WC, triglycerides, blood pressure, and fasting glucose, and reduced HDL cholesterol), 
were exactly defined according to the revised criteria of the National Cholesterol 
Education Program-Adult Treatment Panel III (Grundy et al., 2005). WC was measured 
with a measuring tape at the central point between the lowest rib and the highest point 
of the iliac crest, on light clothing. Triglycerides, HDL cholesterol, and glucose levels were 
determined by standardized routine laboratory assays, and diastolic and systolic blood 
pressures were measured during supine rest (OMRON M4 IntelliSense Digital Blood 
Pressure Monitor, HEM-752A, Omron Healthcare, Inc., Bannockburn, Illinois). Use of 
triglyceride or HDL cholesterol-influencing medication and use of antihypertensive or 
glucose reducing drug were registered. In addition, we used continuous variables for the 
MetSyn components (which is preferable when aiming for more statistical power) 
(MacCallum et al., 2002). In these analyses, we “adjusted” the values for those subjects, 
using a MetSyn component influencing medication. This was done following the methods 
described in several previous publications (Bays et al., 2003; Grundy et al., 2005). For the 
use of fibrates, 0.10 mmol/L (3.8 mg/dL) was subtracted from HDL cholesterol, and 0.67 
mmol/L (60 mg/dL) was added to the triglycerides. For the use of nicotinic acid, 0.15 
mmol/L (5.8 mg/dL) was subtracted from HDL cholesterol, and 0.19 mmol/L (17 mg/dL) 
was added to the triglycerides. For the use of antidiabetic medication and a glucose level 
of < 7 mmol/L (126 mg/dL), a value of 7 mmol/L (126 mg/dL) was given to glucose, as was 
done previously (33). Mean blood pressure (MBP) was expressed as the arithmetic mean 
of systolic and diastolic blood pressures, which were both measured twice during supine 
rest on the right arm (OMRON M4 IntelliSense Digital Blood Pressure Monitor, HEM-752A, 
Omron Healthcare, Inc.) and averaged over the two measurements. For persons using 




antihypertensive medication, 10 mm Hg was added to systolic blood pressure, and 5 mm 
Hg was added to diastolic blood pressure, in line with earlier studies (Vogelzangs et al., 
2007). These values represent the average decline in blood pressure in antihypertensive 
medication trials (SHEP, 1991; Tannen et al., 2006). 
 
Table 5.1: This table lists all the symptoms incorporated in the three symptom 
dimensions of the MASQ-D30.  
Negative Affect Positive Affect 
 
Somatic Arousal 





Felt really happy Felt nauseous 
Felt irritable 
 
Felt optimistic Felt dizzy or light-
headed 
 
Felt hopeless Felt like I was having a lot of 
fun 
 
Was trembling or 
shaking 
Blamed myself for a lot of 
things 
 
Felt like I accomplished a lot Had pain in my chest 
Felt dissatisfied with 
everything 
 
Felt like I had a lot to look 
forward to 
Had hot or cold spells 
Felt pessimistic about the 
future 
 
Felt really talkative Was short of breath 
Felt inferior to others Felt really ‘up’ or lively Muscles were tense or 
sore 
 
Had trouble making 
decisions 
Felt like I had a lot of energy Heart was racing or 
pounding 
 




Information on depression and anxiety severity was collected during the baseline 
measurement of the NESDA study (Penninx et al., 2008), using the Beck Anxiety Inventory 




www.ids-qids.org), in which the most severe groups were defined as “severe anxiety 
symptoms” with a score of ≥ 29 on the BAI and “very severe depressive symptoms” with a 
score of ≥ 49 on the IDS-SD. Previous NESDA research (Reedt Dortland et al., 2010) indicated 
that the prevalence rates of the MetSyn were increased in those with severe anxiety 
symptoms (n=185) in crude models and independently increased in those with very 
severe depressive symptoms (n=102) after fully adjusted models. Because information on 
the BAI and IDS-SR scores was available for our sample, we decided to investigate 
whether the previous found associations in the same cohort between the highest scores 




Covariates were grouped into two types of variables: sociodemographic and life-style 
variables. Sociodemographic variables included age, sex, and years of education. Life-style 
characteristics included smoking status (never/ former/current), alcohol use (<1/1–2/>2 
drinks per day), both assessed by standardized questionnaires, and physical activity, 
which was assessed by the International Physical Activity Questionnaire (Booth, 2000) and 
expressed in 1000 Metabolic Equivalent-minutes in the past week. Metabolic Equivalent-
minutes reflects the ratio of the associated metabolic rate for specific activities divided by 
the resting metabolic rate multiplied by the minutes performed activity. CVD was 
considered to be present when participants self-reported a diagnosis of coronary heart 
disease, cardiac arrhythmia, angina, heart failure, or myocardial infarction, confirmed 
with the use of cardiovascular medication. Medication use of any kind within the past 
month was registered by observation of drug containers brought in and coded according 




Sample characteristics were summarized, using means and standard deviations (SD) for 
quantitative variables and by percentages for categorical variables. Multivariate linear 
regression analyses were conducted to assess the association between each MASQ-D30 
dimensions (i.e., PA, NA, and SA) and the individual continuous MetSyn components and 
the total number of MetSyn components. Analyses for each dimension were performed 
separately. To normalize residuals, non-normally distributed dependent variables were 
naturally log-transformed. After running crude models, we adjusted for basic covariates 
(i.e., age, sex, and years of education) in model 1, and for additional life-style-related 
covariates (i.e., smoking status, alcohol use, and physical activity) in model 2. Because sex 
differences in the association between anxiety, depression, and the MetSyn have 
previously been observed (Token et al., 2008; Kinder et al., 2004), appropriate interaction 
terms with sex were explored. To evaluate the influence of prevalent CVD, participants 
diagnosed with CVD were excluded in a sensitivity analysis.  




 To evaluate whether the earlier described association between severity of 
depressive and anxious symptoms and MetSyn abnormalities were driven by symptom 
dimensions, additional regression analyses were performed. We analyzed the association 
of BAI and IDS-SR severity categories with the individual MetSyn components and the 
total number of components by performing linear regression analyses, adjusting for 
models 1 and 2 covariates, and additionally adjusting for those symptom dimensions that 
demonstrated to be associated significantly with the MetSyn components in the main 
analyses.  
 Multivariate logistic regression analyses were performed to assess the association 
between the SDs of continuous scores of the three symptom dimensions and the MetSyn 
diagnosis. All assumptions for linearity were tested and fulfilled. All tests were two-tailed 
with p < .05 denoting statistical significance. Statistical analyses were done with SPSS 16.0 





Sample characteristics are shown in Table 5.2. The mean age was 42.3 years (SD=13.1), 
33.1% were men, and mean number of years of education was 12.3 years (SD=3.3). The 
criteria for the MetSyn were fulfilled by 20.1% (n=490). The reported means and SDs for 
each dimension are calculated from the continuous values of all subjects included 
(n=2433) for that dimension. 
 
Symptom dimensions and MetSyn components 
Outcomes of the linear regression analyses between MASQ-D30 dimensions and MetSyn 
components are shown in Table 5.3. PA showed a significant association with every 
MetSyn component in the crude model. Adjustments in model 1 led to a decrease of the 
β with >10% and to nonsignificant associations with WC, fasting glucose levels, and MBP. 
Analyses with the separate covariates of model 1 showed age to be the most important 
confounder. Associations of PA with triglycerides and HDL cholesterol became statistically 
nonsignificant after adjustment for life-style factors (model 2). No significant associations 
were found for NA with any of the MetSyn components, in the unadjusted and fully 
adjusted models.  
 On the contrary, in the crude unadjusted model, SA showed a significant 
association with all MetSyn components except for fasting glucose. The associations for 
SA remained significant in both adjusted models with regard to WC (WCcrude: β=0.061, 
p=.003; WCmodel 2: β=0.046, p=.01), triglycerides (Trigcrude: β=0.077, p<.001; Trigmodel 2: 







Table 5.2. Sample characteristics (n=2433) 
General characteristics   
Age  42.3 (13.1) 
Sex (% men) 33.1  
Years of education  12.3 (3.3) 
Cardiovascular disease 5.8 
Smoking   
     Never 29.3 
     Former 34.9 
     Current 35.8 
Alcohol consumption   
     < 1 glasses/day 61.0 
     1-2 glasses/day 22.4 
     > 2 glasses/day 16.4 
Physical activity (1000 MET minutes)  3.7 (3.06) 
Metabolic syndrome components  
Waist circumference total (cm)  88.7 (13.8) 
HDL- cholesterol (mmol/l)  1.6 (0.4) 
Triglycerides (mmol/l)  1.3 (0.8) 
Glucose (mmol/l)  5.2 (0.9) 
Systolic blood pressure (mmHg)  136.2 (19.7) 
Diastolic blood pressure (mmHg)  81.5 (11.1) 
Mean blood pressure (mmHg) 108.9 (14.7) 
Number MetSyn components  1.45 (1.3) 
Metabolic syndrome (%) 20.1 
Symptom dimensions (mean scores)  
MASQ Positive affect 33.4 (9.7) 
MASQ Negative affect 20.0 (8.6) 
MASQ Somatic arousal 15.7 (6.1) 
Means and standard deviations (SD) are given for age, years of education, physical 
activity, number of metabolic syndrome components and the three symptom 
dimensions. Percentages are given for sex, smoking status, alcohol consumption, and 
presence of metabolic syndrome.  





Table 5.3: Linear regression for association between MASQ dimensions and metabolic syndrome components in 2433 subjects. 
 Waist Circumference Triglycerides HDL Cholesterol Glucose Blood Pressure Number 
of MetSyn 
Components 
 Β p-value β p-value β p-value β p-value β p-value β p-value 
Negative  
Affect 
         
   
Crude .070 .001 .097 < .001 - .063 .002 .079 < .001 .076 < .001 .107 < .001 
Model 1 - .001 .94 .044 .02 - .039 .04 .027 .15 .008 .64 .036 .05 




       
   
Crude - .002 .93 .031 .12 - .036 .08 .008 .68 - .028 .17 .018 .37 
Model 1 .016 .34 .042 .03 - .017 .36 .036 .05 - .001 .94 .033 .07 




       
   
Crude .061 .003 .077 < .001 - .056 .01 .025 .22 .069 < .001 .098 < .001 
Model 1 .050 .01 .064 .001 - .045 .02 .023 .21 .062 < .001 .074 < .001 
Model 2 .046 .01 .046 .02 - .018 .32 .023 .22 .068 < .001 .062 .001 
β, standardised  β  by linear regression analyses.  
Abbreviations: HDL, high density lipoprotein.  
Model 1: adjusted for age, sex and years of education (sociodemographic factors) 





 The significant crude association of SA with HDL cholesterol weakened after 
adjustment in model 1, and further in model 2 to a nonsignificant level. Also, the 
association of SA with the number of metabolic syndrome components (Nr.) remained 
highly statistically significant throughout all models (Nr.crude: β=0.098, p<.001; Nr.model 2: 
β=0.062, p<.001). The graded, positive association between SA and the number of 
MetSyn components, and SA and quartiles of the individual fully adjusted MetSyn 
components are shown in Figure 5.1. In sensitivity analyses in which 141 subjects with 
CVD were excluded excluded, results did not change (data not shown). None of the 
interaction terms between dimensions with sex were statistically significant, which 
suggests that associations were largely similar for men and women.  
To evaluate whether another measure for somatic symptoms would give 
comparable results, we repeated the linear regression model analyses with the validated 
BAI somatic subscale (36). These analyses confirmed an association for the somatic BAI 
subscale and a much less consistent association for the nonsomatic BAI subscale. The 
associations with the BAI somatic scale score remained significant in the fully adjusted 
models for the number of MetSyn components (Nr. MetSyn: β =0.072, p<.001), and all 
MetSyn components, except for HDL cholesterol, which showed a trend toward 
significance with a β=-0.033, p=.08 (WC: β=0.056, p<.001; Trig: β=0.083, p<.001; Gluc: 
β=0.038, p=.04; MBP: β=0.046, p=.01). There was a strong Intercorrelation between the 
somatic symptom dimension of the MASQ (SA) and the subscale of the BAI (rsBAI=0.73, 
p<.001). We did not analyze associations with subscales of the IDS-SR because earlier 
work by Wardenaar et al. (2010) did identify three subscales but none of these was a 
clear somatic subscale (in factor analyses, the rather restricted somatic items were 
attributed to all three subscales). So, no valid somatic IDS subscale exists. Therefore, it is 
not appropriate to use a subscale in a comparative analysis. To explore whether results 
would also be consistent for the nonsomatic symptom subscale, we also conducted linear 
regression analyses with the nonsomatic BAI subscale (BAI subjective scale score). We 
expected that associations for the subjective BAI subscale would be similar to those for 
the PA and NA dimensions of the MASQ-30, which was confirmed. None of the 
associations with the BAI subjective scale score were statistically significant in the fully 
adjusted models, with exception of the number of MetSyn components (β=0.041, p =.02).  
Regression analyses performed to investigate whether previously found positive 
associations between MetSyn abnormalities and symptom severity were driven by 
symptom dimensions, in particular, the SA dimension, showed the following: Initial 
significant outcomes (in which the number of MetSyn components was the dependent 
variable and BAI and IDS-SR severity categories were the independent variables) lost 
statistical significance after adjustment with the SA dimension. This means that the earlier 
described associations between the high severe groups according to the BAI and IDS-SR 
with the MetSyn were largely attributable to a high SA score. 
 





Table 5.4: Logistic regression for the association between standard deviations (SDs) of 
continuous scores on MASQ dimensions and the odds of metabolic syndrome in 2433 
subjects 
 OR of MetSyn 







Crude  1.16 1.05-1.28 .004 
Model 1 1.02 0.92-1.14 .67 
Model 2 0.99 0.88-1.10 .99 
Negative Affect 
Crude  1.01 0.92-1.12 .78 
Model 1 1.01 0.99-1.02 .28 
Model 2 1.04 0.93-1.16 .51 
Somatic Arousal 
Crude  1.19 1.08-1.31 < .001 
Model 1 1.18 1.06-1.30 .002 
Model 2 1.15 1.04-1.28 .008 
 
Abbreviations: OR, odds ratio per SD increase, by logistic regression analysis; CI, 
confidence interval 
Model 1: adjusted for age, sex, years of education.  
Model 2: additionally adjusted for lifestyle factors: smoking status, alcohol use and 
physical activity.  
 
  
Symptom dimensions and cluster of the MetSyn 
Logistic regression analyses of the symptom dimension with the MetSyn showed a small 
but significant crude relationship between PA and the MetSyn. NA was not significantly 
associated with the MetSyn. The initial significant crude relationship between SA and the 
MetSyn remained statistically significant throughout multivariable adjustment (odds ratio 
per SD increase, 1.15; 95% confidence interval, 1.04–1.28; p=.008) (Table 5.4). Analyses, 
in which the associations of BAI or IDS severity categories with the MetSyn were adjusted 




The main finding of this study is that only SA symptom dimension is strongly and 




triglycerides, and MBP) and shows a graded association with the number of MetSyn 
components. Using a dimensional approach, SA was thus associated with an increased 
metabolic risk. No independent associations between MetSyn with NA and PA were 
observed. These results are supported by our finding that the somatic scale of the BAI is 
associated with the MetSyn components, whereas the non-somatic scales are not. 
Approaching depression and anxiety dimensionally, the aspecific NA dimension and the 
depression specific PA dimension did not show any association with the MetSyn. We only 
found a strong and consistent relationship between the somatic arousal dimension and 
multiple MetSyn components. This is in line with previous research on symptom 
dimensions of especially depression in relation to somatic outcomes, in which the 
somatic/affective sub-dimension, rather than other important dimensions (e.g., 
cognitive/affective and appetitive), was most strongly associated with cardiovascular risk 
and outcome (De Jonge et al., 2006; Bosch et al., 2009). It seems we are looking at a 
specific sub-dimension: the “somatic depression/anxiety” sub-dimension. On the one 
hand, this subtype could be reflective of underlying dysregulated homeostasis 
mechanisms due to anxious or depressed mood states, such as inflammation (Howren et 
al., 2009), impaired hypothalamus-pituitary-adrenal axis function (Brown et al., 2004; 
Vreeburg et al., 2009a), or a higher sympathetic and lower parasympathetic autonomic 
tone (Licht et al., 2010). 
 






Figure 5.1: Adjusted (geometric) means across quartiles of somatic arousal on the MASQ-D30, for the 
individual MetSyn components and the total number of MetSyn components. Data are adjusted for age, 
sex, educational level, alcohol consumption, smoking status and physical activity. Error bars indicate 95% 
confidence intervals of the mean, and regression lines are shown. N quartile 1 =744; N quartile 2 =436; N quartile 3 





Elevated levels of inflammatory markers could induce a depressive episode (48); altered 
lipid patterns caused by high levels of cortisol (Bjorntorp, 2001; Chrousos, 2000) could 
lead to other lipid-related symptoms (overweight, abdominal obesity, and 
hypertriglyceridemia) (Veen et al 2011; Vogelzangs et al., 2009); and activation of 
sympathetic nervous system leads to increased blood pressure (Shibao et al., 2007) and, 
thus, to hypertension (Bjorntorp, 2001; Lambert et al., 2010). This network of pathways 
can, thus, result in an increased metabolic or cardiovascular risk and cardiovascular 
disease. On the other hand, the reverse mechanism could be active. Ongoing metabolic 
dysregulations could be causing (especially SA) symptoms of depression and anxiety 
(Mast et al., 2008l Alexopoulos et al., 1997; Steffens et al., 2002; Ajilore et al., 2007; 
Huber, 2008). Regardless of the underlying mechanisms and the direction of causality, the 
dose-response gradient between the number of MetSyn components and levels of SA 
indicates that, when more SA symptoms are present, more MetSyn abnormalities are 
present. Apart from biological mechanisms, other processes may be involved during a 
depressive episode as a consequence of anhedonia, such as altered life-style patterns 
(poor diet and decreased physical activity) (LaMonte et al., 2005; Hu & Willett, 2002), 
which might induce metabolic changes and cardiovascular risk factors.  
 Previous research based on NESDA data (8) showed that the prevalence rates of 
the MetSyn were increased in those with the highest levels of depressive symptoms 
based on the BAI and the IDS-SR. After adjustment for the MASQ SA dimension, the 
earlier described associations lost statistical significance. These results indicate that the 
earlier described association between MetSyn and the most severe depression and 
anxiety symptom scales can be explained by the fact that these persons had high scores 
on the SA dimension.  
 In terms of metabolic risk evaluation and detection, a dimensional approach has 
more differentiating capacities compared with the widely used diagnostic DSM-IV 
categories. The somatic symptom dimension could, therefore, be the key feature in the 
association between depression/anxiety and somatic outcomes.  
 Using a dimensional approach, the level of a symptom dimension varies 
differentially between diagnostic groups (e.g., singular depression, singular anxiety, or 
comorbid state). At the same time, all symptom dimensions can be present at a 
significant level within every diagnostic group. This means that the clinical presentation of 
a subject is dependent on the symptom dimension(s) with the highest scores. Our results 
demonstrate that the SA dimension is associated with several MetSyn components. The 
fact that SA levels are not equally high for every depressed and/or anxious subject might 
explain the inconsistent findings in literature on the association with the MetSyn.  
 Our study has several strengths. This is, to our knowledge, the first study 
describing the relationship between depression and anxiety dimensions in relation to the 
MetSyn. We not only approached the MetSyn and its components as continua, in line 
with the idea that MetSyn components have a natural continuous distribution (Ingram, 
2009), but also depression and anxiety symptom dimensions (Ingram, 2009). Because we 




chose this approach, we were able to show a dose-response gradient with SA levels. 
Furthermore, the results are based on a large sample, making results reliable. Finally, in 
the analyses, we adjusted for a substantial number of covariates, minimizing the chance 
that the findings can be explained by confounding.  
 This study presents some limitations. First, the tripartite model is a rather simple 
dimensional model. Probably, there are more relevant subdimensions present (Hollander-
Gijsman et al., 2010). Second, the sample includes both healthy controls and subjects 
with (remitted) psychopathology, who were recruited from the community as well as 
mental healthcare settings. As inpatients were excluded, our results cannot be 
generalized to this group. Third, the concept of the MetSyn has been criticized (Kahn et 
al., 2005; Reaven, 2005), and our findings support the idea that it may be worthwhile to 
study (the number of) individual metabolic components in addition to a dichotomous 
MetSyn variable. Finally, due to the cross-sectional design, our results cannot be used to 
make any causal inferences. Prospective studies, especially across more heterogeneous 
populations, would help to understand the direction of the potential causal relationship.  
 In this sample, in which previously the association between a categorical 
diagnosis, on the one hand, and the MetSyn components, on the other hand, was found 
only for the most severe depressive symptoms (Reedt Dortland et al., 2010), we 
demonstrate a strong association between the SA symptom dimension and the metabolic 
syndrome and its individual components, especially WC, triglycerides, and blood pressure, 
and the number of MetSyn components. Not every depressed subject is at increased 
metabolic risk. But our findings suggest that those with an elevated SA level are. Those 
with elevated non-somatic dimensions scores (i.e., PA and NA) did not show an increased 
metabolic risk. This indicates the additional value of a dimensional approach in terms of 
metabolic risk evaluation. In addition, we found that the association between depression 
severity (BAI severity categories) and the MetSyn is, in part, driven by the SA dimension. 
Although our results need to be replicated, the discriminating ability of a dimensional 
approach could facilitate the identification of those with a higher metabolic risk within a  
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Background: Results on the association between life-events and depression and anxiety 
have been inconsistent. This could be due to heterogeneity of DSM diagnoses, which does 
not allow the detection of symptom-specific effects of life events. Therefore, the current 
longitudinal study was aimed to close in on more specific associations between different 
types of life-events and change in different symptom dimensions over time.  
Methods: Data from 2267 participants with or without psychiatric diagnoses were 
included. Dimensions of the tripartite model (general distress, anhedonic depression and 
anxious arousal) were assessed at three times (baseline, 1-year, 2-year), to model change 
over time. The positive and negative life-events that occurred between the measurement 
points were assessed retrospectively at 1-year and 2-year follow-up. The data were 
analysed with linear mixed models to adjust for repeated measures and several 
covariates. 
Results: Negative life-events (e.g. financial problems, getting ill or wounded) were 
associated with increased general distress and anxious arousal. Positive life events (e.g. 
making new friends, going on holiday) were associated with decreased anhedonic 
depression. These associations were independent for both types of life-events and 
persisted when adjusted for demographic covariates and DSM-based course-trajectories. 
Conclusions: Different types of life-events lead to specific symptomatology. Negative life 
events affect both general distress and anxiety symptomatology, whereas positive life 
events specifically affected depression-specific symptomatology. These findings 
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Many authors have suggested a relationship between life events and the onset (e.g. 
Kendler et al., 1995; 2000; Kessler, 1997) and course of depression (e.g. Mundt et al., 
2000; Friis et al., 2002) and anxiety (e.g. Lteif & Mavissakalian, 1985; Roy-Byrne, 1986; 
Blazer et al., 1987). Unfortunately, findings on the association between life events and 
psychopathology have been inconsistent with studies that reported varying (reviewed by 
Mundt et al., 2000) or no associations between life events and depression and/or anxiety 
(e.g. Spinhoven et al., 2010). These inconsistent results could be explained by the use of 
different samples, definitions, instruments, and analyses across studies (reviewed by 
Mundt et al., 2000; Kessler, 1997). However, the heterogeneity and arbitrary boundaries 
of the used DSM-diagnoses are also likely contributors to the inconsistent results found 
so far (Widiger & Samuel, 2005). From this perspective, it could pay off to use better-
specified and more homogeneous outcome measures in life event research.      
Several studies have shown that different types of life-events are associated with 
specific types of symptoms. Keller and Nesse (2005; 2006) showed that in healthy 
participants, social loss (e.g. death of a loved one, romantic breakup) led to increased 
crying, desire for social support, and decreased appetite, and that chronic stress and 
failure led to increased feelings of guilt, hopelessness, and fatigue. In a later longitudinal 
study in participants with previous depressive symptoms, Keller et al (2007) showed that 
social loss was followed by symptom patterns with increased sadness, anhedonia and 
decreased appetite, and that chronic stress and failure were followed by symptom 
patterns with increased fatigue and hypersomnia. Although they did not include all types 
of life events (e.g. positive events) and symptoms (e.g. anxiety symptoms), the results of 
these studies strongly suggest that life events affect specific symptoms rather than 
complete syndromes.    
A good way to define and measure symptoms more specifically, is through the 
assessment of symptom dimensions with reliable psychometric instruments. Dimensions 
cover distinct symptom domains and follow a severity-continuum from healthy to 
severely pathological (Goldberg, 2000). In addition to being homogeneous, dimensions 
conveniently circumvent the DSM-related problems of comorbidity and arbitrary 
dichotomous boundaries between ill and non-ill (Widiger & Clark, 2000; Widiger & 
Samuel, 2005). Moreover, dimensions provide more statistical power in etiological 
research because they are continuous, which makes them more sensitive to variation 
between and within patients (MacCallum et al., 2005).  
The tripartite model  is a well-known dimensional approach, which assumes the 
existence of three basic symptom dimensions of depressive and anxiety symptomatology 
(Clark & Watson, 1991). The dimension of general distress covers symptoms of 
psychological distress (e.g. feeling guilty, worry), which are common in both depression 
and anxiety. The more specific dimension of anhedonic depression covers symptoms that 
involve decreased positive affect and energy, which are specific features of a depressed 




are specific for anxiety, and panic disorder in particular. The tripartite model has been 
thoroughly validated through the years; studies have shown its structure to be valid (e.g. 
Watson et al., 1995; Keogh & Reidy, 2000) and its dimensions to be associated with 
different biological mechanisms, such as the stress system (Wardenaar et al., 2011) and 
metabolic factors (Luppino et al., 2010). In line with this, studies in healthy subjects have 
shown the tripartite dimensions to be associated with different life events: negative life-
events were associated with increased general distress and positive life events with 
increased positive  affect/decreased anhedonic depression (e.g. Reich & Zautra, 1981; 
Zautra & Reich, 1988; Suh et al., 1996). However, these studies were limited to healthy 
subjects and did not include anxious arousal. Therefore, it is still unclear to what extent 
the tripartite dimensions can help to clarify the link between life events and 
symptomatology when looking at a broader spectrum of symptoms. Also, previous 
studies have been cross-sectional, comparing dimensional scores between those that did 
and those that did not experience a certain event. However, to optimally benefit from the 
dimensions’ sensitivity to change, a prospective design should be used to evaluate the 
effects of life-events on the development of symptoms within individuals. Previous work 
has shown that such change is clearly detected in response to daily hassles on a day-to-
day ‘micro’ timescale (e.g. Peeters et al., 2003; Gable et al., 2000; Suls et al., 1998). So far, 
this approach has not been used to investigate the associations between major life-
events and symptom-dimensions on a ‘macro’ time-scale of months or years.  
A final issue is that studies should ideally address whether the employed 
dimensions actually help to uncover associations that would go undetected when only 
using categorical measures of psychopathology. Research could do this by checking 
whether dimensional results hold when adjusted for DSM-based clinical features. 
Likewise, analyses of longitudinal course of dimensional scores could be adjusted for 
DSM-based course trajectories to see if and how much variation in symptomatology is 
uniquely captured by the dimensions.    
We aimed to investigate the associations between, on the one hand, negative and 
positive life-events, and on the other hand, change on the tripartite dimensions in a large 
group of subjects from the Netherlands Study of Depression and Anxiety (NESDA; 
n=2981). We used a 2-year longitudinal design with three measurements (baseline, 1 
year, 2 years) and we analysed the data with multilevel regression analyses to account for 
repeated measures. These analyses were adjusted for demographic covariates, but also 
for DSM-based course trajectories to evaluate whether the dimensions captured unique 





Participants came from the NESDA study, a large longitudinal study to investigate the 
course of depressive and anxiety disorders (N=2981), who were recruited from 
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community, primary care and specialized mental health care organizations. At baseline, 
the mean age was 41.9 years (range 18-65), there were 1002 men and 1979 women, and 
2329 participants had a lifetime diagnosis of major depressive disorder (MDD) and/or an 
anxiety disorder. Six hundred fifty two participants had no lifetime psychiatric diagnosis. 
Exclusion criteria were not being fluent in Dutch and a primary diagnosis of psychotic, 
obsessive-compulsive, bipolar or severe addiction disorder because these latter low 
prevalent disorders would largely affect the course trajectories in NESDA. Detailed 
objectives and rationales of NESDA can be found elsewhere (Penninx et al., 2008). The 
Ethical Review Boards of all participating universities approved the research protocol. All 
participants signed informed consent. 
 All participants were seen for a baseline assessment (T0), which consisted of a 
face-to-face structured psychiatric interview by a trained research-assistant, 
administration of self-report questionnaires, biological measurements and a blood-draw. 
After 1 year (T1), all participants were sent a booklet of self-report questionnaires to 
complete at home and return by post. Two years after baseline (T2), participants were 
assessed again in a face-to face session, similar to the one at baseline. The used 
dimensional scores were collected at T0, T1 and T2 and all participants were included, 
who provided all dimensional scores on these time-points and information about life-
event occurrence (independent variable) for at least one of the two covered years. In 
total, 2267 participants (76.0%) provided sufficient data to be included in the study. The 
included participants were older (t=-5.8; p<0.001), had more years of education (t=-7.5; 
p<0.001), and were less probable to be male (χ2=5.58; p=0.02) than excluded subjects.  
 
Study design 
The study design is illustrated in Figure 6.1. To investigate if change on symptom-
dimensions was associated with the occurrence of life-events, change in dimensional 
score between T0 and T1 was associated with life-events between T0 and T1 and change 
between T1 and T2 was associated with life-events between T1 and T2 and T0 and T1. By 
clustering repeated measurements within persons in LMM analyses, an effect-estimation 
(β) could be calculated, while accounting for interdependence between repeated 
measures. To evaluate whether the dimensions actually captured unique specific 
symptom variation in response to life events, very strict multivariable adjustment was 
used: all variation that was also explained by DSM-based course-trajectory variables 
(confounding) and their interactions with life events (effect-modification), was covaried 
out.  
The main analyses were done with negative and positive life events clustered in 
two respective variables. Additional exploratory analyses were done to investigate the 

















Figure 6.1: the used study design: change in the dimensions of the Dutch 30-item 
adaptation of the Mood and Anxiety Symptoms Questionnaire (MASQ-D30) was modelled 
over 2 years. Life events that occurred in the meantime were assessed retrospectively at 
T1 and T2. 
 
Instruments      
 
Dimensions: MASQ-D30  
To measure the tripartite dimensions at T0, T1 and T2, the 30-item Dutch adaptation of 
the Mood and Anxiety Symptoms Questionnaire: the MASQ-D30 was used (Wardenaar et 
al., 2010; original MASQ by Watson et al., 1995a, 1995b). On the MASQ-D30, participants 
are asked to rate to what extent in the past week they have experienced “feelings, 
sensations, problems and experiences that people sometimes have” on a 5-point scale, 
with 1 being “not at all” and 5 being “extremely”. The MASQ-D30 consists of three 10-
item subscales: ‘general distress’, ‘anhedonic depression’ and ‘anxious arousal’. The 
anhedonic depression scale items are reverse-keyed and are rescored before subscale 
computation. The MASQ-D30 scales have been shown to have adequate psychometric 
characteristics (Wardenaar et al., 2010).   
 
Life-events 
To assess the occurrence of negative life-events between respectively T0 and T1 and T1 
and T2, the List of Threatening Events Questionnaire (LTE-Q; Brugha et al., 1985) was 
(retrospectively) administered at T1 and T2. The LTE-Q has been shown to have good 
test–retest reliability, high agreement between participant and informant ratings and 
good agreement with interview-based ratings (Brugha and Cragg, 1990). Examples of the 
assessed negative life events were: ‘financial problems’, ‘the death of a close friend or 
family-member’, and ‘getting fired’. Positive life-events were also assessed at T1 and T2 
with an additional list of seven positive life-events. Examples of the assessed positive life 
events were: ‘making new friends’, ‘getting a new job or an important promotion’, and 
‘finding a new partner’.  For each listed event, participants were asked to indicate if it 
MASQ-D30 
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happened in the period before the assessment and - if yes – when the event occurred or 
started (in case of long-lasting events). The complete lists of assessed individual life 
events are displayed in Figure 6.2. Positive and negative life-events were clustered to 
investigate the effects of the occurrence of any (yes/no) and the number of negative or 
positive life-events. As outlined above, the individual life events were also used in 
additional analyses.   
 
Course-trajectory variables 
The DSM-based course-trajectory variables were computed on the basis of two data-
sources. At To and T2, the presence of DSM-IV diagnoses (MDD, Dysthymia, Panic 
disorder, Social Phobia, GAD, and Agoraphobia) was established with the Composite 
Interview Diagnostic Instrument (CIDI, WHO version 2.1). The organic exclusion rules 
were used and diagnoses were hierarchy-free. If at T2 participants met the criteria for any 
diagnosis since T0, the Life Chart Interview (LCI) was also administered to assess the 
course of this disorder. The presence (yes/no) of symptoms was evaluated for each 
month during follow-up by use of a calendar method (Lyketsos et al., 1994). Participants 
rated the symptom-severity for each symptomatic month on a 5-point scale (no/minimal, 
mild, moderate, severe, very severe). Symptomatology was only considered to be present 
if at least mildly severe. Remission was considered present after at least 3 consecutive 
months without symptoms.  
The CIDI and LCI data were combined to define three course-trajectory groups: (a) 
the stable healthy group (no disorder between T0 and T2), (b) the stable chronic group 
(persistent disorder between T0 and T2), and (c) the unstable course group (onset of a 
new disorder/remission from a disorder/remission and recurrence of a disorder). 
Membership of each group (0=no, 1=yes) was used as a dummy variable in the analyses.    
 
Statistical Analyses 
Both the dependent variables (dimensions) and the independent variables (life events) 
were standardized to enable effect-size comparisons across different event types and 
dimensions. Several LMM analyses were conducted, each with a MASQ-D30 scale as 
dependent variable and one of the investigated life-event-variables as independent 
variable. ‘Time’ was used as a repeated measures factor in all analyses and an 
unstructured covariance structure was used to account for the dependence between 
repeated measures. The T0 value of the MASQ-D30 dimension under investigation was 
always added as a covariate to model all dimensional change across T0, T1 and T2. The 
main analyses were run with two different independent variables: between change on 
dimensions and (1) the occurrence of any negative or positive life-event, and between 
dimensions and (2) the number of negative and/or positive life-events. The analyses were 
adjusted for several covariates. Age and gender were added as covariates in Model 1 to 
adjust for potential confounding and to increase the general precision of model-




with life events (e.g. positive life event occurrence*stable chronic) were added to covary 
out all dimensional variation that was explained by the course-trajectory groups. 
Additional exploratory LMM analyses, each with an individual life event as independent 
variable and one of the dimensions as dependent variable, were done to explore the 
patterns of effects of the individual life-events on symptomatology. All analyses were 




Demographic and psychiatric characteristics 
The sample characteristics are listed in Table 6.1. In the complete sample, there were 
1531 (67.5%) women and the mean age at baseline was 42.6 years (SD=13.1). Of the 
group, 949 (41.9%) had a stable healthy course, 431 (19.0%) had a stable chronic course, 
and 887 (39.1%) had an unstable course between T0 and T2. Anhedonic depression and 
anxious arousal were only moderately correlated (ρ=0.43), in line with their distinct 
symptom coverage. General distress was moderate-strongly correlated with anhedonic 
depression (ρ=0.60) and anxious arousal (ρ=0.61), in line with its general role in the 
tripartite model. 
 
The occurrence of life events  
The results of the LMM analyses of the association between the occurrence of any (1,0) 
negative or positive life-event and the MASQ-D30 scores are shown in Table 6.2. In model 
1, negative life-event occurrence was associated with increased general distress (β=0.19) 
and with increased anxious arousal (β=0.12). Negative life-events were not associated 
with change in anhedonic depression. The significant effects both increased after 
additional adjustment for course trajectories in model 2. Positive life-event occurrence 
was most strongly associated with decreases in anhedonic depression (β =-0.22), but also 
with anxious arousal (β =-0.18), and general distress (β =-0.15). When adjusted for course-
trajectories in model 2, the effect on anhedonic depression was much less decreased 
(∆β=0.01 [4.5%]), compared to general distress (∆β=0.04 [26.7%]) and anxious arousal 
(∆β=0.06 [33.3%]).  
These results indicated that general distress and anxious arousal showed the 
strongest and most consistent increase in reaction to the occurrence of a negative life 
event, and that anhedonic depression consistently decreased in reaction to the 
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Table 6.1: Baseline descriptive characteristics of the used study samples 
N 2267 
Mean Age at baseline (SD) 42.6 (13.1) 
Number of women (%) 1531 (67.5%) 
Mean years of education (SD) 12.4 (3.2) 
MASQ-D30 scores, mean (SD)  
 General Distress  19.8 (8.4) 
 Anhedonic Depression 33.2 (9.6) 
 Anxious Arousal 15.5 (5.8) 
DSM-IV diagnoses  
 No disorder 1240 (54.7%) 
 Depressive disorders 225 (9.9%) 
 Anxiety disorders 418 (18.4%) 
 Depression and Anxiety 384 (16.9%) 
Course-trajectory groups  
Stable Healthy 949 (41.9%) 
Stable Chronic 431 (19.0%) 
Unstable course 887 (39.1%) 
MASQ-D30 = Dutch short adaptation of the Mood and Anxiety Symptoms Questionnaire; 
DSM-IV= Diagnostic and Statistical Manual of Mental Disorders Fourth Edition  
 
Table 6.2: Multivariate longitudinal Linear Mixed Models analyses of the change in the 















Negative life event 
(yes/no)  
Model 1 0.19 (<0.001) 0.05 (0.12) 0.12 (<0.001) 
Model 2 0.20 (<0.001) 0.01 (0.84) 0.18 (<0.001) 
Positive life event  
(yes/no) 
Model 1 -0.15 (0.001) -0.22 (<0.001) -0.18 (<0.001) 
Model 2 -0.11 (0.04) -0.21 (<0.001) -0.12 (0.03) 
Data based on Linear Mixed Models analyses: an unstructured covariance matrix was 
used to account for repeated measures  
Model 1: adjusted for age, gender and MASQ scale-score at T1.  
Model 2: additional variables: stable chronic (1,0); stable healthy course (1,0) unstable 







The number of life events 
The results of the LMM analyses of the association between the number of negative and 
positive life events and MASQ-D30 scores are shown in Table 6.3. In model 1, the number 
of negative life-events was associated with increased anhedonic depression (β=0.05), but 
more strongly with general distress (β=0.11) and anxious arousal (β=0.08). When adjusted 
for course trajectories in model 2, the associations remained significant and unchanged 
with general distress (∆β=0) and increased with anxious arousal (∆β=0.2). The association 
with anhedonic depression was no longer significant in model 2. The number of positive 
life-events was associated with general distress (β=-0.06) and Anxious Arousal (β =-0.05), 
but most strongly with anhedonic depression (β=-0.12). When adjusted for the course 
trajectories in model 2, the associations with general distress and anxious arousal 
decreased and were no longer significant (p=0.05-0.10). The association with anhedonic 
depression only decreased with 8.3% (∆β=0.01).   
These results indicated that general distress and anxious arousal were consistently 
associated with the number of negative life events, and that anhedonic depression was 
associated with the number of positive life events. 
 
Individual life-events 
The associations of the individual life-events with each of the tripartite dimensions are 
illustrated in Figure 6.2. The results showed that most life events had effects on one or 
Table 6.3: Multivariate longitudinal Linear Mixed Models analyses of the change in the 




















0.11 (<0.001) 0.05 (<0.001) 0.08 (<0.001) 
Model 2 
 
0.11 (<0.001) 0.03 (0.07) 0.10 (<0.001) 
Number of  
Positive life events  
Model 1 -0.06 (<0.001) 
 
-0.12 (<0.001) -0.05 (<0.001) 
Model 2 -0.04 (0.05) 
 
-0.11 (<0.001) -0.04 (0.10) 
Data based on Linear Mixed Models analyses: an unstructured covariance matrix was 
used to account for repeated measures  
Model 1: adjusted for age, gender and MASQ scale-score at T1.  
Model 2: additional variables: stable chronic (1,0); stable healthy course (1,0) unstable 
course (1,0), and six interactions between the course variables and life event variables.  
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more dimensions. Only four events were not associated with any dimension (e.g. ‘contact 
with police or justice system’ and ‘completion of education’). 
Figure 6.2 clearly shows that negative life events were primarily associated with 
general distress and/or anxious arousal. ‘Financial problems’, ‘being seriously ill or 
wounded’ and ‘becoming unemployed’ led to increases in all dimensions, but strongest in 
general distress. This indicated that events with a broad and long-lasting impact on 
quality of life had a general effect on symptomatology. ‘Death of a parent, child, brother 
or sister’ and ‘death of a friend or other family member’ specifically led to increased 
general distress, ‘Getting fired’ led to increased anxious arousal, and ‘a serious problem 
with a friend, family member or neighbour’, ‘the ending of a friendship with a friend, 
family member or neighbour’ and ‘a close family member getting ill or wounded’ led to 
increases on both dimensions. Only ‘separation from a partner’ was associated with 
increased general distress and anhedonic depression. These results indicated that general 
distress was mainly affected by events that involved social loss. Figure 6.2 clearly 
illustrates that positive life events had most effect on anhedonic depression. ‘Making new 
friends’ and ‘going on holiday’ led to decreases on all dimensions, but most strongly on 
anhedonic depression. ‘Meeting a new partner’, ‘being better off financially’, and ‘a new 
job or promotion’ specifically decreased anhedonic depression.   
 
6.4 Discussion 
The current longitudinal study investigated the association between life-events and 
change on the dimensions of the tripartite model over a 2-year period. The results 
showed that different types of life-events led to change in different symptom dimensions. 
Negative life-events led to increases in general distress and anxious arousal and positive 
life-events led to a decrease in anhedonic depression. These associations were not 
affected by the adjustment for (confounding and effect-modification by) DSM-based 
course trajectories, indicating that the dimensions captured unique symptom variation in 
response to life events. Additional analyses of the individual life events showed that some 
life events had larger effects than others. Several high-impact events (e.g. ‘financial 
problems’, ‘being seriously ill or wounded’) led to increases on all dimensions. However, 
most negative life events (e.g. ‘death of a parent, child, brother or sister’) primarily led to 
increases in general distress and/or anxious arousal. Positive life events (e.g. ‘making new 
friends’) primarily led to decreased anhedonic depression. Taken together, these findings 
indicated that dimensions can be used to detect specific effects of life events on 
psychiatric symptomatology.     
The current results had several interesting implications. The findings of consistent 
effects of negative and positive life-events on respectively general distress and anhedonic 
depression, was in line with previous research in healthy subjects (e.g. Reich & Zautra, 
1981; Zautra & Reich, 1988; Suh et al., 1996). The present findings suggested that the 
specificity of the effects of negative and positive life events to different symptom-






























Figure 6.2: β ‘s (on x-axis) and standard errors for the associations between individual negative and positive life-events (on y-axis) and change 
on the three dimensions of the tripartite model over time (T1, T2 and T3) in a large group of subjects with or without depression and/or anxiety 
(n=2267). Results based on Linear Mixed Models analyses with an unstructured covariance matrix to account for repeated measures. All 
associations adjusted for age, gender, MASQ scale-score at T1 and time (as repeated measures factor). 
*) p<0.05; **) p<0.01; ***) p<0.001 
 





individuals. Also, the results were largely in line with the expectation of the tripartite 
model that the dimensions of general distress and anhedonic depression represent 
separate constructs with separate etiology. In line with their previously reported 
moderate interrelatedness (e.g. Wardenaar et al., 2010), some life events (e.g. ‘serious 
financial problems’, ‘being seriously ill or wounded’ or ‘making new friends’) were found 
to significantly affect both general distress and anhedonic depression. However, in all 
cases the effects of these events were still stronger on one of the two dimensions. Thus, 
on the one hand, these results indicated that some etiological mechanisms are shared 
between the dimensions (based on significance alone). On the other hand, the results 
also showed that there is still differentiation between the dimensions (based on effect-
sizes), supporting the validity of the tripartite model assumptions. 
 
Change in anxious arousal was primarily associated with negative life-events, 
although the effects were slightly smaller than for general distress. In addition, analyses 
of the individual events showed anxious arousal was associated with several negative life 
events and specifically with ‘being fired’ and ‘becoming unemployed’.  Although not 
previously investigated in a similar fashion, these findings were in line with the idea that 
negative life events play a role in the onset of anxiety and panic disorders in particular 
(Klauke et al., 2010). The above described findings that anhedonic depression changed in 
response to positive life events is also in line with previous work, which showed that 
positive life events predicted future depressive disorders and do not predict anxiety 
disorders (Spinhoven et al., in press). 
The current results illustrate the ability of dimensions to detect temporal 
variations in mental state in reaction to external triggers. Even within groups of patients 
with a supposedly stable course (e.g. chronic over 2 years), there was notable variation in 
dimensional scores.  The pattern of symptoms could differ across persons but the 
development of each symptom dimension could also change within each person over 
time. All this variation is not captured by categorical classifications and likely to reflect the 
complex effects of many etiological mechanisms. In the current study, part of the 
variation turned out to be explained by the occurrence of particular types of life-events. 
This was in line with previous work on a much smaller time-scale, which found that 
emotional responsivity to particular daily hassles was also captured very effectively with 
repeated dimensional assessments (Peeters et al., 2003; Gable et al., 2000; Suls et al., 
1998). Expanding this previous work, our results indicate that dimensions can be used in a 
comparable fashion to detect emotional reactivity across a much larger time-span.  
The effects of life events on change in symptom dimensions were only minimally 
affected by the inclusion of DSM-based course trajectories and their interactions with life 
events. This indicated that the dimensions picked up life event-induced changes in mental 
state that were not also explained by the more traditionally defined course trajectories. 




specific effects of life-events that cannot be picked up by changes in heterogeneous 
syndrome classifications. The reason that life-events have often been observed not to 
cause the onset of full-fledged depression might be due to the fact that all individuals, 
irrespective of diagnosis, react differently to environmental stimuli. These differences in 
emotional reactivity might reflect the widely observed variation in susceptibility to 
depression in reaction to life-events (e.g. Kessler, 1997). The mechanisms underlying this 
variation are still unclear, but might involve coping mechanisms (Billings & Moos, 1981; 
Kraaij et al., 2003), the amount and quality of social support (Cohen & Wills, 1985) but 
also genetic predisposition (Wichers et al., 2007) and early life adversity (Heim & 
Nemeroff, 2001).         
Different life events were found to be associated with different dimensions. As 
described above, the most consistent differential associations were found between 
negative and positive life event types. However, the additional analyses of the individual 
life events also provided some further hints about more event-specific effects. For 
instance, life events that lead to deterioration on all dimensions seemed to mainly deal 
with the loss of aspects like good health and a steady income, which are first 
requirements for a good quality of life. Events that specifically affected general distress all 
involved some amount of social loss, ranging from ‘losing a friend’ to ‘the death of a close 
family member’. Although we should be careful not to overinterpret these explorative 
results, which involved a large number of statistical tests, the observed associations at 
least indicate that it is likely that specific types of psychopathology can be linked to 
specific types of life events, in line with previous findings (Keller et al., 2007; Keller & 
Nesse, 2005; 2006).     
Although the current study had several strong characteristics, including large 
sample-size, a longitudinal approach, sophisticated statistical analyses and the possibility 
to look at both patients and healthy participants, some study-limitations should be kept in 
mind. First, the results apply to a mixed group of healthy persons and psychiatric 
outpatients, but cannot be directly generalized to more severely affected inpatients. 
Second, only three dimensions were used as outcome variables, whereas in reality much 
more relevant symptom-dimensions will exist (e.g. Den Hollander-Gijsman et al., 2011). 
Third, the LMM analyses of the individual events could not be used to account for 
clustering of events because this resulted in an overly complex (19 independent variables, 
without covariates) and unstable model. Fourth, it is known that pre-existent 
psychopathology increases the chance of life-event occurrence, which often leads to an 
overestimation of the causal effect of life-events that precede measured psychopathology 
(e.g. Kessler, 1997). Although we adjusted for the severity of baseline symptomatology in 
our longitudinal analyses, it is possible that the incidence of certain events was associated 
with preexistent psychopathology not included in our models. This should be kept in mind 
when interpreting our results. Future studies could investigate the mediating roles of 
protective factors (e.g. coping, social support) and susceptibility factors (e.g. genetic 
predisposition) in the association between life-events and symptoms over time. 




In conclusion, the current study showed that dimensions capture life-event 
induced changes in mood/emotionality. Moreover, the results indicated that these 
changes transcended the traditional DSM-based course-trajectory distinctions and might 
thus be useful as alternative or additional outcome characteristic in the etiological 









Symptom Dimensions as Predictors  










Background, Because of the heterogeneity of known predictive factors, course-
predictions for depression and anxiety are often unspecific. Therefore, it was investigated 
whether symptom-dimensions could be used as more specific course-predictors, on top 
of already known predictors, such as diagnosis and overall severity. Methods, A sample of 
992 subjects with depressive and/or anxiety disorders was followed in a 2-year 
prospective cohort study. Dimensions of the tripartite model (general distress, anhedonic 
depression and anxious arousal) were assessed at baseline. Diagnostic and course 
information were assessed at baseline and 2-year follow-up. Results, Dimensional scores 
at baseline predicted diagnosis after two years and course-trajectories during follow-up. 
Increased general distress at baseline was associated with comorbid depression-anxiety 
at follow-up, increased anhedonic depression was associated with single depression and 
anxious arousal was associated with (comorbid) panic disorders at follow-up. Baseline 
general distress was associated with an unfavourable course in all patients. All 
associations were independent and added prognostic information on top of diagnosis and 
other predictive factors at baseline. 
Limitations, Only prevalent patients were included at baseline and only three dimensions 
were measured. Conclusions, Symptom dimensions predict the future 2-year course of 
depression and anxiety. Importantly, the dimensions yield predictive information on top 
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7.1 Introduction   
Although several predictive factors are known, course predictions for depression and 
anxiety are usually unspecific. Depression is known to be episodic and sometimes chronic 
(±20%) (e.g. Keller & Baker, 1992; Ormel et al., 1993; Piccinelli & Wilkinson, 1994), anxiety 
disorders are known to remit less often (e.g. Keller & Hanks, 1993; Pollack & Otto, 1997; 
Tiemens et al., 1996), and comorbid depression-anxiety are known to have a particularly 
unfavourable course (e.g. Shankman & Klein, 2002; Merikangas, 2003; Patten et al., 2010; 
Penninx et al., 2011). Other predictors of poor prognosis include old age (Penninx et al., 
2011), young age-of-onset (Karlsson et al. 2008, Penninx et al. 2011), high severity (van 
Beljouw et al., 2010, Penninx et al. 2011) and long disorder duration (Conradi et al., 
2008).  
Still, prognosis varies between individuals with seemingly similar characteristics. 
To account for this heterogeneity, symptom-dimensions could be used as additional 
predictors, increasing homogeneity, circumventing comorbidity (Widiger & Samuel, 2005) 
and increasing statistical power (MacCallum et al., 2002). The tripartite model (Clark & 
Watson, 1991) describes well-validated common and specific dimensions for depression 
and anxiety (e.g. Keogh & Reidy, 2000; de Beurs et al., 2007). The common dimension of 
‘General distress (GD)’ covers psychological distress seen in both depression and anxiety 
and accounts for their comorbidity. The specific dimension of ‘Anhedonic depression (AD)’ 
covers depression-specific anhedonia/energy loss and ‘Anxious arousal (AA)’ covers 
anxiety/panic-specific somatic arousal. Each tripartite dimension was hypothesized to 
have specific prognostic value (Clark et al., 1995). Indeed, GD and AD were found to 
predict outcome of depression (Joiner et al., 2000; Lonigan et al., 2003) and generalized 
anxiety disorder (Chambers et al., 2004) and related dimensions made similar predictions 
(Geerts & Bouhuys, 1998; Clark et al., 2003). However, there were large methodological 
differences across studies and the AA-dimension was not often investigated. Moreover, 
anxiety and comorbid depression-anxiety patients were not accounted for in these 
studies, hampering the differentiation between the predictive abilities of GD, AD and AA. 
Importantly, the added value of dimensions on top of known predictors was not 
evaluated. 
Therefore, we investigated the ability and added value of the tripartite dimensions 
in predicting the 2-year course and outcome of depression, anxiety and comorbid 
depression-anxiety in a large outpatient cohort (n=992). 
 
7.2 Methods  
Participants 
Participants came from the Netherlands Study of Depression and Anxiety (NESDA), a large 
longitudinal cohort study (N=2981) of participants with (n=2329) or without (n=652) a 
lifetime depressive/anxiety disorder (see Penninx et al. (2008) for details). Exclusion 




severe addiction disorder. Ethical Review Boards of all participating universities approved 
the study-protocol. All participants signed informed consent.  
At baseline, a face-to-face assessment was conducted (demographic/personal 
information, psychiatric interview, questionnaires) and 2596 (87.1%) participants were 
followed-up after 2-years. For this study, only current patients were included: 1495 
participants had a 1-month diagnosis at baseline or had a 6-month diagnosis and were 
symptomatic in the month prior to baseline. Of these, 1209 (80.9%) completed the 
follow-up. Dropouts were younger and lower educated (Lamers et al., 2011). Of these 
patients, 992 (82.1%) provided all required data to compute dimensional scores and 
covariates. Incomplete data were associated with fewer years of education (p<0.001) but 
not with age or gender.  
Instruments 
The adapted Mood and Anxiety Symptoms Questionnaire  
To measure the tripartite dimensions at baseline, participants completed the 30-item 
adaptation of the Mood and Anxiety Symptoms Questionnaire (MASQ-D30; Wardenaar et 
al., 2010; original: Watson et al., 1995) MASQ-D30-items were rated on a 5-point scale 
and added up to three subscales (GD, AD and AA). The MASQ-D30 was previously shown 
valid and reliable (Wardenaar et al., 2010). 
 
The course of depression and anxiety 
DSM-IV depressive disorders (MDD, Dysthymia) and anxiety disorders (Panic disorder, 
Social Phobia, GAD, and Agoraphobia) were diagnosed at baseline and follow-up with the 
Composite Interview Diagnostic Instrument (CIDI, WHO version 2.1; hierarchy-free 
diagnoses with organic exclusion rules). If participants reported any diagnosis during 
follow-up on the CIDI, the Life Chart Interview (LCI) was administered: using a calendar 
method, the presence and severity of depressive or anxiety symptoms was determined 
for each month during follow-up, using recalled life-events as memory-aids (Lyketsos et 
al., 1994). Symptom-severity was rated on a 5-point scale (no/minimal, mild, moderate, 
severe, very severe). The baseline LCI was used to determine the presence of symptoms 
in the month prior to baseline. The follow-up LCI was used to calculate course-indicators. 
Symptomatology was only considered present if at least mildly severe and remission was 
considered present after ≥3 symptom-free months.  
 Two course indicators were created. The 1-month CIDI diagnosis at follow-up was 
defined as follows: (1) being healthy at follow-up, (2) MDD or dysthymia at follow-up, (3) 
anxiety at follow-up and (4) comorbid MDD and anxiety at follow-up. Additional 
dichotomous variables were created to test the specific prediction of social phobia, panic 
disorder, agoraphobia and GAD. The course trajectory was defined as follows: (1) early 
sustained remission (<6 months after baseline), (2) late remission (>6 months after 
baseline) or recurrence following remission, and (3) chronic course. 





Following Penninx et al (2011), sociodemographic covariates were age, gender and years 
of education. Clinical covariates at baseline were: the percentage of symptomatic months 
during the four years before baseline (based on LCI), the CIDI-based age-at-onset of the 
baseline disorder (youngest age for comorbid cases). Treatment was not included 
because a previous study in the same sample found no treatment effects of either 
antidepressant use or the receipt of psychological interventions on course in multivariate 
analyses (Penninx et al., 2011). 
Statistical analyses 
Multinomial regression analyses were used to investigate the associations between the 
dimensions at baseline on the one hand and diagnosis at follow-up (using ‘no diagnosis’ 
as reference) and course trajectory (using ‘early-sustained remission’ as reference) on the 
other hand. Additional anxiety-disorder specific associations were tested with logistic 
regression. Different models were used to investigate if dimensions predicted course 
independently from diagnosis and demographics. In model 1, baseline DSM-IV dummies 
were added (depression, anxiety and comorbidity). In model 2, demographic and clinical 
covariates were added. P<0.05 was considered significant. Analyses were done with SPSS-
17 for Windows. 
 
7.3 Results  
Baseline characteristics 
Of the sample, 66.2% was female and the mean age was 42.5 years (s.d.=12.3, see Table 
7.1). Of the participants 227 (22.9%) had a single depressive disorder, 400 (40.3%) had 
single anxiety, and 365 (36.8%) had comorbid depression-anxiety. At baseline, mean age-
at-onset was 20.9 (s.d.=12.5), the mean percentage of months with symptomatology 
prior to baseline was 31.6 (s.d.=20.1) and 384 participants (38.7%) used antidepressants. 
AD and AA were weakly correlated (r=0.31) and GD was moderately correlated with both 
AD (r=0.58) and AA (r=0.48). 
Diagnoses at follow-up 
At follow-up, 118 participants (11.9%) had single depression, 224 (22.6%) had single 
anxiety, 178 (17.9%) had comorbid depression-anxiety and 472 (47.6%) had no disorder 
(see Table 7.2). Only increased baseline AD was associated with increased odds of single 
depression at follow-up (OR=1.24). Both increased baseline GD and AA were associated 
with increased odds of comorbid depression-anxiety at follow-up after adjustment 
(OR=1.25 and OR=1.37). Only increased baseline AA was associated with increased odds 
of single anxiety after adjustment (OR=1.32). In the analyses with separate anxiety 
disorders at follow-up (see Table 7.1 for frequencies), baseline AA was only associated 
with the risk of a panic disorder at follow-up, even when adjusted for panic disorder at 




anxiety disorders (OR=1.11 to 1.28), overall single anxiety (OR=1.12 [95% CI, 0.93-1.36]) 
and comorbid depression-anxiety (OR=1.13 [95% CI, 0.92-1.39]) all disappeared when 
panic-patients were excluded (n=842), indicating that the initially observed predictions of 
anxiety (and comorbidity) by AA were all driven by AA’s specific predictive value for panic 
disorder.  
 
Course trajectories during follow-up 
During follow-up, 252 participants (25.4%) went into early-sustained remission, 324 
participants (32.7%) went into late remission or into remission followed by recurrence, 
and 416 participants (41.9%) had a chronic course (see Table 7.2). Only increased GD was 
associated with increased odds of unfavorable course.  
 
7.4 Discussion 
The current study showed that common and specific dimensions of depression and 
anxiety, each add specific prognostic information on top of baseline DSM-diagnosis and 
other prognostic factors. Increased baseline GD was associated with increased odds of 
comorbid depression-anxiety at follow-up. Increased AD was associated with increased 
odds of single depression and increased AA was associated with increased odds of 
anxiety. In addition, increased GD predicted unfavourable course trajectories. These 
results showed the added value of using three (common GD; specific AD and AA) instead 
of two (depression and anxiety) dimensions, because each of the former had different 
implications for prognosis, which would go unnoticed when looking solely at depression 
and anxiety severity, without accounting for their heterogeneity and overlap. Thus, the 
results further empirically supported the tripartite model assumptions. 
 As in previous studies (e.g. Joiner et al., 2000; Lonigan et al., 2003; Clark et al., 
2003) AD predicted risk of future depression. Also, AA predicted risk of future anxiety, 
particularly panic disorder. All associations of AA with other anxiety disorders, but also 
with comorbid depression-anxiety at follow-up disappeared when participants with a 
panic disorder were excluded. These results suggest that the prognostic value of AA is 
limited to panic disorders. Thus, more dimensions are needed to cover all anxiety 
disorders (e.g. Mineka et al., 1998).  
In line with its presumed common role, increased GD only predicted increased risk 
of future comorbid depression-anxiety. Previously, general distress was also found to be 
associated with later comorbidity (Chamber et al., 2004). Thus, other findings of 
associations between GD and depression (Joiner et al., 2000; Lonigan et al., 2003; Clark et 
al., 2003) were most likely driven by both depression and anxiety in these groups. These 
findings confirm the idea that comorbidity is mostly accounted for by overlapping 
symptoms of depression and anxiety, and not by disorder-specific symptom-domains, 
showing the added value of the tripartite dimensions to increase prognostic 
differentiation. GD also was the only dimension to predict unfavourable course 
trajectories; probably because the trajectories were pooled across depressive, anxious 
and comorbid cases to limit the number of specific trajectory subgroups (5 instead of 12). 






Table 7.1: Baseline characteristics of the study group 
Baseline variable Study Group 
N 992 
% female 66.2% 
Mean years of age (s.d.) 42.5 (12.3) 
Age range 18-65 
Level of education (years), mean (s.d.) 11.9 (3.3) 
MASQ-D30 scales: median (Interquartile range)  
General distress 24 (18-32) 
Anhedonic depression 40 (34-46) 
Anxious arousal 17 (13-21) 
Psychiatric Characteristics  
Only depressive disorder (MDD or dysthymia), n (%) 227 (22.9%) 
Only anxiety disorder, n (%)* 400 (40.3%) 
        Panic Disorder, n (%) 170 (42.5%) 
        Social Anxiety, n (%) 187 (46.8%) 
        Generalized Anxiety Disorder, n (%) 78 (19.5%) 
        Agoraphobia (without panic) 65 (16.2%) 
Comorbid MDD, dysthymia and anxiety disorders, n (%) 365 (36.8%) 
Antidepressant use at baseline, n (%) 384 (38.7%) 
Percentage of months with symptoms in past 4 years, mean (s.d.) 31.6 (20.1) 
Age of onset of index episode, mean (s.d.) 20.9 (12.5) 
Care setting, n (%)  
Primary care 443 (44.7%) 
Specialized mental health care 458 (46.2%) 
General population 91 (9.2%) 
 
SD, standard deviation; MASQ-D30, Mood and Anxiety Symptoms Questionnaire Dutch 
short adaptation; IDS-SR, Inventory of Depressive Symptomatology Self Report; FQ, Fear 
Questionnaire. 
*) 63 patient with single Social phobia, 46 with Panic disorder, 33 with Agoraphobia, 15 
with GAD, 5 with Panic disorder + GAD, 18 with panic disorder + social phobia, 3 with GAD 
+ Agoraphobia, 8 with GAD + Social phobia, 12 with Social phobia + Agoraphobia, 9 with 
>2 anxiety diagnoses. 
 
GD is often described as a general indicator of depression and anxiety severity (Clark & 
Watson, 1991; Mineka et al., 1998). Thus, its general predictive value for course 
trajectories was in line with expectations. However, it also pointed out that depression or 




From a clinical perspective, the current findings indicate that within a group of 
patients with the same diagnosis, dimensions capture inter-individual differences in 
symptomatology, which account for differences in prognosis. For instance, varying levels 
of AA in a depressed group could reflect varying risk of future (comorbid) panic disorder 
and varying levels of AD in a panic disorder group could reflect varying risk of future 
(comorbid) depression. Eventually, symptom dimensions could become part of routine 
risk assessment, which may for instance be useful to judge the potential efficacy of 
therapy (Sotsky et al., 1991).  
 The present study had several strengths, including a large sample size, systematic 
course assessments and thorough statistical adjustment. However, there were also study-
limitations. (1) Sample attrition may have caused selection and/or attrition bias. (2) Only 
three symptom dimensions were used, whereas much more dimensions may exist (Den 
Hollander-Gijsman et al., 2010; 2011). (3) Only prevalent cases were included at baseline, 
excluding incident cases during the follow-up period. (4) Not all anxiety disorders (e.g. 
post-traumatic stress disorder) were assessed at baseline. Future research could focus on 







Table 7.2: Associations of the tripartite dimensions at baseline with the 1-month diagnosis at follow-up and the 2-year course trajectories of 





































OR (95% CI) 
GeneralDistress:         
     Crude Ref. 1.16 (0.99-1.35) 1.06 (0.93-1.20) 1.30 (1.13-1.50)***  Ref. 1.24 (1.08-1.43)** 1.29 (1.13-1.47)*** 
     Model 1 Ref. 1.11 (0.94-1.30) 1.09 (0.95-1.24) 1.27 (1.09-1.47)**  Ref. 1.24 (1.08-1.43)** 1.27 (1.10-1.45)*** 
     Model 2 Ref. 1.12 (0.94-1.33) 1.01 (0.88-1.17) 1.25 (1.07-1.45)**  Ref. 1.21 (1.05-1.41)** 1.21 (1.04-1.39)* 
Anhedonic Depression:        
     Crude Ref. 1.36 (1.15-1.59)*** 1.00 (0.89-1.12) 1.19 (1.03-1.38)*  Ref. 1.05 (0.93-1.18) 1.09 (0.97-1.22) 
     Model 1 Ref. 1.27 (1.08-1.50)** 1.05 (0.93-1.18) 1.18 (1.02-1.37)*  Ref. 1.05 (0.93-1.18) 1.10 (0.98-1.24) 
     Model 2 Ref. 1.24 (1.05-1.46)* 1.05 (0.92-1.19) 1.14 (0.98-1.33)  Ref. 1.06 (0.94-1.20) 1.10 (0.97-1.24) 
AnxiousArousal:         
     Crude Ref. 0.99 (0.82-1.20) 1.35 (1.16-1.56)*** 1.43 (1.22-1.67)***  Ref. 1.05 (0.89-1.21) 1.19 (1.02-1.39)** 
     Model 1 Ref. 0.97 (0.80-1.18) 1.28 (1.10-1.49)** 1.35 (1.15-1.59)***  Ref. 1.03 (0.88-1.21) 1.11 (0.95-1.29) 
     Model 2 Ref. 0.97 (0.80-1.19) 1.32 (1.12-1.55)** 1.37 (1.16-1.62)***  Ref. 1.02 (0.87-1.21) 1.13 (0.96-1.32) 
Results of multinomial regression analyses: Odds Ratio’s (OR) are given for 5-point increments on each dimension with 95% Confidence intervals 
(CI). MASQ-D30=Mood and Anxiety Symptoms Questionnaire Dutch 30-item adaptation.  
Crude: dimensions adjusted for each other; Model 1: adjusted for DSM-IV diagnosis; Model 2: additionally adjusted for age, gender, years of 
education, duration of disorder at baseline, age of onset of the disorder at baseline. 









Dimensions of the Inventory of Depressive Symptomatology as 
Predictors of the  












Objective: For depressive and/or anxiety disorders general course characteristics are 
known. However, prognosis varies among patients with the same diagnosis. The current 
study investigated whether the use of the more homogeneous symptom dimensions of 
mood/cognition and anxiety/arousal, would yield more specific prognoses than overall 
severity and course-categories. Method: 1053 subjects with a depressive and/or anxiety 
disorder from the Netherlands Study of Depression and Anxiety (NESDA) were assessed at 
baseline and at 2-year follow-up. Dimensions of mood/cognition and anxiety/arousal 
were extracted from the Self Report Inventory of Depressive Symptomatology (IDS-SR). 
Diagnoses at baseline and follow-up were assessed with a standardized psychiatric 
interview. Course trajectories were assessed with a life chart interview. Results: Increased 
mood/cognition scores predicted single depression (OR=1.80) and comorbid depression-
anxiety (OR=2.00) at follow-up and unfavourable course trajectories of depressive 
symptomatology (OR=1.94-2.08). Increased anxiety/arousal predicted single panic 
disorder) at follow-up (OR=2.24) and unfavourable course trajectories of anxiety 
symptomatology (OR=1.38-1.42). All associations remained significant when adjusted for 
diagnosis and prognostic factors, including baseline diagnosis. Conclusion: The widely 
used IDS-SR can be used to measure two dimensions, with specific prognostic value on 
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Both depressive and anxiety disorders are characterized by a chronic-intermittent course 
and a high disease burden and both have a continuous impact on well-being functioning 
and productivity throughout the lifecycle (Ormel et al., 2008). Given their large impact, 
understanding of the factors that contribute to the course of depression and anxiety is 
essential. Several course characteristics have been described previously. Depression is 
characterized by periods of remission and recurrence and becomes chronic in circa 20% of 
patients (Keller & Baker, 1992; Spijker et al., 2002; Ormel et al., 1993; Piccinelli & 
Wilkinson, 1994) Anxiety disorders show more chronicity and recurrence after remission 
(Ormel et al., 1993; Keller & Hanks, 1993; Pollack & Otto, 1997; Keller, 2006; Tiemens et 
al., 1996; Penninx et al., 2011). When depression and anxiety co-occur, prognosis is 
especially poor (Shankman & Klein, 2002; Merikangas, 2003; van Beljouw et al., 2010; 
Fichter et al., 2010; Patten et al., 2010; Penninx et al., 2011) Other clinical predictors of 
poor prognosis include: older age (Mueller et al., 2004; Penninx et al., 2011), younger 
age-of-onset (Karlsson et al. 2008; Penninx et al., 2011), higher severity (Conradi et al., 
2008; van Beljouw et al., 2010; Penninx et al., 2011) and longer duration of the disorder 
(Conradi et al., 2008; Penninx et al., 2011).  
 Although general course characteristics have been described for each disorder, 
the prognosis can vary widely between patients with similar diagnoses. To account for 
these variations, symptom-dimensions could be used in addition to DSM-IV diagnoses. 
With this approach, an individual’s clinical state is described by a specific pattern of 
dimensional scores on spectra that range from healthy to pathological (Goldberg, 2000). 
Importantly, continuous dimensions provide more statistical power to detect etiological 
or prognostic associations than categorical diagnoses (MacCallum et al., 2002). Because of 
these potential advantages, the inclusion of dimensions in addition to categorical 
diagnoses in the new DSM-V is currently under consideration. However, as of yet only 
limited information is available on which dimensions could have most use in predicting a 
patients’ prognosis.   
 A well-known dimensional model of depression and anxiety, with clear clinical 
implications, is the tripartite model (Clark & Watson, 1991), which consists of 3 
dimensions. (1) ‘General distress’ (also called ‘negative affect’) covers symptoms of 
general psychological distress (e.g. pessimism, feelings of guilt), which are usually 
increased in all patients with depression and/or anxiety and could account for the high 
observed rates of comorbidity between depression and anxiety. (2) ‘Anhedonic 
depression’ (or ‘lack of positive affect’) covers depression specific symptoms of anhedonia 
and energy loss (e.g. lack of enthusiasm). (3) ‘Anxious arousal’ (or ‘somatic arousal’) 
covers anxiety/panic specific symptoms of somatic hyper-arousal (e.g. palpitations, 
sweating). According to the tripartite model, an individual’s clinical picture and prognosis 




Several studies have investigated the structural validity of the tripartite model and the 3-
dimensional structure has repeatedly been found to fit well on data from different 
populations (e.g. Keogh & Reidy, 2000; Marshall et al., 2003; de Beurs et al., 2007).   
 About the prognostic role of the tripartite dimensions, several hypotheses have 
been formulated. Clark et al (1994) hypothesized that increased general distress and 
anhedonic depression predict increased chronicity and poorer prognosis of depression. 
Indeed, increased general distress and anhedonic depression predicted an increase of 
depressive symptoms in youth psychiatric patients (n=58; Joiner et al., 2000) and in 
healthy children (n=270; Lonigan et al., 2003) as well as increased comorbidity in patients 
with generalized anxiety disorder (n=83; Chambers et al., 2004). Increases on constructs 
related to general distress and anhedonic depression were also associated with an 
unfavourable course of depression (Geerts & Bouhuys, 1998; Clark et al., 2003) However, 
these studies showed large methodological differences and investigated limited aspects 
of psychopathology course. For instance, several studies were focussed on children and 
adolescents (Joiner et al., 2000; Lonigan et al., 2003), whereas others focussed on adults 
(Geerts & Bouhuys, 1998; Clark et al., 2003; Chambers et al., 2004). Also, follow-up time 
varied and ranged from only 6 weeks (Geerts & Bouhuys, 1998) to 7 months (Lonigan et 
al., 2003), sample sizes ranged from 26 (Geerts & Bouhuys, 1998)  to 270 (Lonigan et al., 
2003). Further, follow-up was limited to a single depression measurement, anxiety and 
comorbid depression-anxiety were mostly omitted, course during follow-up was not 
investigated and the anxious arousal dimension was not included in any of the studies 
(Geerts & Bouhuys, 1998; Joiner et al., 2000; Lonigan et al., 2003; Clark et al., 2003; 
Chambers et al., 2004). Importantly, it was not investigated how much prognostic 
information the dimension add on top of traditional predictors, by statistically accounting 
for diagnosis and prognostic factors at baseline.  
In the present study, we aimed to gain more insight into the added value of 
symptom-dimensions in predicting the course of psychopathology, and thus in their 
potential clinical use. We investigated the ability of the tripartite dimensions to predict 
the course and outcome of psychopathology over a 2-year period in a large cohort of 992 
outpatients with a depressive and/or anxiety disorder at baseline. Specifically, we 
evaluated whether the dimensions added extra information on top of the DSM-IV 
diagnosis and other important prognostic factors at baseline. The analyses were 





Participants came from the NESDA, a large longitudinal study to investigate the course of 
depressive and anxiety disorders. The NESDA sample consists of 2981 participants with a 
mean age of 41.9 (range 18-65), who were recruited from community, primary care and 
specialized mental health care organizations. At baseline, there were 1002 men and 1979 




women and 2329 participants had a lifetime diagnosis of major depressive disorder 
(MDD) and/or an anxiety disorder. Six hundred fifty two participants had no lifetime 
psychiatric diagnosis. Exclusion criteria were not being fluent in Dutch and a primary 
diagnosis of psychotic, obsessive-compulsive, bipolar or severe addiction disorder 
because these latter low prevalent disorders would largely affect the course trajectories, 
found in NESDA (Penninx et al., 2008). Detailed objectives and rationales of NESDA can be 
found elsewhere (Penninx et al., 2008). The research protocol was approved by the 
Ethical Review Boards of all participating universities and all participants signed an 
informed consent form. 
 The baseline assessment was conducted face-to-face by trained research staff at 
one of seven research locations and consisted of an extensive assessment of demographic 
and personal characteristics, a standardized psychiatric interview, a medical assessment 
and the administration of self-report questionnaires. After 2 years, the assessments were 
repeated in a follow-up session. The mean duration until follow-up was 24.0 months 
(s.d.=1.5) and this duration did not differ across gender (p=0.30) or across different 
disorder groups at baseline (depressive, anxious, comorbid) (p=0.30). Of the 2981 
participants that were included at baseline, 2596 (87.1%) were assessed again at follow-
up. Persons that did not participate in the follow-up assessments were younger, lower 
educated and more often had a MDD (Lamers et al., 2011). Of the 2596 participants with 
baseline and follow-up data, 2253 (86.8%) completed the questionnaire that we needed 
to compute the dimensional scores for this study. Here, non-response was associated 
with older age (t=-1.98; df=2594; p=0.05), less years of education (t=4.93; df=2594; 
p<0.001) and the presence of baseline psychopathology (χ2=15.0; df=3; p=0.002). 
Because we wanted to investigate the added value of dimensions to predict the course of 
disease in participants with an established DSM-IV diagnosis, we only selected the 
participants with a diagnosis at baseline that were symptomatic in the month prior to 
baseline (n=1018; 56.3%). This was confirmed with either the CIDI recency question or the 
Life Chart Interview (see below). Of these 1018 participants, 992 (97.4%) provided all 
needed psychopathology-course information and covariates and were included in the 




Dimensional measures at baseline 
All participants completed the short, 30-item Dutch adaptation of the Mood and Anxiety 
Symptoms Questionnaire: the MASQ-D30 (Wardenaar et al., 2010; original MASQ by 
Watson et al., 1995a, 1995b). On the MASQ-D30, individuals rate to what extent in the 
past week they have experienced “feelings, sensations, problems and experiences that 
people sometimes have” on a 5-point scale, with 1 being “not at all” and 5 being 
“extremely”. The MASQ-D30 consists of three 10-item subscales that cover the tripartite 




items that are included in each scale are listed in Table 8.1. The anhedonic depression 
scale consists wholly of negatively keyed items that assess the presence of positive affect, 
which are rescored before computation of the anhedonic depression scale score. The 
MASQ-D30 scales were found to have adequate internal consistency (Cronbach’s alpha 
ranged from 0.87-0.93), construct validity and convergent validity (Wardenaar et al., 
2010). 
  
Measurement of the course of depression and anxiety 
The course of psychopathology was assessed in two ways. At baseline and at follow-up 
the presence of DSM-IV depressive disorders (MDD, Dysthymia) and/or a selection of 
anxiety disorders (Panic disorder, Social Phobia, GAD, and Agoraphobia) were established 
using the DSM-IV based Composite Interview Diagnostic Instrument (CIDI, WHO version 
2.1). The organic exclusion rules were used and hierarchy-free diagnoses were 
determined.  
If participants met the criteria of MDD or an anxiety diagnosis on the CIDI, the Life Chart 
Interview (LCI) was also administered. With the LCI, using a calendar method, life events 
were recalled to refresh memory and the presence of depressive or anxiety symptoms 
were separately determined for each month during the follow-up period (Lyketsos et al., 
1994). For each month with symptoms, participants rated the severity of the symptoms 
on a scale ranging from no/minimal severity, mild, moderate, severe to very severe 
severity. The LCI data collected at baseline were used to check whether participants were 
symptomatic in the month prior to baseline and to calculate the amount of time with 
symptoms prior to baseline (for use as a covariate). The data collected at follow-up were 
used to calculate indicators of the course of the participants’ disorders during the follow-
up period. In determining course indicators, symptomatology on the LCI was only 
considered to be present if a participant reported at least mild severity. Remission was 
considered present if at least 3 months without symptoms were reported.  
 Several course indicators were created based on the CIDI and/or the LCI. The 1-
month diagnosis at follow-up was defined with the CIDI. A categorical variable was 
created with the categories: (1) being healthy at follow-up, (2) MDD or dysthymia at 
follow-up, (3) anxiety disorder at follow-up and (4) comorbid MDD and anxiety disorder at 
follow-up. For analyses with each of the specific anxiety disorders, dichotomous variables 
were created for social phobia, panic disorder (with and without agoraphobia), 
agoraphobia (without panic) and GAD (disorder present at follow-up vs. no disorder at 
follow-up). The course trajectory (for all disorders combined) was divided into three 
categories: (1) early sustained remission (<6 months after baseline), (2) late remission (>6 
months after baseline) or recurrence following remission, and (3) chronic course (no 
remission and enduring presence of symptoms with at least mild severity). 
   
 
 





Several previously described prognostic variables (Penninx et al., 2011) were selected as 
covariates in the analyses. Sociodemographic covariates were age, gender and mean 
years of education. Clinical characteristics at baseline that were used as additional 
covariates: (1) The percentage of time the patient spent with depressive and/or anxiety 
symptoms in the four years prior to baseline, derived from the LCI. (2) The age at onset of 
the index disorder was assessed in the CIDI interview (the earliest age for comorbid 
cases). (3) Antidepressant-use during the month before baseline (yes/no) was assessed 
during the interview. 
 
Statistical analyses 
To evaluate the interrelatedness between the tripartite dimensions, we calculated 
Pearson correlation coefficients. We used multinomial regression analysis to investigate 
the associations between the dimensions at baseline (independent variables) and the 
categorical (dependent) variable: diagnosis at follow-up (categories: no diagnosis 
[reference], MDD, anxiety disorder, and comorbid MDD-anxiety disorder). We used 
logistic regression analyses to investigate specific associations between the dimensions 
(independent variables) and different anxiety disorders at follow-up (dichotomous). We 
used multinomial regression analysis to investigate the associations between the 
dimensions at baseline (independent variables) and the categorical (dependent) variable: 
course trajectory (categories: early-sustained remission [reference], late 
remission/remission with recurrence, and chronic course). The three dimensions were 
entered simultaneously in each analysis to investigate their independent effects. Each 
regression model was run three times: crude and twice with covariates. In model 1, DSM-
IV dummy-variables were added for single MDD, single anxiety disorder and comorbid 
MDD and anxiety disorders. In model 2, demographic and disease characteristics were 
added. These models were intended to evaluate if the dimensions predicted the course of 
psychopathology independently from diagnosis and demographics. Two sided p-values of 
less than 0.05 were considered to indicate statistical significance. All analyses were done 





The characteristics of the study-group (n=992) are shown in Table 8.2. Of the sample, 
66.2% was female and the mean age was 42.5 (s.d.=12.3). Of the participants 227 (22.9%) 
had a single MDD, 400 (40.3%) only had an anxiety disorder, and 365 (36.8%) had a 
comorbid MDD and anxiety disorder. Mean age at onset was 20.9 (s.d.=12.5) and the 
mean percentage of months with at least mild symptoms during the 4 years prior to 
baseline was 31.6 (s.d.=20.1). Three hundred eighty four participants (38.7%) used 




The correlations between the tripartite dimensions were weak to moderate. In line with 
their specific roles in the tripartite model, anhedonic depression and anxious arousal 
were only weakly correlated (Pearson r=0.31; p<0.001). General distress was correlated 
moderately with both anhedonic depression (r=0.58; p<0.001) and anxious arousal 
(r=0.48; p<0.001), in line with its common role in the model. 
 
Diagnoses at follow-up 
At follow-up, 118 participants (11.9%) had a MDD, 224 (22.6%) had an anxiety disorder, 
178 (17.9%) had a comorbid MDD and anxiety disorder and 472 (47.6%) had no disorder. 
The results of the analyses are shown in Table 8.3. When adjusted for the other 
dimensions, diagnosis and other covariates, only increased baseline anhedonic depression 
was independently associated with increased risk of a depressive disorder at follow-up 
(OR=1.24), which indicated that this dimension provided independent prognostic 
information on top of other predictive factors.  
Both increased general distress and increased anxious arousal were associated with an 
increased risk of comorbid depression and anxiety at follow-up, even when adjusted for 
baseline diagnosis and other covariates (respectively OR=1.25 and OR=1.38). Anhedonic 
depression also showed an association with comorbidity at follow-up (OR=1.18), but after 
adjustment for covariates (model 2) this was only borderline significant (OR=1.14). This 
indicated that dimensions provided prognostic information on top of other predictive 
factors. 
Only increased baseline anxious arousal was independently associated with increased risk 
of an anxiety disorder at follow-up, when adjusted for baseline diagnosis and other 
covariates (OR=1.31). We conducted additional analyses with the separate anxiety 
disorders at follow-up.  Of the participants, 63 had only social phobia, 46 had only a panic 
disorder, 33 had agoraphobia and 15 had GAD. Seventy participants had more than 1 
anxiety diagnosis: 5 participants had panic disorder and GAD, 18 had panic disorder and 
social phobia, 3 had GAD and agoraphobia, 8 had GAD and social phobia and 12 had social 
phobia and agoraphobia. Nine participants had 3 anxiety diagnoses. The analyses with the 
separate anxiety disorders showed that baseline anxious arousal was associated with the 
risk of a panic disorder at follow-up (OR=1.56 [95% CI: 1.18-2.05]). Even when specifically 
adjusted for the presence of a panic disorder at baseline, this association remained 
significant (OR=1.47 [95% CI: 1.16-1.87]). For social phobia, agoraphobia and GAD, the 
associations were not statistically significant when participants with (comorbid) panic 
disorder were excluded (n=842; OR=1.03 to 1.33). Using the same sample without panic 
disorder at follow-up (n=842), we also found that the association of anxious arousal with 
anxiety disorders at follow-up (OR=1.12 [95% CI: 0.93-1.36]) and with comorbid 
depressive and anxiety disorders (OR=1.13 [95% CI: 0.92-1.39]) were both no longer 
significant. This indicated that the initially observed associations between anxious arousal 
and anxiety or comorbidity at follow-up in the complete sample were driven by the 
participants who turned out with a (comorbid) panic disorder at follow-up. This confirmed 




that anxious arousal is a specific prognostic factor for both single and comorbid panic 
disorder. Together, these results indicate that anxious arousal added prognostic 
information about the risk of future anxiety/panic disorder, on top of DSM-IV diagnosis at 
baseline and other covariates.  
 
Course trajectories during follow-up 
During follow-up, 252 participants (25.4%) went into early-sustained remission, 324 
participants (32.7%) went into late remission or into remission followed by recurrence, 
and 416 participants (41.9%) had a chronic course. The results of the analyses are shown 
in Table 8.4. Only increased general distress was associated with an increased risk of 
late/temporary remission (OR=1.20) and chronic course (OR=1.21) and these associations 
remained significant when adjusted for diagnosis and other prognostic factors at baseline. 
This indicated that general distress provided independent prognostic information on top 
of other known prognostic factors.  
 
8.4 Discussion 
The present study evaluated whether two dimensions derived from the widely used IDS-
SR had added value as predictors of the course and outcome of depressive and/or anxiety 
disorders. The results showed that increased severity on the ‘mood/cognition’ dimension 
at baseline predicted increased risk of single depression at follow-up, and that increased 
severity on the ‘anxiety/arousal’ dimension at baseline predicted increased risk of single 
anxiety (mainly panic disorder) at follow-up. Increases on both dimensions predicted 
increased risk of comorbid depression and anxiety at 2-year follow-up. The IDS-SR total 
scale-score was associated with all three diagnoses at follow-up, indicating a less specific 
prognostic ability than its two separate subdimensions. Increased mood/cognition 
predicted a higher probability of unfavourable course-trajectories of depressive 
symptomatology. Increased anxiety/arousal predicted a higher probability of 
unfavourable course-trajectories of depressive symptomatology. Increases on the IDS-SR 
total scale score also predicted an increased probability of worse course-trajectories for 
depressive symptomatology and anxious symptomatology. However, both for depressive-
and anxious symptomatology the predictive effects of the IDS-SR total scale were similar 
to that of mood/cognition or anxiety/arousal.  
Mood/cognition predicted the risk of single depression (with or without comorbid 
anxiety) after 2 years and also predicted the risk of an unfavourable course of depressive 
symptomatology, independently of anxiety/arousal and all other included prognostic 
factors. These results showed the particular prognostic importance of the 
mood/cognition-domain for depression, in line with previous work (e.g. Lux & Kendler, 
2010). Anxiety-arousal was shown to mainly have added value as a predictor of panic 
disorder at follow-up. GAD and Social Phobia were predicted by anxiety/arousal, but also 
by mood/cognition. This observation was in line with previous work, which has shown 




Mineka et al., 1998). The predictive role of mood/cognition in GAD and Social Phobia was 
in line with the oft-observed overlap between GAD/Social Phobia and depressive 
disorders (e.g. van Ameringen et al., 1991). In addition, anxiety/arousal predicted course 
trajectories of anxious symptomatology. Here also, mood/cognition had a predictive 
effect. This was likely due to the same reasons as discussed above.   
 






% female 692 (65.7%) 
Mean years of age (SD) 42.2 (12.1) 
Age range 18-65 
Level of education (years), mean (SD) 11.8 (3.3) 
 IDS-SR Subdimensions: mean (SD) 
 Mood/Cognition, mean (SD) 9.3 (3.7) 
 Mood/Cognition, range 0-21 
 Anxiety/Arousal, mean (SD) 6.4 (2.2) 
 Anxiety/Arousal, range 0-16 
Psychiatric Characteristics 
Only depressive disorder: n (%) 243 (23.1%) 
Only anxiety disorder: n (%) 396 (37.6%) 
 Panic Disorder 367 (34.9) 
 Social Anxiety 405 (38.5%) 
 Generalized Anxiety Disorder 276 (26.2%) 
 Agoraphobia (without panic) 103 (9.8%) 
Comorbid depression and anxiety: n (%) 414 (39.3%) 
Antidepressant use at baseline: n (%) 379 (36.0%) 
Months with symptoms in past 4 years, mean % (SD) 32.0 (20.0) 
Age of onset of index episode: mean (SD) 37.2 (11.9) 
Care setting n (%) 
 Primary care 456 (43.3%) 
 Specialized mental health care 510 (48.4%) 
 General population 87 (8.3%) 
SD=standard deviation; MASQ-D30= Mood and Anxiety Symptoms Questionnaire Dutch 
short adaptation; IDS-SR=Inventory of Depressive Symptomatology Self Report; 
BAI=Beck anxiety inventory;  
 
We compared the standardized predictive effects of the two dimensions with the effects 
of the IDS-SR total score. The prediction of diagnoses after two years became more 
specific if the IDS-SR was broken up into mood/cognition and anxiety/arousal. Also, 




mood/cognition dimension was an equally effective predictor of the course of depressive 
symptomatology as the IDS-SR total scale and the anxiety/arousal dimension was an 
equally effective predictor of the course of anxious symptomatology as the IDS-SR total 
scale. These observations indicate that mood-cognition would be a more efficient and 
cost-effective choice than the IDS-SR total scale when the aim is to specifically predict the 
course of depression. In addition, the IDS-SR was shown not only to predict depression; 
the IDS-SR anxiety/arousal dimension even specifically predicted future panic disorder 
and the course of anxiety symptomatology. The IDS-SR dimensions can thus be used to 
increase specificity when using the IDS-SR to formulate prognoses of depression and/or 
anxiety.        
The predictive associations of the dimensions persisted after multivariable adjustment. 
This indicates that within a group of individuals with similar DSM-IV diagnoses, the 
dimensions provide unique prognostic information. This is in line with previous work by 
our group, where we showed the added value of the dimensions of the tripartite model  
(Clark & Watson et al., 1991; General Distress, Anhedonic Depression and Anxious 
Arousal) in predicting the course and outcome of depression and anxiety (Wardenaar et 
al., 2011).  
 
Table 8.2: Symptom dimensions as predictors of DSM-IV diagnosis at 2 year follow-up in 
1053 subjects with a depressive and/or anxiety disorder at baseline. 















OR (95% CI) 













Crude - 1.95 (1.52-2.51)*** 1.58 (1.29-1.92)*** 3.09 (2.47-3.85)*** 
1 - 1.58 (1.19-2.10)** 1.89 (1.50-1.39)*** 2.86 (2.22-3.67)*** 
2 - 1.57 (1.18-2.10)** 1.81 (1.43-2.30)*** 2.73 (2.11-3.52)*** 




crude - 2.11 (1.54-2.89)*** 1.05 (0.83-1.35) 2.12 (1.61-2.80)*** 
1 - 1.70 (1.21-2.38)** 1.27 (0.97-1.67) 2.00 (1.49-2.68)*** 
2 - 1.80 (1.28-2.54)** 1.25 (0.95-1.64) 2.00 (1.48-2.69)*** 




crude - 0.98 (0.71-1.35) 1.69 (1.31-2.19)*** 1.79 (1.36-2.35)*** 
1 - 0.97 (0.70-1.34) 1.61 (1.22-2.11)** 1.63 (1.23-2.15)** 
2 - 0.92 (0.66-1.27) 1.57 (1.19-2.07)** 1.55 (1.16-2.06)** 
     
Results of multinomial regression analyses: OR (Odds Ratio’s) are given for 1 SD 
increments on each dimension. IDS-SR= Inventory of Depressive Symptomatology Self 
Report; M/C=Mood/Cognition; A/A=Anxiety/Arousal. Crude: dimensions adjusted for 
each other; Model 1: adjusted for DSM-IV diagnosis; Model 2: additionally adjusted for 
age, duration of disorder at baseline, age of onset of the disorder at baseline. 





In addition, our findings confirmed the hypothesis of Lux and Kendler (2010) that 
different symptom-domains of within the same diagnosis are related to different clinical 
variables. 
The current study had several strengths, including large sample size, thorough 
assessment of course and diagnoses and consideration of several covariates. However, 
some limitations should also be considered. The study included prevalent DSM-IV 
outpatients, and the results are not directly generalizable to incident cases and inpatients 
with more severe disorders. Also, the follow-up period was only 2-years; predictions 
about the course and outcome beyond this duration could not be evaluated.  
 In conclusion, the current results showed that the IDS-SR dimensions had clear 
added prognostic value. They increased the specificity of prognoses and are easy to apply, 
which makes them very useful for clinical and research applications. These results can 
also be seen as an encouragement to decrease the heterogeneity of diagnostic 
instruments and to include more specific dimensional aspects in future diagnostic 
classifications. 
  





Table 8.3: Associations between specific symptom dimensions and course-trajectories 















































1 - 2.05 (1.66-2.54)*** 2.47 (1.94-3.15)*** 
2 - 2.03 (1.63-2.52)*** 2.39 (1.87-3.05)*** 




crude - 2.32 (1.83-2.95)*** 2.92 (2.24-3.81)*** 
1 - 2.07 (1.61-2.66)*** 1.93 (1.45-2.56)*** 
2 - 2.08 (1.61-2.68)*** 1.94 (1.45-2.58)*** 




crude - 1.06 (0.82-1.33) 1.51 (1.16-1.93)** 
1 - 1.07 (0.84-1.36) 1.36 (1.04-1.79)* 
2 - 1.05 (0.82-1.34) 1.30 (0.98-1.71) 
    
Results of multinomial regression analyses with standardized scales (z-values): OR 
(Odds Ratio’s) are given for 1 SD increments on each dimension. IDS-SR=Inventory of 
Depressive Symptomatology Self Report. Crude: dimensions adjusted for each other; 
Model 1: adjusted for presence of a single depressive disorder, single anxiety disorder 
or comorbid depressive and anxiety disorders at baseline; Model 2: additionally 
adjusted for age, duration of disorder at baseline, age of onset of the disorder at 
baseline. 

























Table 8.4: Associations between specific symptom dimensions and course-trajectories of 















































1 - 1.53 (1.20-1.95)** 1.96 (1.59-2.42)*** 
2 - 1.49 (1.17-1.90)** 1.84 (1.48-2.28)*** 




crude - 0.94 (0.73-1.20) 1.18 (0.95-1.46) 
1 - 1.23 (0.93-1.63) 1.44 (1.12-1.83)** 
2 - 1.20 (0.90-1.59) 1.38 (1.07-1.77)* 




crude - 1.50 (1.15-1.95)** 1.66 (1.32-2.08)*** 
1 - 1.38 (1.04-1.83)* 1.44 (1.12-1.83)** 
2 - 1.38 (1.03-1.84)* 1.42 (1.11-1.83)* 
    
Results of multinomial regression analyses with standardized scales (z-values): OR (Odds 
Ratio’s) are given for 1 SD increments on each dimension. IDS-SR= Inventory of 
Depressive Symptomatology Self Report. Crude: dimensions adjusted for each other; 
Model 1: adjusted for presence of a single depressive disorder, single anxiety disorder or 
comorbid depressive and anxiety disorders at baseline; Model 2: additionally adjusted 
for age, duration of disorder at baseline, age of onset of the disorder at baseline. 
 




Chapter 9: Discussion 
 
9.1 Background 
The current categorical DSM-diagnoses have brought marked advantages to the field of 
psychiatry. However, they also have had clear disadvantages, which have hampered 
research into the underlying mechanisms of diagnostic categories and, in clinical practice, 
have led to unclear and unspecific treatment indications (Clark et al., 1995; Widiger & 
Clark, 2000; Widiger & Samuel, 2005). Therefore, the interest for other paradigms to 
classify patients has been growing. An alternative dimensional approach has gained 
consistent and serious attention (e.g. Kendell, 1989). Multi-dimensional symptom-
patterns to describe patients are very specific, do justice to continuity of 
psychopathological phenomena and do not have the problem of comorbidity (Widiger & 
Samuel, 2005). The idea of dimensional diagnostics appeals to many and it was even 
considered for inclusion in the DSM-V (Helzer et al., 2008). However, it was concluded 
that the evidence for a fixed set of valid and clinically useful dimensions is presently too 
limited to merit a paradigm-shift in psychiatric diagnostics (First, 2005; Frances, 2009). 
Dimensions should first be shown to be valid beyond reproach and to have considerable 
added value compared to the existing system (Frances, 2009).  
 
9.2 Aims of this dissertation 
Thus far, the majority of dimensional research has focussed on the structure of symptom 
dimensions on a phenomenological level (e.g. Clark & Watson 1991; Watson 2005; 
Krueger, 1999; Kotov et al., 2011). Although very important, these investigations of 
internal validity should be expanded with investigations of external validity: the 
dimensions should be associated with other, hypothetically related variables that were 
not used to define them. In addition, it should be evaluated whether dimensional 
associations explain more variation in putative etiological variables than associations with 
DSM-categories. This is the only way to find out to what extent research has thus far been 
hampered by a flawed categorical diagnostic system. Therefore, the current project was 
aimed to gain more insight in the overall validity and added value of dimensions in 
depression and anxiety research.  
The first part of this thesis focused on the issue of dimensional measurements and 
structural validity of dimensions. The rest of the studies were to investigate the external 
validity and added value of dimensions in etiological and clinical research. Also, it was 
evaluated whether dimensions capture dynamic symptom changes over time, enabling a 
new kind of research into the factors that affect mood and emotionality. Overall, the aim 
of the current project was to provide a substantiated overview of the possibilities of 







9.3 Measuring dimensions 
Although much is known about the internal validity of dimensional models, in the areas of 
actual model-operationalisation and measurement, studies have been sparse and results 
have been variable (e.g. Shankman & Klein, 2000). The original mood and anxiety 
symptoms questionnaire (MASQ; Watson et al., 1995) was developed to measure the 
dimensions of the tripartite model. However, results on the psychometric quality and 
construct validity of the MASQ have been mixed (e.g. Buckby et al., 2008; Boschen et al., 
2006). In addition, the MASQ was very long (90 items) making it cumbersome and time-
consuming, and therefore expensive to administer. Therefore, we made several 
alterations and improvements, resulting in a shortened 30-item adaptation: the MASQ-
D30. In chapter 2, we showed that the MASQ-D30 had good and consistent psychometric 
characteristics. In addition, the results had two generic implications with regard to 
dimensional measurement. First, the results showed that, to achieve better 
differentiation between dimensions, scales should have limited and well-specified 
symptom coverage. This might seem very logical, but it is likely that previous tests of the 
tripartite model have been hampered by the fact that the used scales overlapped 
substantially and were too heterogeneous (e.g. Keogh & Reidy, 2000; Boschen & Oei, 
2006; Buckby et al., 2008), making them unsuitable to measure distinct dimensions, with 
potentially distinct underlying mechanisms. Second, the case of the MASQ-D30 showed 
that measurement of dimensions is possible with simple 10-item scales and does not 
require elaborate questionnaires, clinician ratings or interviewing. Thus, including 
dimensions in research or clinical settings can be easy and quick, taking away some of the 
reservations against the use of dimensions (e.g. Frances, 2009).   
In chapter 3, using an existing and widely used generic depression severity 
questionnaire, we developed and validated specific dimensional measures. This approach 
to dimensional measurement yielded additional insights in the way dimensions can be 
identified and measured. The results showed that the symptom coverage of the total IDS-
SR is heterogeneous, multi-dimensional and falls apart into three distinct sets of items 
with different symptom-coverage. After fine-tuning with item-response theory (IRT) 
analyses, two of these item-sets (‘mood/cognition’ and ‘anxiety/arousal’) were shown to 
function well as dimensional measures, and thus, as IDS-SR subscales.  
In addition to their practical use, these results had some general implications for 
the measurement of dimensions. First, the study showed that dimensions of depression 
and/or anxiety could be measured with existing severity scales, without having to resort 
to a new and specialized instrument. A downside of this approach could be that the 
number and coverage of the dimensions depend more on the available instrument than 
theory-driven instruments, such as the MASQ-D30. However, data-driven methods could 
be very helpful to verify if hypothesized distinctions between symptom-domains are 
generalizable and occur across different depression severity scales. Indeed, the distinction 
between mood/cognition and anxiety/arousal underlying the IDS-SR was in line with 




much previous research using other scales (e.g. Shafer, 2006; Mineka et al., 1998). A 
second interesting implication stems from the fact that item-response theory (IRT)/Rasch 
analyses were used in addition to traditional factor analyses. These methods enabled the 
investigation of the actual unidimensionality and psychometric quality of each of the 
identified factors. Unlike popular belief, factor-analyses do not identify dimensions but 
latent structures. A factor is not a dimensional entity with a scale of measurement, but 
focuses on clumping items together on one point, based on optimisation of their 
covariance. Therefore, it cannot be assumed that the items falling onto one factor 
function together as a unidimensional additive subscale, with items lined up along an 
underlying severity dimension and with a higher score actually indicating higher severity 
(Wright & Masters, 1982). IRT/Rasch analyses can be done to evaluate whether items 
function in this way and the items can be added up to a truly unidimensional additive 
measurement scale. The IDS-SR results showed that after factor-analyses, thorough fine-
tuning in the form of item-deletion or rescoring based on IRT/Rasch analyses was needed 
to achieve this optimal dimensional measurement. This indicates that the development of 
dimensional measurements should go further than only the establishment of factor 
structures. Initially, item response theory analyses were only conducted for the IDS-SR 
subscales and not for the MASQ-D30. Later Rasch-analyses of the MASQ-D30 showed that 
its subscales could indeed be regarded as unidimensional measurement scales (all items 
fit to the Rasch model; data not shown)   
Taken together, dimensional measurement could be markedly improved and 
optimised by aiming for adequate differentiation between subscales and checking their 
unidimensionality. Also, measurement of dimensions does not have to be overly complex 
or time-consuming in daily practice.  
 
9.4 Dimensions of depression and anxiety and biological factors 
If dimensions were shown to have more specific or simple biological underpinnings than 
traditional diagnoses, this would support the assumption that specific symptom 
dimensions of disease rather than complete diagnoses are the natural end-points of 
pathological pathways. Therefore, the current dissertation set out to investigate the 
associations between dimensions and different biological pathways. In the next 
paragraphs, the results for two biological pathways are discussed. 
 
9.4.1 Dimensions and the Hypothalamo-Pituitary-Adrenal (HPA) axis 
In chapter 4, we described findings on the association between the tripartite dimensions 
and HPA-axis activity. The results showed that all three dimensions were associated with 
cortisol exposure during the hour after awakening in the morning. Interestingly, all 
associations had an inversed U-shape and were consistent across DSM-IV defined 
diagnostic groups.  
Previous studies on the association between the HPA-axis and depression have 




Bhagwagar et al., 2005; Vreeburg et al., 2009; Holsboer et al., 2010). However, others 
found lower HPA-axis activity in depressed patients than in controls (Stetler & Miller, 
2005; Huber et al., 2006; Knight et al., 2010) or found no difference between the groups 
(Strickland et al., 2002). Thus, so far findings have been inconsistent when using DSM-IV 
diagnoses. Interestingly, our findings in chapter 4 could explain this observed 
inconsistency. Depending on symptomatology, a group of patients can either have a low 
or high HPA-axis activity. In hindsight, previous finding need not be seen as inconsistent, 
but rather as only partly informative. The used categorical approach could only be used to 
detect point-to-point differences without seeing the much larger underlying continuum 
on which these points are located. 
Our findings were in line with previous research. Veen et al (2010) used similar 
measures in a smaller sample and found a similarly shaped association with HPA-axis 
activity. In addition, of the studies that looked at severely affected inpatients, some found 
decreased HPA-axis activity (Posener et al., 2000) and some found increased HPA-axis 
activity (Maes et al., 1994; Posener et al., 2000). Also, within groups of elderly depressed 
patients, evidence was found for both hypo- and hypercortisolemia (Penninx et al., 2007; 
Bremmer et al., 2007). Although varied, these findings are all in line with the central 
implication of chapter 4: HPA-axis activity can vary within patient-groups as a function of 
symptom severity. Interestingly, Vreeburg et al (submitted) showed that outpatients with 
a low HPA-axis activity had a worse prognosis than those with a high HPA-axis activity. 
This is in line with the results in this dissertation, which showed that increased severity on 
e.g. General Distress is associated with lower HPA-axis activity (chapter 4) and worse 
prognosis (chapter 7). 
Several possible mechanisms may contribute to lower HPA-axis activity in severely 
ill patients. It is most plausible that following prolonged severe stress, a decrease or 
downregulation of HPA-axis activity occurs (Oldehinkel et al., 2001; Meinlschmidt & Heim, 
2005). The underlying mechanism is yet unknown but could consist of downregulation of 
CRH receptors in the pituitary, reduced synthesis or depletion of CRH, or increased 
sensitivity to negative feedback (Heim, 2000). Because the current results were based on 
epidemiological data, no conclusions could be drawn about this. However, the results did 
indicate how dimensions enable us to detect and incorporate the dynamic of these 
systems in psychiatric research. 
 
9.4.2 Dimensions and the Metabolic Syndrome 
The study described in chapter 5 was aimed to break down the previously reported 
association between depression and the metabolic syndrome into more specific parts. 
Earlier findings on this association have been mixed with reports of increased prevalence 
in depressed patients compared to healthy controls (e.g. Heiskanen et al., 2006) and 
others reporting no difference (e.g. Reedt-Dortland et al, 2010a; 2010b). These 
inconsistent findings were not surprising, given the observed heterogeneity of both DSM-
defined depression and of the metabolic syndrome concept. In chapter 5, we decreased 




this heterogeneity by associating specific symptom dimensions (General Distress, 
Anhedonic Depression and Anxious Arousal) with separate metabolic syndrome 
components (waist circumference, triglyceride level, HDL-cholesterol level, glucose level 
and blood pressure). The results showed that of the tripartite dimensions, only Anxious 
Arousal was associated with increased odds of the metabolic syndrome and with an 
increased number of metabolic syndrome components. Moreover, the associations were 
only significant for three of the five metabolic syndrome components (waist 
circumference, triglycerides and blood-pressure). These findings were replicated with the 
somatic symptoms subscale of the Beck Anxiety Inventory (BAI-som). Both in the analyses 
with the tripartite dimensions and the BAI, non-somatic anxiety symptoms were not 
associated with metabolic factors. Also, these findings were consistent across diagnoses 
and not explained by confounders.   
Our results were in line with previous work. De Jonge et al (2006) proposed a 
specific somatic subtype of depression in patients with CVD, and Vogelzangs et al. (2011) 
suggested a metabolic subtype of chronic depression. The current results indicated that 
somatic symptoms are associated with CVD risk, irrespective of DSM-diagnosis, thus 
expanding these previous results. 
Several possible mechanisms are thought to underlie the association between 
metabolic factors and psychiatric symptoms. From one direction, depressed/anxious state 
could lead to metabolic dysregulations through various pathways. Increased 
inflammatory markers have been found to be associated with more depression (Bremmer 
et al., 2008). Also, HPA axis overactivation could lead to altered lipid patterns, which 
could lead to other symptoms, such as overweight, abdominal obesity, and 
hypertriglyceridemia (Vogelzangs et al., 2009). In addition, prolonged activation of the 
sympathetic nervous system and deactivation of the parasympathetic nervous system 
could lead to hypertension and, thus, feelings of hyperarousal (Lambert et al., 2011). 
From the other direction, metabolic dysregulations could cause (somatic) symptoms of 
depression and anxiety (Alexopoulos et al., 1997; Mast et al., 2008). Alternatively, the link 
between psychopathology and metabolic dysregulation could be explained by external 
factors, such as a depression-related unhealthy life-style (Reedt-Dortland et al 2010b). 
Because of the observational design of the current study, the mechanisms and their 
causal directions could not be uncovered. However, the results clearly illustrated how 
breaking down heterogeneous syndromes into more specific parts is a feasible way to 
close in on specific underlying mechanisms.  
 
9.4.3 Dimensions and other biological factors 
Dimensions have also been shown to be very useful in other lines of biological research, 
not covered in this dissertation. Moreover, other research has also shown dimensions to 
be useful and valid.  
 Given the paucity of any or replicable results for DSM-diagnoses, the potential use 




relatively successful in showing that depression and anxiety are heritable and that this 
heritability is driven by different components (e.g. Mineka et al., 1998; Hettema et al., 
2006). Interestingly, the structure of these heritability components was found to be quite 
similar to the tripartite and hierarchical models do (e.g. Hettema et al., 2006), suggesting 
that the heritability components correspond to phenotypic symptom-dimensions. 
However, to prove that dimensions (e.g. the tripartite model) really have a well-defined 
genetic basis, their variation should be shown to be (partly) heritable. Indeed, twin-
research has shown that increased genetic load for psychiatric problems (an affected 
sibling), was associated with more variation in negative affect (Wichers et al., 2007). Thus, 
there seems to be preliminary evidence supporting the heritability of dimensions. 
In contrast to heritability research, genetic localization studies have yielded 
limited or poorly replicable results (Bosker et al., 2010; Breen et al., 2011). Therefore, 
many have argued that studies have been too small to reliably detect the small effects of 
individual genetic loci (Wray et al., 2009; Abbott, 2008). However, as summarized in the 
introduction, the arbitrariness, discontinuity and heterogeneity of the used DSM-
definitions are important contributors to the lack of power and lack of associations 
between genes and psychopathology. Using more homogeneous, empirically defined 
dimensional phenotypes could increase statistical power, forgoing the need to increase 
sample-size. Surprisingly, only few studies have tried to do this. Van Veen et al. 
(submitted) investigated the associations between the tripartite dimensions and several 
pathway-related gene-sets. They found that different dimensions showed associations 
with different gene-sets and thus are likely to have different underlying etiologies. 
Importantly, the effect-sizes were substantial in this study with R-squares ranging from 
3.3 to 6.4. Although they need replication, these results indicate that the search for 
genetic loci underlying psychopathology does not have to be in vain if researchers are 
prepared to look outside the realm of DSM-defined diagnoses.  
 
9.5 Dimensions and environmental factors    
Adverse life-events have often been identified as risk factors for the development of 
depression and anxiety. However, the associated risk varies greatly across individuals 
(Kessler, 1997) and some life events are more strongly related with depression (e.g. 
Brown et al., 1995; Brilman & Ormel, 2001) or anxiety (Kendler et al., 1998; Goodyer et 
al., 1985) than others. Like for other etiological mechanisms, there seem to be no 
consistently identifiable associations between life-events and depression and anxiety. 
Instead, it is has been suggested that different life-events lead to changes in different 
symptom-domains (Keller et al., 2007; Keller & Nesse, 2005; 2006; Tiet et al., 2001). In 
addition, several factors have been proposed to affect or mediate the relation between 
life-events and psychopathology, such as social support (Cohen & Wills, 1985), coping 
(Billings & Moos, 1981), habituation and scarring (Kendler et al., 2000). Thus, the relations 
between life-events and psychopathology are very complex and are unlikely to be 
unraveled by simply comparing their occurrence-rates between groups of patients and 




controls. In chapter 6, we investigated the associations between different life-events and 
specific symptom-dimensions. We used a longitudinal approach to model the change over 
time of dimensional scores induced by both negative and positive life-events that 
occurred between repeated measurements. The results showed that general distress 
increased in response to negative life-events and that anhedonic depression decreased in 
response to positive life-events. The life-event induced changes on dimensions were seen 
across groups with different course-trajectories (i.e. early remission, late 
remission/recurrent, chronic). Thus, life events induced similar dimensional changes in, 
for instance, chronically diseased and in people who were healthy and stable. Closer 
inspection of the associations of individual life events showed that some life-events 
affected all dimensions and some had dimension-specific effects, illustrating the 
complexity of the relationship between life events and mental well-being. Taken 
together, our results had several implications.  
1) Our results showed that general and symptom specific effects of life-events on 
symptomatology could both be captured by using multiple separate symptom-
dimensions.  
2) Our results indicated that different classes of life-events induced longitudinal 
change in one or more symptom-dimensions. Making a distinction between 
negative and positive life-events, we found on the one hand that negative life-
events led to increases in general distress. On the other hand, we found a more 
specific effect of positive life-events on anhedonic depression.  
3) Our results further supported the validity of anhedonic depression (lack of positive 
affect) as a distinct clinical entity, which responds independently to particular 
environmental triggers. In contrast, general distress was shown to respond to both 
negative (mainly) and positive life-events, which was in line with its supposed role 
as a general severity indicator (Clark & Watson, 1991). 
4) We found that life-events have detectable effects on within subject change in 
mental state. Importantly, life-events explained variance in mental state that was 
not captured by traditional diagnostic methods, because change on dimensional 
scales better captured the dynamic of psychiatric problems over time. This 
dynamic has been shown previously to play an important role in the susceptibility 
to psychopathology (e.g. Wichers et al., 2007, Peeters et al, 2003) and in the 
outcome (Wichers et al., 2009) and treatment-response of depression and anxiety 
(Wichers et al., 2009; Geschwind et al, 2010), so could be a promising subject for 
further research.  
Taken together, the presented results illustrate how dimensions can be used to uncover 
the specific and subtle associations between life events and depression and anxiety and 
support their role as independent clinical entities. Moreover, the results illustrated the 






9.6 Dimensions and the course of depression and anxiety 
The currently known predictive factors for the course and outcome of depression and 
anxiety are very general, and patients with similar diagnoses and clinical characteristics 
(e.g. severity, age-at-onset) can still have different course trajectories. To enable more 
specific estimates of prognoses, more specific predictors should be identified. In chapters 
7 and 8 we aimed to find out whether dimensions could be used as such specific 
predictors of the course of depression and anxiety. In chapter 7, we showed that different 
dimensions were associated with different diagnoses after 2 years and that mainly 
general distress was predictive of an unfavorable course trajectory (i.e. more chronicity). 
In chapter 8, we took a different approach and used the IDS-SR dimensions as predictors 
and showed that different dimensions predicted different diagnoses at follow-up. 
Mood/cognition predicted depression at follow-up and the course of depressive 
symptomatology, and anxiety/arousal predicted anxiety at follow-up and the course of 
anxiety symptomatology. Importantly, in both studies, we found that the dimensions 
yielded predictive information on top of DSM-IV diagnoses and other well-known 
prognostic factors, such as severity and duration of disease. We found somewhat 
different results for chapters 7 and 8 because we used different dimensions (tripartite 
model versus IDS-SR dimensions). However, the general conclusions regarding the added 
specific predictive information by each symptom-dimension were similar. 
As expected, we found dimensions that included somatic- and anxiety-related 
symptomatology (anxious arousal in chapter 7 and anxiety/arousal in chapter 8) to be 
predictive of anxiety disorders at follow-up, either on itself or comorbid with a depressive 
disorder. Closer scrutiny of the results showed that in chapter 7 the anxious arousal 
dimension, which only covers somatic hyperarousal, was mainly predictive of panic 
disorder and generalized anxiety disorder (GAD), in line with the idea that more 
dimensions are needed to cover all anxiety disorders (Mineka et al., 1998). It was similar 
for the IDS-SR analyses in chapter 8, where we found anxiety/arousal to be predictive of 
panic disorder at follow-up. In addition, both mood/cognition and anxiety/arousal were 
predictive of GAD and social phobia. These findings were also in line with the idea that 
depression is closely related to GAD and social phobia (e.g. Van Ameringen et al., 1991; 
Kessler et al., 2000).  
       Several dimensions included mood-related symptoms and cognitions. General distress 
and anhedonic depression (chapter 7) and mood/cognition (chapter 8), the latter of 
which could be seen as a slightly more heterogeneous mix of the symptoms covered by 
two of the tripartite dimensions. As expected, we found anhedonic depression to 
specifically predict a single depressive disorder at follow-up and general distress to 
predict a comorbid depressive and anxiety disorder at follow-up. In line with its mixed 
content, mood/cognition predicted both a single depressive disorder and comorbid 
depressive and anxiety disorders at follow-up. Together our findings show that symptom 
dimensions can be used on top of other predictors to achieve more prognostic specificity, 




with different dimensions being associated with the course and outcome of different 
(combinations of) disorders 
In addition to our main findings, the IDS-SR results in chapter 8 clearly illustrated 
the issue with generic scale-scores (e.g. IDS-SR total score, CES-D, HAM-D) as prognostic 
factors. Because all of these scales assume unidimensionality where in fact they are not 
(review: Shafer, 2006). On these instruments, individuals with the same total-score may 
have different symptomatology. For instance, the same score can either consist of mainly 
increased somatic symptoms or of mainly increased mood/cognition symptoms. Both of 
these domains have distinct prognostic value and thus, the generic severity scale only 
gives an indication of overall severity and outcome but is not helpful in formulating 
specific prognoses.  
 
 
9.7 Synthesis: the use of dimensions 
The presented results provides a broader view on the validity and potential applications 
of symptom-dimensions in psychiatric research. Based on the results, several conclusions 
can be drawn..  
 
1 In both the etiological (chapters 4-6) and clinical (chapters 7 and 8) studies, it was 
found that dimensions capture more variation within and across subjects than is 
captured by DSM-diagnoses. The results confirmed the expectation that, because 
of their specific and continuous nature, dimensions detected more variation in the 
underlying mechanisms.  
 
2 Across various studies on the metabolic syndrome (chapter 4), life-events (chapter 
7) and disease-course (chapters 7 and 8), dimensions were found to enable the 
detection of symptom-specific associations. Thus, using more homogenous clinical 
descriptions in scientific research clearly brings us closer to the specific 
mechanisms that underlie depression and anxiety.  
 
3 The used continuous dimensions were shown to have two general advantages in 
addition to increased power. (A) Non-linear associations could be investigated, 
where appropriate, allowing for the investigation of more complex underlying 
processes that would be impossible to uncover with dichotomous or categorical 
variables (chapter 4). (B) Approaching psychopathology as continuous phenomena 
often enabled the inclusion of participants from the whole population 
(irrespective of DSM-diagnosis) in psychopathology research. This increased the 
generalizability to the population as a whole and adhered to the idea that 
psychopathology is continuously distributed in the population: associations 






4 The results from chapter 6 show that dimensions can be used to capture subtle 
changes of affect and emotions over time. Such responsivity could be regarded as 
a new kind of psychiatric outcome-measure, which is sensitive to variations in 
etiological factors (e.g. life-events). 
 
5 From a more practical perspective, the presented work showed that including 
dimensions in depression and anxiety research can have notable added value 
without being overly cumbersome or expensive. In fact, based on the current 
dissertation, it would be fair to state that the ratio between investment and 
scientific return could in many cases be fruitful. 
 
9.8 Study limitations 
Although the presented studies had several strong characteristics, including thoroughly 
validated dimensional measurements, large sample sizes, high generalizability, careful 
adjustment for confounders/mediators and a high response at follow-up, all results 
should be interpreted in the light of some overall limitations (in random order): 
 
1 All results applied to participants with no or low to medium-high psychopathology 
severity. Therefore, results cannot be generalized to more severely affected 
psychiatric (in)patients.  
 
2 The studied dimensions are an obvious oversimplification of reality. Although the 
tripartite model and the more general distinction between somatic and 
mood/cognitive symptoms has found widespread support, many more specific 
subdimensions are thought to exist (see below). In addition, the studied 
dimensions were limited to the phenomenology of depression and anxiety; 
whereas many additional dimensions will exist that cover other symptomatology 
(e.g. psychotic experiences, impulsivity, apathy, somatoform symptoms etc.).  
 
3 As in virtually all psychiatric research, the presented associations had relatively 
small effect-sizes, indicating that many additional factors play a role. It will be a big 
challenge to identify as many as possible of these factors and study their 
combined roles in psychopathology. In addition, measures should be improved in 
such a way to allow minimal random error. 
 
4 In all studies, participants were excluded from analyses because of missing values 
on the MASQ-D30 or IDS-SR, which could have led to some selection bias. 
Unfortunately, the categorical and non-normal nature of self-report data did not 
allow for reliable imputation of missing items. 
 




5 The studies showed that different dimensional approaches can be used (e.g. IDS-
SR dimensions versus MASQ-D30 dimensions). However, in order to build up a 
consistent knowledge base about the added value of dimensions, standardization 
across studies should ideally be implemented. However, it is still too early to make 
recommendations about such standardization, based on the current results. 
 
9.9 Future directions 
The presented findings have given a thorough insight in the way dimensions can be used 
and how they can contribute to different fields of investigation. Still, more questions arise 
from the presented work. Most importantly, the presented findings need independent 
replication in similar and different populations. Dimensions could be used in other lines of 
etiological (e.g. neuro imaging) and/or clinical research (e.g. medication trials) to provide 
further information about their external validity. Furthermore, there seems to be ample 
opportunity to elaborate on and integrate the etiological findings from this dissertation.  
With regard to etiological research the role of different dimensions in the link 
between depression, the HPA-axis and metabolic risk could be investigated. Also, the 
association between trauma, life-events, social support, coping and other risk/buffering-
factors could be further disentangled, using dimensions as highly sensitive outcome 
measures. In addition, it could be evaluated how the biological factors (e.g. HPA-axis) 
interact with environmental factors (life-events) in acting on different symptom-
dimensions. From a methodological perspective, it would be very interesting to address 
symptom variations over time within subjects, when evaluating the effects of biological 
and environmental factors and interventions. For instance, studies have monitored 
variations in positive and negative affect during the day, using an ambulatory self-report 
system, to see how persons respond emotionally to daily hassles. These studies have 
shown that this emotional responsivity among others determined by biological factors, 
such as heritability (Wichers et al., 2007). On a larger month-to-month scale, such an 
approach could also be used to uncover the factors that determine the way individuals 
react to high-impact life events.   
With regard to clinical research, a next step would be to evaluate whether 
dimensional patterns have the ability to predict more specific and informative clinical 
parameters than only course-trajectories and DSM-outcome. Such factors could be: 
response to pharmacological or psychotherapeutic treatment, psychosocial functioning 
and/or suicidality. Pharmacological research could focus on symptom dimensions as more 
specific treatment targets for medication. For instance, it has been suggested that 
patients, who experience a pronounced reduction of positive affect, respond better to 
medication that acts on noradrenergic and dopaminergic activity (e.g. bupropion) than to 
serotonergic antidepressants (reviewed by: Nutt et al., 2007).  
A more general aim should be to further investigate the internal validity of 




seen in reality. Several of such extensions have been proposed (e.g. Watson, 2007, 2008; 
Simms et al., 2008, 2011; Den Hollander-Gijsman et al., 2010, 2011).  
 
9.10 Concluding remarks 
This dissertation was aimed to find out whether dimensions of depression and anxiety are 
valid and are of added value in research and, potentially, clinical settings. The different 
chapters provided many useful insights in the way dimensions are ideally constructed and 
measured and how they can be used in etiological and clinical research. From all chosen 
perspectives in this dissertation, dimensions were seen to have clear added value on top 
of categorical diagnoses, when it came to uncovering symptom-specific, non-linear and 
population-wide associations with etiological and clinical factors. In addition, both the 
internal and external validity of dimensions was thoroughly investigated and confirmed. 
Taken together, this leads to the conclusion that dimensions of depression and anxiety 
are valid and have clear added value compared to categorical DSM-diagnoses. The use of 
symptom dimensions could eventually bring us closer to disentangling all the complex 
specific associations that underlie psychopathology and that determine how psychiatric 
problems develop over time. Given the accumulating proof for the added value of 
dimensions and the current lack of progress in the field, researchers should embrace such 
new possibilities and include dimensions in their design.  
Currently, many scientists and professionals are held back from using dimensions by a 
healthy skepticism, but also by the habits and conventions that they have grown attached 
to and that prevent them from thinking along alternative lines. However, if dimensions 
will prove themselves useful and valid across many research-areas, these will no longer 
be defensible reasons to oppose the shift to a formal dimensional approach to 
psychopathology. Eventually, such a paradigm-shift could stimulate progress in the field 
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Depressive and anxiety disorders are very common in the general population and cause a 
great deal of disability and health-related costs. The disorders often have a chronic-
intermittent course with interchanging periods of remission and recurrence. These course 
characteristics make the disease burden of depression and anxiety especially heavy, 
because the disorders are long-lasting and hard to cure completely. Unfortunately, the 
knowledge about the etiological mechanisms that underlie the onset and course of 
depression and anxiety are largely unknown. In addition, although general guidelines 
exist, the treatment of patients often relies on trial and error, since well-defined one-to-
one treatment indications are still unavailable. 
 A large amount of research has been conducted to investigate the underlying 
mechanisms that cause depression and anxiety. In recent years, research has come to 
focus especially on biological mechanisms, including: the stress-system, genetics, 
structural and functional neuro-imaging and more. In addition, environmental aspects 
that have been investigated are childhood trauma and life-events. Psychological 
mechanisms that have been proposed, include: coping mechanisms and the experience of 
social support. More recently, studies have looked at the interactions between genetic 
and environmental factors in causing psychopathology. Despite many results and a large 
volume of suggestive evidence, etiological research has yielded relatively little results. In 
addition, effect sizes of the few consistent findings have been small.  
 Several reasons for the lack of progress in understanding the etiology of 
depression and anxiety have been proposed, including lack of statistical power and focus 
on the wrong mechanisms. However, it has also become clear that the nature of the 
currently used Diagnostic and Statistical Manual (DSM)-diagnoses hampers scientific 
research in three important ways. First, an inherent problem of DSM-diagnoses is the 
occurrence of comorbidity. Depressive and anxiety disorders co-occur more often than 
expected by their strict separation in the DSM. In fact, depression and anxiety show 
considerable overlap in their symptomatology and it is likely that, given their frequent co-
occurrence, they share a considerable part of their etiology. The latter is further 
supported by the similar treatment indications for depression and anxiety (usually 
selective serotonin reuptake inhibitors and/or cognitive therapy). Restricting research to 
either depression or anxiety is bound to limit the insight that can be gained in their 
shared etiology. A second issue of DSM disorders is their large within-diagnosis 
heterogeneity: no two depression patients are the same. This has important implications 
for research and clinical practice. Etiological research is hampered by diagnostic 
heterogeneity because within-diagnosis differences are likely to obscure between-group 
differences (e.g. patients vs. controls). In other words: DSM-diagnoses decrease the 
statistical power to detect effects of etiological and/or cinical factors. In addition, the 
large variability in symptomatology across patients with similar diagnoses suggests that 
different underlying mechanisms play a role. In addition, in clinical practice, within-




on prior experience and/or trial-and-error. To better capture symptom-specific etiological 
effects, the specificity of the clinical description should be increased. The third and final 
problem of the DSM categories is the assumed discontinuity between ill and non-ill. In 
reality, symptoms of depression and anxiety are continuously distributed in the general 
population without a clear cut-off between depressed and non-depressed. The 
implication of dichotomising these continuous phenomena is that the statistical power to 
detect any etiological/treatment effect is seriously decreased. In addition, a large group 
of sub-threshold patients, who do not meet DSM-criteria but have relevant problems are 
excluded from research and have no formal diagnostic status or treatment indication in 
clinical settings. 
 Several attempts have been made to solve the problems summarized above in 
new and/or upcoming versions of the DSM. For instance, depression subtypes were 
proposed to decrease diagnostic heterogeneity. Also, the diagnosis of mixed depression-
anxiety was proposed to overcome comorbidity between the two disorders and sub-
threshold categories were proposed to cover persons, who do not meet full disorder 
criteria. However, these measures do not address the elemental problems of the DSM, 
but only tackle specific problems in a piecemeal fashion. To really overcome the 
abovementioned problems, the approach of the DSM should be changed on a more 
elemental level. A viable alternative could be a dimensional approach to describe 
individuals’ patterns of symptomatology. Dimensions have two defining characteristics. 
First, they are continuous without a fixed cut-off between healthy and diseased. Second, 
they cover specific symptom-domains. A dimensional approach assumes that multiple 
dimensions coexist and that an individual’s clinical state can be described by the pattern 
of scores on the dimensions. 
 A well-known and simple dimensional model to describe the symptomatology of 
depression and anxiety is the tripartite model, developed by Clark & Watson in 1991. This 
model was developed to describe common and specific symptom-dimensions of 
depression and anxiety with three dimensions. A dimension of General Distress (GD) 
included symptoms of negative affect and general psychological distress, which are 
common for depression and anxiety and account for much of their overlap and/or 
comorbidity. In addition, two more specific dimensions were proposed. The dimension of 
Anhedonic Depression (AD) includes the lack of positive affect and energy, which is 
specific to depression. The dimension of Anxious Arousal (AA) includes symptoms of 
somatic hyperarousal, which are specific to anxiety, and panic in particular. This three-
dimensional structure has been shown to be a valid - although simplified - description of 
the symptomatology of depression and anxiety. The initial model was followed by a series 
of model-elaborations (e.g. the hierarchical model), which have been successfully used to 
describe the latent structure of DSM-disorders and uncover the shared basis of both 
depression and anxiety. Thus, the tripartite model and its cousins have been shown 
internally valid by a large body of scientific work, supporting the validity of a dimensional 




One of the most urgent problems of the current DSM-diagnoses is the lack of 
correspondence between the diagnoses and underlying etiological mechanisms and 
between diagnoses and clinical implications. If dimensions were shown to have consistent 
associations with etiological mechanisms and clinical characteristics, this would indicate 
that they are externally valid and that they better explain the way symptoms occur in 
reality. Although there is ample support for the internal validity of dimensional 
approaches such as the tripartite model, the external validity of the dimensions has not 
been thoroughly evaluated. For dimensions to be implemented as standard diagnostic 
tools, they should first be shown to be internally and externally valid beyond reproach, 
especially given the reservations many working clinicians still hold against dimensions. 
 The aim of this dissertation was to evaluate the internal and external validity of a 
dimensional approach to depression and anxiety. Different approaches were taken: the 
optimal measurement of dimensions was investigated (Chapters 2 and 3), the 
associations between dimensions and etiological factors were investigated (Chapters 4-6) 
and the associations between dimensions and clinical course were investigated (Chapters 
7 and 8). 
The first two chapters were intended to evaluate and, if necessary, to improve the 
measurement of dimensions. In Chapter 2, the development and validation of a measure 
of the tripartite dimensions was described: the 30-item adaptation of the Mood and 
Anxiety Symptoms Questionnaire (MASQ-D30). The scales were shown to have good 
internal consistency across healthy and anxious/depressed groups. Also, construct validity 
and convergent validity were found to be adequate. Therefore, the MASQ-D30 was used 
in several of the subsequent chapters as the main dimensional measure. In Chapter 3, a 
different approach was taken to the development and validation of dimensional 
measures. Here, the best-fitting factor-structure of the widely used Inventory of 
Depressive Symptomatology was identified with confirmatory factor analyses. A 3-factor 
structure was shown to fit best and most consistently. Of these 3 factors, two were 
shown to be usable as reliable one-dimensional subscales with item-response analyses 
(Rasch). These dimensional scales were: ‘mood/cognition’ and ‘anxiety/arousal’. 
Importantly, these results showed that more specific dimensional measurement does not 
have to rely on specialized instruments but is also possible with an existing and already 
widely used questionnaire. 
In the next three chapters, the validated dimensional measures from chapter 2 
were associated with biological and environmental etiological factors. In Chapter 4, the 
association between the tripartite dimensions and the activity of the Hypothalamo-
Pituitary-Adrenal (HPA) axis was investigated. The HPA-axis activity was assessed with a 
series of saliva samples, taken across one day (at awakening and after 30, 45 and 60 
minutes; at 22.00 and 23.00 pm) and the next morning after awakening, following 
dexamethasone ingestion the evening before. These data enabled assessment of the 




results showed that the tripartite dimensions were only associated with the CAR and that 
this association had the shape of an inverted U. These non-linear associations persisted 
after adjustment for demographic, psychiatric (including DSM-diagnosis) and sampling 
factors. These results indicated that the CAR first increased with increasing dimensional 
severity, but from a certain point started to decrease again, which indicated the existence 
of a negative feedback system. These findings could explain why both increased and 
decreased HPA-axis activity have previously been observed in depressed patients and 
showed the dynamic role of the HPA-axis in psychopathology. In Chapter 5, the 
association between the tripartite dimensions and the metabolic syndrome and its 
components were investigated. There has been a well-documented bidirectional link 
between depression and the metabolic syndrome and the present study was intended to 
see which symptom-specific associations underlie this general association. The metabolic 
syndrome (elevated waist circumference, increased triglycerides, increased blood 
pressure, and fasting glucose, and reduced high-density lipoprotein [HDL] cholesterol) 
was present in 20.1% of participants. Only increases on the AA dimension were associated 
with increased risk of having the complete metabolic syndrome. In addition, AA was only 
significantly associated with three of the five individual components (waist 
circumference, triglycerides and blood-pressure). This indicated that the generally 
observed association between depression and the metabolic syndrome was primarily 
driven by more specific underlying associations between AA and particular metabolic 
syndrome components.     
Chapter 6 focused on environmental etiological factors. Life events  have 
repeatedly been suggested to play a role in the onset and course of depression and 
anxiety.  A longitudinal approach was used to model the change over time of dimensional 
scores in reaction to both negative and positive life events that occurred between 
repeated measurements. The results showed that GD most consistently increased in 
response to negative life events and that  AD most consistently decreased in response to 
positive life-events. The life event induced changes were seen across groups with 
different course-trajectories (i.e. early remission, late remission/recurrent, chronic). This 
indicated that by modeling within-person change, specific effects of life events were 
captured that would not be captured by single measurements and/or DSM-defined 
course-trajectories. Closer inspection of the associations of individual life events showed 
that some life events affected all dimensions and some had dimension-specific effects, 
illustrating the complexity of the relationship between life events and mental well-being.   
 The next chapters dealt with the prediction of the course of depression and 
anxiety. Despite similar DSM-diagnoses, two patients can have different prognoses due to 
the large within-diagnosis heterogeneity of symptomatology, severity and context. 
Dimensions could be used to more specifically describe patients’ clinical picture and, thus, 
to increase the specificity of patients’ prognoses. This approach was evaluated in 
Chapters 7 and 8, using different dimensional models. In Chapter 7, the added value of 




evaluated. The dimensional scores were assessed at baseline and the course over the 
following 2 years was assessed with standardized diagnostic interviews and a life-chart 
method. Two outcome variables were used: (1) diagnosis after two years (healthy, single 
depression, single anxiety and comorbid depression-anxiety) and (2) course-trajectory 
(early remission, late remission/recurrence and chronic course). The results showed that 
AD specifically predicted increased risk of single depression, AA predicted single anxiety 
(mainly panic disorder) and GD predicted comorbid depression-anxiety after two years. In 
addition, GD predicted an increased risk of less favorable overall course-trajectories (late 
remission or chronicity). These results persisted after adjustment for traditionally used 
prognostic factors at baseline, such as DSM-diagnosis. Taken together, these results 
indicated that specific dimensions have added value as prognostic factors. In Chapter 8, a 
similar approach was taken, but here the IDS dimensions of mood-cognition and anxiety-
arousal were used and their prognostic ability was compared with the IDS total score. The 
results showed that the IDS total scale predicted single depression, anxiety and comorbid 
depression-anxiety after two years. The dimensions showed more specific associations. 
Mood/cognition at baseline predicted an increased risk of single depression and worse 
course trajectories of depressive symptomatology. Anxiety/arousal  predicted single 
anxiety (mainly panic) after two years and worse course trajectories of anxiety 
symptomatology during follow-up. Both dimensions predicted comorbid depression-
anxiety after two years. All associations persisted when adjusted for other well-known 
prognostic factors. These results supported the idea that breaking up generic instruments 
into more specific dimensions enables us to better specify prognosis.  
 Together, the presented chapters were intended to validate a dimensional 
approach to depression and anxiety. Chapters 2 and 3 clearly showed that it is possible to 
validly measure dimensions with optimized instruments. Chapters 4 and 5 showed that 
the use of dimensions benefits the investigation of complex (non-linear) biological 
associations and the identification of symptom-specific associations. Importantly, the 
results could explain previous inconsistencies in the literature. Chapter 6 showed that 
dimensions capture the dynamic and complex effects  of life events on depressive and 
anxiety symptomatology. In addition, chapter 6 showed the potential of modeling within-
person change on dimensions as a very useful outcome variable to capture etiological 
effects. Chapters 7 and 8 showed that dimensions could be used to predict the prognoses 
of depressive and anxiety disorders more specifically.  
This research project had several strengths (e.g. validated dimensional 
measurements, large sample sizes and careful adjustment for confounders/mediators). 
However, the results should also be interpreted in the light of some limitations including: 
limited generalizability outside outpatient populations, the use of simplified dimensional 
models and sample attrition over time. 
 In conclusion, the results of this dissertation provided a comprehensive overview 




confirmed that dimensions are not merely internally, but also externally valid. 
Importantly, the results showed that dimensions can have much added value in research,  





Depressieve- en angststoornissen komen veel voor in de algemene bevolking en 
veroorzaken veel invaliditeit en medische kosten. De stoornissen hebben vaak een 
chronisch beloop met afwisselende periodes van remissie en recidive. Depressie en angst 
zijn vaak langdurig en moeilijk te behandelen, wat hun ziektelast en invloed op het leven 
vergroot. Helaas is er slechts beperkte kennis over de etiologische mechanismen die aan 
het ontstaan en beloop van depressie en angst ten grondslag liggen. Bovendien berust de 
behandeling, ondanks het bestaan van richtlijnen, vaak op ‘trial-and-error’, want goed 
gedefinieerde één-op-één behandelindicaties zijn er niet.  
Er is veel onderzoek gedaan naar de oorzakelijke mechanismen van depressie en 
angst. In het afgelopen decennium is dat onderzoek zich steeds meer gaan richten op 
biologische mechanismen, zoals bijvoorbeeld het stress-systeem, genetica en 
beeldvormende technieken, zoals MRI. Daarnaast is er ook gekeken naar de rol van 
omgevings factoren, zoals bijvoorbeeld jeugdtrauma’s en ingrijpende 
levensgebeurtenissen. Ook zijn psychologische mechanismen, zoals coping-mechanismen 
en het ervaren van sociale steun, uitgebreid onderzocht. Meer recentelijk is er in 
onderzoek ook meer gekeken naar de interacties tussen deze verschillende factoren. Zo 
interacteren omgevings- en genetische factoren in het ontstaan van psychopathologie. 
Ondanks deze veelheid aan wetenschappelijk werk, zijn er maar weinig resultaten 
repliceerbaar gebleken. Daarnaast zijn de gevonden effecten statistisch gezien erg klein. 
Bij elkaar beschouwd is er dus maar beperkt vooruitgang geboekt in het doorgronden van 
de oorzaken van depressie en angst. 
Er zijn verschillende aanwijsbare redenen voor het gebrek aan wetenschappelijke 
vooruitgang. Het zou door een systematisch gebrek aan statistische power kunnen komen 
en als gevolg van te kleine onderzoeksgroepen. Ook zou men naar de verkeerde 
mechanismen gekeken kunnen hebben. Wat echter ook steeds duidelijker is geworden, is 
dat de aard van de momenteel gebruikte Diagnostic and Statistical Manual (DSM) 
diagnoses leidt tot problemen die het doen van goed wetenschappelijk onderzoek 
bemoeilijken. Het eerste probleem is dat DSM-diagnoses veel samen voorkomen: er is 
dus sprake van overvloedige comorbiditeit. Depressieve- en angststoornissen komen 
bijvoorbeeld veel vaker samen voor dan je zou verwachten op basis van hun strikte 
scheiding in de DSM. In de realiteit tonen depressie en angst inderdaad grote overlap in 
hun symptomatologie en het is waarschijnlijk dat ze, gelet op hun frequente samen 
voorkomen, een aanzienlijk deel van hun etiologie delen. Dit wordt verder ondersteund 
door de vergelijkbare behandel-indicaties voor depressie en angst (meestal selectieve 
serotonine heropname remmers en/of cognitieve therapie). Veel onderzoek kijkt echter 
alleen naar depressie of angst en mist daardoor dus de belangrijke gedeelde 
mechanismen van de twee stoornissen. Door meer rekening te houden met overlap 
tussen depressie en angst, zou een veel completer beeld kunnen worden verkregen van 
de etiologie van affectieve stoornissen als geheel. Een tweede probleem met DSM-




dezelfde diagnose zijn hetzelfde. Dit heeft belangrijke implicaties voor onderzoek en de 
klinische praktijk. Etiologisch onderzoek wordt belemmerd door diagnostische 
heterogeniteit, want de variatie binnen een diagnosegroep kan de verschillen tussen 
patient- en controlegroep overschaduwen. Met andere woorden: de statistische power 
om kleine verschillen tussen groepen te vinden is klein. Daarnaast suggereren de grote 
verschillen in symptomatologie tussen patienten met dezelfde diagnose dat verschillende 
mechanismen er een rol spelen. Om deze symptoom-specifieke effecten te kunnen 
vangen in onderzoek moet de specificiteit van de klinische beschrijving worden verhoogd. 
Naast de problemen voor onderzoek, leidt binnen-diagnose heterogeniteit ook tot 
aspecifieke behandel-indicaties. Omdat patienten zo sterk van elkaar kunnen verschillen, 
moeten hulpverleners vaak vertrouwen op hun klinische ervaring en ‘trial-and-error’. Het 
derde probleem van de DSM-diagnoses is de veronderstelde discontinuïteit tussen ziekte 
en gezondheid. In werkelijkheid volgen symptomen van depressie en angst een continue 
verdeling in de algemene populatie zonder een duidelijk afkappunt tussen gezond en ziek. 
Het plaatsen van een afkappunt op deze continue verdeling in de vorm van een 
dichotome diagnose, heeft als gevolg dat de statistische power om (bijvoorbeeld 
etiologische) effecten te detecteren sterk wordt gereduceerd. Daarnaast is er een grote 
groep van subklinische patiënten, die niet voldoen aan de DSM-criteria, maar wel zeer 
relevante psychische problemen hebben. In het huidige DSM-systeem hebben deze 
mensen geen formele status. Bovendien, worden zij vaak van deelname aan onderzoek 
uitgesloten of in de gezonde controlegroep geplaatst, waardoor de verschillen tussen 
patiënten en gezonde controlepersonen weer verder verwateren. 
Er zijn verschillende voorstellen gedaan om de hierboven genoemde problemen in 
nieuwe versies van de DSM op te lossen. Er zijn bijvoorbeeld subtypen van depressie 
voorgesteld om de diagnostische heterogeniteit te verminderen. Ook is er een nieuwe 
diagnose voor ‘gemengde depressie-angst’ voorgesteld om recht te doen aan de overlap 
en comorbiditeit tussen de twee stoornissen. Ten slotte zijn er ook sub-klinische 
categorieën voorgesteld om de mensen te kunnen vatten die niet voldoen aan de 
volledige diagnose-criteria. Echter, deze maatregelen doen niets aan de meer elementaire 
problemen van de DSM, maar pakken alleen specifieke problemen aan. Om de 
bovengenoemde problemen echt te overwinnen, zou de DSM op een meer elementair 
niveau moeten worden veranderd. Een alternatief is een dimensionele benadering, 
waarmee meer individuele symptoom-patronen kunnen worden beschreven. Dimensies 
hebben twee belangrijke kenmerken. Ten eerste zijn ze continu zonder vast afkappunt 
tussen gezond en ziek. Ten tweede, dekken zij specifieke symptoom-domeinen. Een 
dimensionele benadering gaat ervan uit dat er meerdere dimensies naast elkaar bestaan 
en dat iemands klinische toestand kan worden beschreven door het patroon van scores 
op deze dimensies. Op deze manier gebruikt, kunnen dimensies de problemen van 
comorbiditeit, heterogeniteit en discontinuiteit oplossen of omzeilen.  
Een bekend en eenvoudig dimensioneel model van de symptomen van depressie 




ontwikkeld om de gemeenschappelijke en specifieke symptoom-domeinen van depressie 
en angst te beschrijven met drie dimensies. Een algemene dimensie General Distress (GD) 
bestaat uit symptomen van negatief affect en algemeen psychologisch onwelbevinden, 
die vaak voorkomen bij zowel depressie als angst en verantwoordelijk zijn voor hun 
overlap en comorbiditeit. Daarnaast zijn er twee specifieke dimensies waarop patiënten 
meer van elkaar kunnen worden onderscheiden. De dimensie Anhedonic Depression (AD) 
bestaat uit symptomen van gebrek aan positief affect en energie, die specifiek zijn voor 
depressie. De dimensie Anxious Arousal (AA) bestaat uit symptomen van somatische 
opwinding en/of geprikkeldheid, die specifiek is voor angst (en met name paniek). Door 
veel studies is aangetoond dat drie-dimensionele structuur van het tripartite model 
inderdaad een goed, zij het vereenvoudigd, model voor de symptomatologie van 
depressie en angst vormt. Het tripartite model werd gevolgd door een reeks modellen die 
erop voortbouwden (bijv. het hiërarchische model). Deze modellen zijn met succes 
gebruikt om de eigenlijke onderliggende structuur van de DSM-stoornissen te beschrijven 
en de gemeenschappelijke basis van depressie en angst bloot te leggen. Zo is in veel 
onderzoek aangetoond dat het tripartite model en haar opvolgers intern valide zijn en dat 
ze potentiële aanknopingspunten bieden voor het oplossen van de problemen van de 
DSM.  
Eén van de duidelijkste problemen van de huidige DSM-diagnoses is het ontbreken 
van overeenstemming tussen de diagnoses en onderliggende etiologische mechanismen 
en tussen de diagnoses en klinische implicaties; met andere woorden: de diagnoses zijn 
niet extern valide. Als van dimensies werd aangetoond dat ze wel consistent geassocieerd 
zijn met etiologische mechanismen en klinische kenmerken, dan zou dat erop wijzen dat 
zij wel extern valide zijn en een betere reflectie vormen van de dynamische manier 
waarop symptomen in de werkelijkheid voorkomen. Hoewel er veel ondersteuning is voor 
de interne validiteit van de dimensionale benaderingen, is de externe validiteit van 
dimensies niet grondig onderzocht. Om dimensies als serieus alternatief voor categoriële 
DSM-diagnoses te kunnen presenteren, moet eerst worden aangetoond dat ze zowel 
intern als extern valide zijn en dat ze hierin superieur zijn aan DSM-diagnoses. Dit is zeker 
van belang gezien de terughoudendheid die veel hulpverleners nog steeds voelen jegens 
het gebruik van dimensies in de praktijk.  
Daarom was het doel van dit proefschrift om de interne en externe validiteit van 
een dimensionale benadering van depressie en angst grondig te evalueren. Er werden 
hiervoor verschillende benaderingen genomen: de optimale meting van de dimensies 
werd onderzocht (hoofdstukken 2 en 3), de associaties tussen dimensies en etiologische 
factoren werden onderzocht (hoofdstukken 4-6) en de associaties tussen dimensies en 
het klinisch beloop van depressie en/of angst werden onderzocht (hoofdstukken 7 en 8) .  
De eerste twee hoofdstukken gingen over het optimaliseren van de meting van 
dimensies. In hoofdstuk 2, werd de ontwikkeling en validatie beschreven van een 
instrument om de dimensies van het tripartite model te meten: de verkorte Nederlandse 




aangetoond dat de schalen een goede interne consistentie hadden in zowel gezonde als 
zieke groepen deelnemers. Ook bleken de construct validiteit en de convergente validiteit 
van de schalen adequaat. Omdat de MASQ-D30 een goed instrument bleek te zijn, werd 
deze in meerdere hoofdstukken van dit proefschrift gebruikt om de tripartite dimensies te 
meten. Voor hoofdstuk 3, werd een andere insteek gekozen om dimensionele 
meetinstrumenten te ontwikkelen en te valideren op basis van de items van de reeds veel 
gebruikte ‘Inventory of Depressive Symptomatology (IDS)’. Eerst werd de best passende 
factor-structuur van de IDS geïdentificeerd met confirmatieve factor analyses. Deze 
analyses lieten zien dat een 3-factor-structuur het beste op de data paste. Van deze 3 
factoren, werd met item-response (Rasch) analyses vastgesteld dat er twee geschikt 
waren voor gebruik als één-dimensionele subschalen: een 'mood/cognition' schaal en een 
'anxiety/arousal' schaal. Het belangrijke van deze resultaten is dat ze aantoonden dat 
specifieke dimensies niet uitsluitend kunnen worden gemeten met gespecialiseerde 
instrumenten, maar ook met een bestaand en veel gebruikt instrument als de IDS.  
In de volgende drie hoofdstukken werden de associaties tussen de dimensies en 
biologische en omgevingsfactoren onderzocht. In hoofdstuk 4, werd de associatie tussen 
de tripartite dimensies en de activiteit van de hypothalamus-hypofyse-bijnier (HPA)-as 
onderzocht. De HPA-as-activiteit werd gemeten met een reeks van speekselmonsters, 
genomen over de dag (bij het ontwaken en na 30, 45 en 60 minuten, om 22.00 uur en om 
23.00 uur) en de volgende ochtend na het ontwaken volgend op dexamethason-inname 
de avond ervoor. Met deze gegevens konden de ‘cortisol awakening rise (CAR)’ curve, het 
‘basale cortisol niveau’ en ‘dexamethason suppressie’ worden onderzocht. De resultaten 
lieten zien dat de tripartite dimensies alleen waren geassocieerd met de CAR en dat deze 
associatie de vorm had van een omgekeerde U. Deze associaties bleven staan na correctie 
voor demografische, psychiatrische (waaronder DSM-diagnoses) en sampling-factoren. De 
resultaten lieten zien dat de CAR aanvankelijk steeg met toenemende ernst op de 
dimensies, maar vanaf een bepaald punt weer begon te dalen, wat wijst op een ‘negatief 
terugkoppelingssysteem’. Deze bevindingen kunnen verklaren waarom in eerder 
onderzoek zowel verhoogde en verlaagde HPA-as activiteit werd waargenomen bij 
depressieve patiënten, afhankelijk van de ernst van de klachten in de gebruikte 
onderzoeksgroepen. Bovendien toonden de resultaten ook de non-lineaire en complexe 
associatie tussen de HPA-as en psychopathologie. In hoofdstuk 5 werden de associaties 
tussen de tripartite dimensies en het metabool syndroom en de onderdelen ervan 
onderzocht. Er lijkt sprake te zijn van een tweezijdige link tussen depressie en het 
metabool syndroom. De huidige studie was bedoeld om te zien welke symptoom-
specifieke associaties aan deze deze globale associatie ten grondslag liggen. Het metabool 
syndroom (verhoogde taille omtrek, verhoogde triglyceriden, verhoogde bloeddruk, 
verhoogd nuchter bloedglucose, en minder high-density lipoprotein [HDL] cholesterol) 
was aanwezig bij 20.1% van de deelnemers. Alleen verhogingen op de AA dimensie waren 
geassocieerd met een verhoogde kans op het metabool syndroom. Daarnaast was AA 




componenten (tailleomtrek, triglyceriden en bloeddruk). Dit wijst erop dat de vaak 
geobserveerde associatie tussen depressie en het metabool syndroom waarschijnlijk 
gedreven wordt door AA symptomen en een aantal specifieke metabole componenten. 
Deze resultaten toonden hoe het verminderen van de heterogeniteit van zowel de 
onderzochte psychopathologische als de metabolische concepten hielp om de schijnbaar 
algemene associatie tussen depressie en metabool syndroom uit elkaar te trekken.  
Hoofdstuk 6 was gericht op omgevingsfactoren. Al lang wordt vermoed dat 
levensgebeurtenissen een rol spelen bij het ontstaan en het beloop van depressie en 
angst. Een longitudinale benadering werd gebruikt om te kijken hoe verschillende 
levensgebeurtenissen (gedurende de volwassenheid) leiden tot veranderingen in 
dimensionele scores over tijd. De resultaten toonden aan dat GD steeg in reactie op 
negatieve levensgebeurtenissen en dat AD daalde in reactie op positieve 
levensgebeurtenissen. Dezelfde associaties werden gezien in groepen patiënten met 
verschillend beloopstrajecten (vroege remissie, late remissie/recidive, chronisch beloop). 
Dit wijst erop dat door verandering binnen personen te modelleren, specifieke effecten 
van levensgebeurtenissen werden opgemerkt, die niet werden gevat door eenmalige 
dimensionele metingen en DSM-gedefinieerde beloopstrajecten. Verdere analyses van 
individuele levensgebeurtenissen liet zien dat sommige een algemeen effect op alle 
dimensies hadden en dat sommigen een meer dimensie-specifiek effect hadden. Deze 
resultaten vormden een goede illustratie van de manier waarop dimensies kunnen 
worden gebruikt om complexe etiologische mechanismen bloot te leggen.  
De volgende hoofdstukken gingen over het voorspellen van het beloop van 
depressie en angst. Twee patiënten met dezelfde DSM-diagnose hebben vaak 
verschillende prognoses als gevolg van de grote binnen-diagnose heterogeniteit. 
Dimensies zouden kunnen worden gebruikt om  het klinisch beeld van patiënten meer 
specifiek te beschrijven, en daarmee ook de prognose specifieker te maken. Of dimensies 
die toegevoegde prognostische waarde daadwerkelijk hebben werd geëvalueerd in 
hoofdstukken 7 en 8. In hoofdstuk 7, werd de toegevoegde waarde onderzocht van de 
tripartite dimensies voor het voorspellen van het beloop en de uitkomst van depressie 
en/of angst over een periode van 2 jaar. De dimensionele scores werden bij aanvang 
gemeten en het beloop over de daarop volgende 2 jaar werd gemeten met 
gestandaardiseerde diagnostische interviews en een life-chart methode. Op basis hiervan 
werden twee uitkomstvariabelen gemaakt: (1) de diagnose na twee jaar (gezond, alleen 
depressie, alleen angst, of comorbide depressie-angst) en (2) het beloops-traject (vroege 
remissie, late remissie/recidive, of chronisch beloop). De resultaten lieten zien dat AD 
specifiek een grotere kans op alleen depressie na twee jaar voorspelde. AA voorspelde 
alleen een hogere kans op angst (vooral paniekstoornis) na twee jaar en GD voorspelde 
een hogere kans op comorbide depressie-angst na twee jaar. Daarnaast voorspelde alleen 
GD een grotere kans op minder gunstige beloops-trajecten (late remissie of een chronisch 
beloop). Deze resultaten bleven overeind na correctie voor de traditioneel gebruikte 




specifieke symptoom dimensies toegevoegde waarde hadden als prognostische factoren 
bovenop meer traditionele voorspellers, zoals DSM-diagnose. In hoofdstuk 8 werd een 
vergelijkbare aanpak gebruikt, maar hier werden de IDS dimensies mood/cognition en 
anxiety/arousal gebruikt. De resultaten lieten zien dat waar de totale IDS-schaal 
depressie, angst en comorbide depressie-angst na twee jaar voorspelde, de dimensies 
meer specifieke associaties lieten zien. Mood/cognition was geassocieerd met een 
verhoogde kans op depressie na twee jaar en met een minder gunstig beloop van 
depressieve klachten. Anxiety/arousal was geassocieerd met angst na twee jaar (paniek in 
het bijzonder) en met een minder gunstig beloop van angstklachten. Beide dimensies 
voorspelden comorbide depressie en angst na twee jaar. Net als in hoofdstuk 7, bleven 
alle associaties overeind na correctie voor andere bekende prognostische factoren. Deze 
resultaten toonden de toegevoegde waarde van het opbreken van een generiek 
instrument in afzonderlijke dimensies, om meer specifieke prognoses te formuleren.  
Samen waren de hoofdstukken van dit proefschrift bedoeld om een dimensionele 
benadering van depressie en angst te valideren. Hoofdstukken 2 en 3 lieten duidelijk zien 
dat het mogelijk is om dimensies relatief eenvoudig, maar op valide wijze te meten met 
geoptimaliseerde instrumenten. Hoofdstukken 4 en 5 lieten zien dat dimensies konden 
worden gebruikt om complexe (niet-lineaire) biologische associaties bloot te leggen en 
symptoom-specifieke biologische associaties te detecteren. Uit hoofdstuk 6 bleek dat de 
dimensies konden worden gebruikt om de generieke en specifieke effecten van 
levensgebeurtenissen te detecteren. Daarnaast, toonde hoofdstuk 6 de meerwaarde van 
het modelleren van verandering op dimensies binnen personen. Hoofdstukken 7 en 8 
lieten zien dat dimensies kunnen worden gebruikt om het beloop van depressieve en 
angststoornissen meer specifiek te voorspellen.  
Dit onderzoek had een aantal sterke punten (bijv. gevalideerd dimensionele 
metingen, grote steekproeven en zorgvuldige correctie voor vertekenende factoren). 
Toch moeten de resultaten ook worden geïnterpreteerd in het licht van een aantal 
beperkingen, waaronder beperkte generaliseerbaarheid buiten de poliklinische populatie, 
het gebruik van vereenvoudigde dimensionele modellen en de uitval van deelnemers over 
tijd.  
Als conclusie kan gesteld worden dat resultaten van dit proefschrift de validiteit 
en toegevoegde waarde van een dimensionele benadering in depressie en angst 
onderzoek ondersteunen. Dimensies zijn niet alleen intern, maar ook extern valide en 
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